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ABSTRACT
Renal dysfunction is a major cause of morbidity and mortality in hepatology patients.
In cirrhosis, portal hypertension-related renal dysfunction evolves in parallel with
advancing disease, and has important prognostic implications. Similarly, in acute
liver failure, acute kidney injury is associated with increased mortality and may
impact on distant organ function by driving cardiac, lung, brain, as well as liver
injury. Liver transplantation is the definitive treatment for portal hypertension-related
renal dysfunction in cirrhosis and acute kidney injury in acute liver failure. Yet, liver
transplantation itself is complicated by both acute kidney injury and chronic kidney
disease. Despite the frequency of occurrence and devastating consequences of renal
dysfunction in liver disease, treatment options remain limited and there is a desperate
need for advancement of scientific understanding. In this thesis I have studied 3 main
aspects of renal dysfunction in liver disease.
Firstly, I examined the systemic haemodynamic and renal effects of acute
endothelin-1 receptor antagonism in patients with advanced portal hypertension-
related renal dysfunction. In a randomised, double-blind, placebo controlled,
crossover study of patients with refractory ascites acute combined endothelin-A and
endothelin-B receptor antagonism caused a fall in glomerular filtration rate despite
no change in systemic haemodynamics or total renal blood flow, and a marked
reduction in urinary flow rate. These findings are consistent with a reno-protective
role for endothelin-1 in portal hypertension-related renal dysfunction.
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Secondly, I explored the hypothesis that the acute renal dysfunction that occurs in
acute liver failure is distinct from the hepatorenal syndrome of cirrhosis, and instead
the systemic inflammatory response may be a critical determinant. I demonstrated
that the systemic inflammatory response syndrome is associated with acute kidney
injury in acute liver failure patients. Importantly, this relationship was independent of
the presence of infection and of severity of liver injury. Thereafter, in patients super-
urgently transplanted for acute liver failure I found that, in contrast to patients
undergoing elective liver transplantation, pre-transplant acute kidney injury was not
associated with the development of chronic kidney disease. The results support an
alternative pathophysiological process underlying the renal injury that occurs in
acute liver failure.
Finally, I examined the long-term decline in renal function and progression to
chronic kidney disease in liver transplant recipients. I observed that patients have a
clinically relevant decline in glomerular filtration rate beyond the initial post¬
operative period, and current focus of chronic kidney disease prevention. Mulivariate
modelling identified several potentially modifiable patient factors associated with a
faster rate of decline.
The studies presented have helped to further our knowledge of portal hypertension-
related renal dysfunction, acute kidney injury in acute liver failure and chronic
kidney disease after liver transplantation. By doing so, we have moved one step
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ALF = acute liver failure
ALT = alanine aminotransferase
AKI = acute kidney injury
BMI = body mass index
CARS = compensatory anti-inflammatory response syndrome
CI = confidence interval
CKD = chronic kidney disease
CLD = chronic liver disease
CNI = calcineurin inhibitor
C02 = carbon dioxide
CrCl = measured creatinine clearance
c-statistic = concordance statistic
DAMP = damage-associated molecular pattern
ECE = endothelin-converting enzyme
EFF = effective filtration fraction
eGFR = estimated glomerular filtration rate
eGFR(MDRD4) = estimated glomerular filtration rate derived from 4-variable MDRD
equation
eGFR(MDRD5) = estimated glomerular filtration rate derived from 5-variable MDRD
equation
eGFR(MDRD6) = estimated glomerular filtration rate derived from 6-variable MDRD
equation
eNOS = endothelial nitric oxide synthase
ERBF = effective renal blood flow
ERPF = effective renal plasma flow




G-GSF = granulocyte colony-stimulating factor
GFR = glomerular filtration rate
AGFR = mean annualised change in eGFR from 6 months to 5 years post transplant




HMGB1 = high-mobility group box-1 protein
HR = hazard ratio
ICP = intracranial pressure
IL = interleukin
In = inulin
iNOS = nitric oxide synthase
INR = international normalised ratio
IQR = interquartile range
KCH = Kings College Hospital
LBP = lipopolysaccharide binding protein
LD = low dose
logeGFR(MDRD4) = log eGFR calculated using the MDRD 4-variable equation
logeGFR(MDRD5) = log eGFR calculated using the MDRD 5-variable equation
logeGFR(MDRD6) = log eGFR calculated using the MDRD 6-variable equation
MAP = mean arterial pressure
MARS = molecular adsorbent recirculating system
MDRD = Modification of Diet in Renal Disease
MELD = Model for End Stage Liver Disease
MELD(adj) = MELD score with regression coefficients adjusted for our model
MELD(CrCl) = MELD score with logeCrCl substituted for logecreatinine
MELD(eGFR) = MELD score with logeGFR substituted for logecreatinine
MMF = mycophenolate mofetil
OA = on admission to hospital
OR = odds ratio
PAH = para-aminohippurate sodium
PRA = plasma renin activity
PRR = pattern recognition receptor
RAAS = renin-angiotensin-aldosterone system
RIFLE criteria = acronym indicating Risk of renal dysfunction, Injury to the kidney, Failure
of kidney function, Loss ofkidney function and End-stage renal disease
ROC = receiver-operating characteristic
RRT = renal replacement therapy
SD = standard deviation
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SEM = standard error of the mean
SIRS = systemic inflammatory response syndrome
SNS = sympathetic nervous system
STD = standard dose
SVRI = systemic vascular resistance index
TIPSS = transjugular intrahepatic portosystemic stent-shunt
TLR = Toll-like receptor
TNF = tumour necrosis factor
TNF-a = tumour necrosis factor-alpha
UFR = urinary flow rate
UKELD = UK score for Patients with End-Stage Liver Disease
UKELD(adj) = UKELD score with regression coefficients adjusted for our model
UKELD(CrCl) = UKELD score with logeCrCl substituted for logecreatinine
UKELD(eGFR) = UKELD score with logeGFR substituted for logecreatinine
WCC = white cell count
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1.1 Introduction
Renal dysfunction is a major cause of morbidity and mortality in hepatology patients.
In cirrhosis portal hypertension-related renal dysfunction evolves in parallel with
advancing disease, and has important prognostic implications. Similarly, in acute
liver failure (ALF), acute kidney injury (AKI) is associated with increased mortality
and may have impact on distant organ function by driving cardiac, lung, brain, as
well as liver injury. Liver transplantation is the definitive treatment for portal
hypertension-related renal dysfunction in cirrhosis and AKI in ALF. Yet, liver
transplantation itself is complicated by both AKI and chronic kidney disease (CKD).
Despite the frequency of occurrence and devastating consequences of renal
dysfunction in liver disease, treatment options remain limited and there is a desperate
need for advancement of scientific understanding in this field.
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1.2 Chronic liver disease: The spectrum of portal hypertension-related
renal dysfunction
In the UK chronic liver disease (CLD) is the only major cause of death that continues
to rise, being the 5th 'big killer' in England and Wales (1). In Scotland specifically
cirrhosis mortality rates have more than doubled in the last 20 years and are now
amongst the highest in Western Europe (2,3).
Renal dysfunction is a common complication of CLD that has significant
implications for patient morbidity and mortality. Portal hypertension, and the
resulting circulatory and neuro-humoral derangement, is associated with a
progressive functional renal impairment that evolves in parallel with advancing
disease (4). This spectrum ranges from tubular dysfunction to hepatorenal syndrome,
and first becomes evident in early, compensated cirrhosis (4). Multiple additional
triggers may exacerbate the physiological changes of portal hypertension, including
large volume paracentesis, gastro-intestinal haemorrhage and diuretic induced intra¬
vascular volume depletion (5,6). Moreover, intrinsic renal disease is relatively
frequent reflecting the prevalence of co-morbidity such as diabetes mellitus and
hypertension, and glomerulonephritides associated with alcoholic liver disease,
hepatitis B and hepatitis C (7,8).
The aetiology of renal dysfunction in patients with CLD has important ramifications
for prognosis. In portal hypertension-related renal dysfunction the glomerular
filtration rate (GFR) only falls appreciably once disease is advanced and circulatory
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derangement severe (4). Consequently, the 3-month probability of survival for
hospitalised patients with hepatorenal syndrome is only 15% compared with 73% for
those with parenchymal nephropathy (5). Despite evolving understanding of the
pathogenetic mechamisms of portal hypertension-related renal dysfunction treatment
options remain limited.
The systemic circulation in chronic liver disease
The currently accepted theory that best explains the systemic circulatory
derangement that accompanies portal hypertension is based on the Peripheral Arterial
Vasodilatation Hypothesis, published in 1988 (Figure 1.1) (9). This suggested that
systemic vasodilatation and relative intravascular underfilling is the driving force,
with the subsequent activation of multiple homeostatic neurohumoral pressor
systems in an effort to maintain the effective circulating volume. More recently it has
become apparent that the vasodilatation is primarily limited to the splanchnic
vascular bed (10). In contrast, blood flow within the renal vessels as well as those
that supply the brain, muscles and skin, is reduced (11,12,13). Thus, peripheral
vasoconstriction probably occurs as a result of the increased pressor activity and is a
compensatory response to progressive splanchnic vasodilatation (14).
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Figure 1.1: Systemic circulatory derangement that accompanies portal
hypertension: Progressive splanchnic vasodilatation and a reduced effective
circulating volume stimulate increased RAAS, SNS, and vasopressin activity, the
primary mediators of renal tubular and haemodynamic dysfunction. In advanced


































Many vasoactive agents have been proposed as mediators of the vasodilatation of the
splanchnic vasculature. However, nitric oxide is considered to be of central
importance in both instigation and potentiation (15,16,17,18). In early portal
hypertension, vascular stretch within the intestinal microcirculation may trigger
endothelial nitric oxide synthase (eNOS) upregulation, and it is speculated that this is
the first step in the neurohumoral and circulatory cascade (19,20). In the
hyperdynamic phase, shear stress, endotoxaemia and vasoactive mediators such as
vascular endothelial growth factor (VEGF), oestrogen and bradykinin have all been
implicated in the increased generation of eNOS (21,22,23,24,25,26,27,28). Inducible
nitric oxide synthase (iNOS) may contribute to the greater nitric oxide activity in this
later stage. Although studies in rats have failed to consistently demonstrate
upregulation of splanchnic or systemic iNOS, the endotoxaemia and hypersecretion
of inflammatory cytokines that is often displayed by cirrhotic patients are known
stimuli of iNOS synthesis (25,28,29,30,31,32). Furthermore, specific iNOS inhibition
in the forearm of cirrhotics suggests that this isoform may be involved in the
regulation of at least peripheral vascular tone (33).
Despite these findings, it is clear that nitric oxide is not the sole mediator of the
splanchnic vasodilatation. eNOS/iNOS knockout mice develop circulatory
dysfunction following portal vein ligation, and chronic nitric oxide inhibition in
cirrhotic rats delays but does not prevent the vasodilatation of the splanchnic
vascular bed (34,35). Angeli et al demonstrated that while nitric oxide may be
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significant in the early phase its role in maintenance may be partial at most (36).
Other vasodilating agents have therefore been implicated including glucagon,
prostacyclin and calcitonin-gene related peptide (37,38,39).
• Compensatory peripheral vasoconstriction
With progressive splanchnic vasodilatation and intravascular underfilling, high
pressure baroreceptors within the aorta, carotid sinus and juxtaglomerular apparatus
of the kidney activate the renin-angiotensin-aldosterone system (RAAS) and the
sympathetic nervous system (SNS), and stimulate non-osmotic hypersecretion of
vasopressin (Figure 1.1) (40,41,42,43). Arterial blood pressure becomes critically
dependent on these pressor agents (44,45,46). However, although peripheral
vasoconstriction ensues, the splanchnic vasodilatation continues to progress due to an
imbalance between vasoactive mediators and a possible vascular hyporesponsiveness
to pressor agents (47,48,49,50,51,52). The circulation becomes increasingly
hyperdynamic with patients displaying the typical clinical picture of reduced
systemic vascular resistance, increased heart rate and cardiac output, expanded blood
volume, and eventually arterial hypotension (53,54,55).
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The spectrum ofportal hypertension-related renal dysfunction
The functional renal impairment of portal hypertension is characterised by increased
tubular sodium reabsorption, impaired free water clearance, renal vasoconstriction
and pre-renal azotemia (4). This spectrum first becomes evident in early,
compensated cirrhosis, and progresses in parallel with advancing disease. The true
incidence of the various stages of renal dysfunction is unclear. However, in one study
the 5-year probability of the development of ascites and hepatorenal syndrome after
presenting with variceal haemorrhage was 73% and 21%, respectively (56).
The RAAS, SNS, vasopressin and possibly endothelin-1 (ET-1) are recognised
amongst the principle mediators of the renal tubular and haemodynamic dysfunction
that accompanies portal hypertension (4). Importantly, these systems have
intertwining positive regulatory effects (57,58,59,60). For example, renal P-
adrenoceptor activation stimulates secretion of renin from the juxtaglomerular
apparatus, whilst angiotensin II in turn enhances the release of noradrenaline (57).
Such complex interactions further exacerbate the neurohumoral overactivity of the
portal hypertensive syndrome.
• Exaggerated renal tubular sodium reabsorption
Renal sodium retention plays a central role in ascites formation and peripheral
oedema in patients with cirrhosis (4). A gradual deterioration in renal tubular
function is observed that begins in the compensated state. Pre-ascitic cirrhotic
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patients demonstrate impaired renal sodium metabolism, with reduced natriuresis in
the standing position and following a saline load (61,62). With disease progression
sodium retention becomes overt, there is a positive sodium balance, and ascites
develops. The onset of refractory ascites is accompanied by profound sodium
retention, with patients excreting less than 10 mmol of sodium per day (63). In early
stages, renal blood flow and GFR remain within normal limits and sodium retention
occurs solely at the tubular level (9,64). Later, once the GFR drops, reduced filtered
sodium contributes and exacerbates sodium retention (4).
Patients with ascites frequently demonstrate increased circulating levels of plasma
renin activity (PRA) and aldosterone (65). Furthermore, the administration of
losartan, an angiotensin II receptor antagonist, and spironolactone, an aldosterone
antagonist, reduces sodium retention (66,67,68). Consequently, the RAAS is thought
to be a key mediator of increased renal tubular sodium reabsorption in this setting
(65). Angiotensin II is known to enhance sodium reabsorption by acting directly on
the proximal convoluted tubule, whilst aldosterone acts primarily on the collecting
duct to upregulate epithelial sodium transport proteins (69,70,71). Moderate SNS
activity that may be insufficient to alter renal haemodynamics similarly increases
sodium retention throughout the nephron via a direct tubular effect. The SNS is
thought to be an important additional stimulus for sodium reabsorption (72,73).
The driving force of the tubular dysfunction in portal hypertension remains unclear
(74,75). In compensated disease even when there is evidence of splanchnic arterial
vasodilatation, a large proportion of patients demonstrate similar serum levels of
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renin, aldosterone and nor-adrenaline to both healthy individuals and compensated
cirrhotics (10,76). It has therefore been suggested that the underlying pathogenesis in
these patients relates to an additional, extremely sensitive sodium retaining
mechanism (14). Alternative explanations include the intra-renal generation of
angiotensinogen, angiotensin I and angiotensin II as a consequence of subtle local
haemodynamic change, or increased tubular sensitivity to the known mediators of
sodium retention (77). Recently, it has been shown that in sodium retaining cirrhotic
rats there is diminished abundance of 1 lbeta-hydroxysteroid dehydrogenase, which
protects the mineralocorticoid receptor from stimulation by circulating
glucocorticoids (78).
• Impaired free water clearance
Impaired free water clearance occurs chronologically after sodium retention, being a
feature of decompensated cirrhosis, and manifests clinically as dilutional
hyponatremia despite the increased total body sodium (4). Fifty percent of patients
with ascites demonstrate hyponatremia and the prevalence is greater in those with
refractory ascites (79). The development of hyponatremia is now recognised as a
strong indicator of poor prognosis in advanced CLD (80).
Vasopressin or antidiuretic hormone (ADH) is considered the chief mediator of
impaired free water clearance (4). Vasopressin stimulates aquaporin-2 channel
insertion into the epithelial cell membrane increasing the permeability of the distal
nephron to water (81). Urinary aquaporin-2 excretion is markedly increased in
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patients with cirrhosis, rises in parallel with Child-Pugh class, and demonstrates a
significant negative correlation with spontaneous free water clearance (81).
Moreover, vasopressin 2 receptor antagonists have been shown to have an aquaretic
effect and to increase serum sodium in cirrhotic patients with hyponatremia and
ascites (82,83). A second postulated mechanism of impaired free water clearance is
reduced delivery of filtrate to the distal nephron. Greater proximal tubular sodium
reabsorption and reduced GFR may therefore be relevant (4).
• Renal haemodynamic dysfunction
Renal haemodynamic dysfunction is a hallmark of advanced portal hypertension-
related renal dysfunction (4). With advancing circulatory derangement and neuro¬
humoral activation there is progressive renal vasoconstriction and a fall in total renal
blood flow. Initially, intra-renal compensatory mechanisms maintain the GFR at
normal or even elevated levels (84,85,86). Local vasodilators including the
prostaglandins and nitric oxide antagonise the vascular effects of the RAAS, the
SNS, vasopressin and ET-1 (87,88,89). The importance of the prostaglandins in
preserving renal function in decompensated cirrhotics is highlighted by the marked
decrease in GFR precipitated by non steroidal anti-inflammatory drugs (87).
Increased post glomerular arteriolar resistance, by maintaining the glomerular
hydrostatic pressure, also appears to be a critical factor in sustaining the GFR. Non-
azotemic patients frequently demonstrate an increased filtration fraction in the face
of a fall in total renal blood flow (85,90). Moreover, a reduced GFR is accompanied
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by a reduction in filtration fraction when the total renal blood flow is comparable
(90). Angiotensin II, vasopressin and atrial natriuretic peptide are potential mediators
of increased efferent arteriole constriction and may serve to counteract the
exaggerated afferent vasoconstriction (65,90,91,92,93,94).
In addition to the extra-glomerular renal vascular changes described, it is likely that
the neuro-humoral overactivity also has implications for the filtration barrier itself.
The contractile mesangial cells that abut the glomerular capillaries are under
hormonal regulation and are essential for the physiological control of GFR
(95,96,97). In vitro studies have shown that angiotensin II, noradrenaline,
vasopressin and ET-1 stimulate mesangial cell contraction and, in contrast, atrial
natriuretic peptide and nitric oxide influence cell relaxation (95,98,99,100,101).
With progressive arterial underfilling the accompanying activity of the
vasoconstricting systems becomes extreme, and the renal production of vasodilators
eventually falls (102). Renal ischaemia stimulates additional intra-renal secretion of
ET-1 and increased SNS activity. A self perpetuating cycle develops within the




Hepatorenal syndrome was first defined in 1996 by The International Ascites Club
and updated in 2007 to take into account recent advances in knowledge (Figure 1.2)
(4,105). Central to the diagnostic criteria is the exclusion of alternative causes of
renal dysfunction such as nephrotoxic drugs, diuretic induced hypovolemia and
renal parenchymal disease. The syndrome is subdivided into two distinct clinical
types despite the pathogenetic similarities.
Type 1 hepatorenal syndrome is classically defined as a doubling of the initial serum
creatinine concentration to a level greater than 226 pmol/1 (2.5 mg/dl) within a 2
week period (105). Most patients demonstrate oliguria, intense sodium and water
retention and dilutional hyponatraemia, and circulatory dysfunction is pronounced
(106,107). Median survival time without treatment has been estimated at 1.7 weeks
with a probability of survival of 25% at one month (106). Type 2 hepatorenal
syndrome is characterised by moderate renal impairment, as indicated by a serum
creatinine concentration greater than 133 pmol/1 (1.5 mg/dl) (105). Renal impairment
is less severe than in type 1 hepatorenal syndrome and progresses slowly, whilst the
predominant clinical feature is refractory ascites. Median survival time for patients
with type 2 hepatorenal syndrome is 6 months (105,108).
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Figure 1.2: International Ascites Club "new" diagnostic criteria for hepatorenal
syndrome, 2007 (105).
Cirrhosis with ascites.
Serum creatinine >133 gmol/l (1.5 mg/dl).
No improvement of serum creatinine (decrease to level £133 gmol/l) after at least 2
days with diuretic withdrawal and volume expansion with albumin. The
recommended dose of albumin is 1 g/kg of body weight per day up to a maximum
of 100 g/day.
Absence of shock.
No current or recent treatment with nephrotoxic drugs.
Absence of parenchymal kidney disease as indicated by proteinuria >500 mg/day,
microhaematuria (>50 red blood cells per high power field) and/or abnormal renal
ultrasonnography.
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Although the diagnostic criteria for hepatorenal syndrome are widely employed,
their dependence on a rigid cut-off value of serum creatinine has rendered them
controversial (389,456). Creatinine production is proportional to muscle mass, and is
greater in men than women, in younger than older individuals and in black people
than in Caucasians despite similar GFR (282). In cirrhosis specifically reduced
creatine production by the liver, muscle wasting and increased renal tubular secretion
contribute to a falsely low serum creatinine (412,413). Furthermore, the poor
prognosis of patients once the hepatorenal syndrome criteria are met is consistent
with extreme renal dysfunction that is rarely reversible even with optimal treatment.
Earlier identification of renal impairment and intervention is likely to be beneficial.
The Kidney Disease Improving Global Outcomes (KDIGO) group have advised that
AKI is defined as an increase in serum creatinine >26.4 pmol/l (0.3 mg/dl) in 48
hours, or a rise to >1.5 times baseline within 7 days (457). This classification has
been shown to predict survival also in patients with cirrhosis (458). Consequently, a
recent working party has proposed new diagnostic criteria for hepatorenal syndrome
based on the KDIGO and NKF KDOQI (National Kidney Foundation Kidney
Diseases Outcomes Quality Initiative) guidelines for defining AKI and CKD,
respectively (Figure 1.3) (389). Yet, opinion remains divided amongst Hepatologists
and the International Ascites Club has advocated further research before adopting
this proposal (456).
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Figure 1.3: Working party proposed diagnostic criteria for kidney dysfunction in
cirrhosis, 2011 (389).
AKI Rise in serum creatinine of >50% from baseline or a rise of serum
creatinine by >26.4 pmol/l (£0.3 mg/dl) in <48 hours.
Hepatorenal syndrome type 1 is a specific form of acute kidney injury.
CKD GFR < 60 ml/min for >3 months calculated using MDRD6 formula.
Hepatorenal syndrome type 2 is a specific form of CKD.
Acute-on-CKD Rise in serum creatinine of >50% from baseline or a rise of serum
creatinine by >26.5 pmol/l (£0.3 mg/dl) in <48 hours in a patient with
cirrhosis whose GFR is <60 ml/min for >3 months calculated using
MDRD6 formula.
Abbreviations: AKI, acute kidney injury: CKD, chronic kidney disease; GFR, glomerular
filtration rate.
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Why some patients develop type 1 hepatorenal syndrome and others type 2 has not
yet been ascertained. In 50% of those with type 1 the onset is chronologically related
to a precipitating event such as severe bacterial infection, gastrointestinal bleeding or
large volume paracentesis (106). Mean arterial pressure is significantly lower and
there is greater stimulation of the RAAS and SNS when patients are compared with
those classified as type 2, suggesting more marked splanchnic arterial vasodilatation
(109).
Impaired cardiac function may also play a role (Figure 1.1). Patients who later
develop hepatorenal syndrome have a lower cardiac output, albeit within the normal
range (109). Moreover, the onset of hepatorenal syndrome is accompanied by a
further significant reduction in cardiac output in those with type 1, but not type 2
(109,110). A possible explanation for the fall in cardiac output is the altered vascular
compliance and hence cardiac preload. However, a cirrhotic cardiomyopathy has
been described that consists of myocardial hypertrophy and diastolic dysfunction,
with an abnormal inotropic and chronotropic response to exercise (111,112). Altered
sensitivity to sympathetic activity with down regulation of p adrenergic receptors of
the cardiomyocyte plasma membrane has been described in animal models
(113,114).
It is therefore postulated that type 1 hepatorenal syndrome occurs as a result of an
acute worsening of arterial vasodilatation on the background of advanced circulatory
dysfunction, exacerbated by a relatively low cardiac output state. Intense activity of
systemic and intra-renal vasoactive mediators leads to a downward spiral of renal
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hypoperfusion, ischaemia, and impaired GFR. In contrast, type 2 hepatorenal
syndrome probably represents the gradual decline in renal haemodynamics
associated with advancing disease, with intra-renal compensatory mechanisms
coming into play (14,109).
The role of the systemic inflammatory response in portal hypertension-related
renal dysfunction
The systemic inflammatory response is increasingly recognised as a pathogenetic
factor in the circulatory dysfunction of advanced cirrhosis, in the absence of overt
infection (Figure 1.1). Patients with Child-Pugh Class C cirrhosis demonstrate an
increased frequency of bacterial translocation of enteric organisms to mesenteric
lymph nodes (115). Bacterial DNA is present in the blood of approximately 40% of
non-infected patients with ascites (116,117,118). In addition, the plasma levels of
lipopolysaccharide binding protein (LBP), which is considered a better marker of
transient endotoxaemia given its longer half-life, are also elevated (119).
In rats with cirrhosis bacterial translocation is associated with eNOS derived nitric
oxide overproduction in the mesenteric vasculature, which appears to aggravate
arterial vasodilatation (120). Humans with advanced cirrhosis display increased
mesenteric lymph node tumour necrosis factor-alpha (TNF-a) expression (121).
Ascitic patients with high LBP levels have higher circulating levels of TNF-a,
interleukin (IL) -6, soluble TNF and lipopolysaccharide receptors, and nitric oxide
metabolites, and a more pronounced circulatory dysfunction (119). Moreover, they
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demonstrate a greater increase in circulating monocytes that have an enhanced
capacity for TNF-a expression, which correlates directly with blood TNF-a levels
(122). The exaggerated immuno-haemodynamic derangement is reversed by the
administration of norfloxacin, an effect that is not reproduced in cirrhotics with
ascites and normal LBP levels (119,122).
Tying this together, bacterial translocation and the secondary systemic response may
result in increased nitric oxide generation and exacerbate the pre-existing portal
hypertensive syndrome. Indeed, long-term prophylactic antibiotics in patients with
advanced CLD reduce the incidence of hepatorenal syndrome and improve survival,
independent of the prevention of infection (123).
Treatment ofportal hypertension-related renal dysfunction
Despite progress in our understanding of the mechanisms underlying the spectrum of
portal hypertension-related renal dysfunction treatment options remain limited. In the
earlier phase, management is supportive aiming to minimise patient morbidity as a
result of sodium and water retention. In later phases specific therapies are employed
to increase the effective circulating volume, renal perfusion and GFR, both directly
and via a reduction in endogenous vasoactive mediators.
The onset of type 1 hepatorenal syndrome should prompt a search for the
precipitating event. In particular, infection should be considered and there should be
a low threshold for antibiotics even in culture negative patients. Intravascular volume
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status should be assessed and corrected as appropriate. Type 2 hepatorenal syndrome
signifies end stage disease and therapy primarily focuses on management of
refractory ascites and hyponatremia. Non steroidal anti-inflammatory drugs and
RAAS antagonists are avoided because of the reno-protective effect of the
prostaglandins and angiotensin II, respectively.
• Management of sodium and water retention
In patients with clinically apparent ascites a salt restricted diet (80 to 120 mmol
sodium per day) is recommended and escalating doses of diuretics are employed
(124). Oral fluid restriction is poorly adhered to and seldom effective (124).
Large volume paracentesis is first line therapy for patients with grade 3 ascites prior
to initiation of maintenance diuretics, or may be the main stay of treatment in
refractory ascites (124). AKI is not a contraindication to paracentesis. In this setting,
large volume paracentesis with albumin administration is accompanied by an
increase in renal perfusion pressure, creatinine clearance and fractional excretion of
sodium possibly as a result of the fall in intra-abdominal pressure (125).
A meta-analysis has suggested that vasopressin 2 receptor antagonists reduce the
time to first paracentesis, and increase the serum sodium. However, the authors
concluded that the cost and modest benefit did not justify their routine clinical use
(126).
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• Therapies that increase the effective circulating volume and renal
function
Terlipressin is a vasopressin analogue with predominant vasopressin 1, although
some vasopressin 2 receptor effects (127). In patients with ascites without
hepatorenal syndrome terlipressin resulted in improved systemic haemodynamics, a
fall in circulating neurohumoral mediators, reduced renal arterial resistive index,
improved GFR and increased urinary sodium excretion (128,129). When ascites is
non refractory the increase in GFR occurs in association with an increase in filtration
fraction but no change in total renal blood flow, supporting the concept that some of
the benefit may be mediated by post glomerular vasoconstriction (129).
Randomised controlled trials have demonstrated that terlipressin reverses type 1
hepatorenal syndrome and results in a small reduction in short term mortality (130).
Nevertheless, prognosis remains poor with a reported 6-month transplant free
survival of only 13% (131,132). In type 2 hepatorenal syndrome renal failure
invariably recurs following treatment withdrawal (105). However, terlipressin may
be beneficial as a bridge to liver transplantation in this cohort (133). Noradrenaline
appears to be as effective as terlipressin for treatment of type 1 hepatorenal
syndrome, but has practical disadvantages and is generally used only in countries
where terlipressin is not available (134,135,136).
Intravenous human albumin has multiple beneficial properties in patients with portal
hypertension. In addition to the volume loading provided by less concentrated
42
preparations and increase in oncotic pressure, albumin binds endotoxin, has anti¬
inflammatory and antioxidant effects, and consequently may impact on endothelial
and cardiac dysfunction (137). Administration of albumin results in an increase in
systemic vascular resistance and improvement in cardiac function, which is not seen
following hydroxethyl starch (138,139).
In patients with ascites receiving diuretics, intravenous albumin therapy is associated
with a faster rate of ascites mobilisation and a lower probability of ascites
reaccumulation (140). Furthermore, albumin has been shown to prevent the systemic
and renal dysfunction precipitated by large volume paracentesis and spontaneous
bacterial peritonitis (138,141,142,143). In those with hepatorenal syndrome, albumin
and terlipressin resulted in reversal of renal dysfunction in 77%, compared with 25%
of patients receiving terlipressin alone (144).
• Non pharmacological therapies
Transjugular intra-hepatic portosystemic shunt (TIPSS) has a role in the management
of select patients with portal hypertension-related renal dysfunction. Although the
immediate effect is an exacerbation of the hyperdynamic state as evidenced by an
increase in cardiac output and reduction in systemic vascular resistance, longer term
the fall in portal pressure is associated with improved circulatory and neuro-humoral
derangement (145,146). Patients demonstrate a marked and sustained fall in PRA,
and plasma aldosterone and noradrenaline concentrations (147,148,149,150). In
those with refractory ascites, and in hepatorenal syndrome, TIPSS results in
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increased total renal blood flow and GFR, and less sodium retention
(147,148,149,150).
Meta-analyses of randomised controlled trials confirm that TIPSS in refractory
ascites is associated with a reduced recurrence of ascites when compared with large
volume paracentesis (151,152). In this group there may be a small but statistically
significant positive effect on survival (153). Nevertheless, patients with poor
synthetic function are unlikely to benefit and a serum bilirubin greater than 85 pmol/l
is considered an absolute contra-indication (124,153). The applicability of TIPSS
once hepatorenal syndrome develops is likely to be limited given the high prevalence
ofjaundice and encephalopathy (124).
Haemofiltration can be useful in patients with hepatorenal syndrome when there is a
reversible super-imposed component such as infection exacerbating the
haemodynamic and renal dysfunction. However, in patients with end stage disease
and type 2 hepatorenal syndrome renal replacement therapy (RRT) has no role.
Albumin dialysis with the molecular adsorbent recirculating system (MARS) has
been shown in a single small randomised controlled trial to improve renal function in
type 1 hepatorenal syndrome when compared with haemodiafiltration alone (154).
Yet, whether the effects are sustained is unknown and MARS remains an
experimental therapy only at present (124).
Liver transplantation is the definitive treatment for portal hypertension-related renal
dysfunction offering a clear survival advantage (155). Most patients with hepatorenal
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syndrome demonstrate an improvement in renal function, although post transplant
CKD is more common in this group (155). Duration of reduced GFR is important in
influencing outcomes, probably reflecting the development of secondary acute
tubular necrosis (156,157). Combined liver kidney transplantation is recommended
for all patients with stage 3 AKI or a GFR of less than 25-35 ml/min for more than 4
weeks (158). This population is considered to gain survival benefit from combined
liver kidney transplantation over liver transplantation alone, although the supporting
literature is flawed by the heterogeneity of the cohorts studied (158).
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1.3 Acute liver failure: Acute kidney Injury
ALF is a condition characterised by sudden severe liver injury that occurs in the
absence of pre-existing liver disease (159). In contrast to cirrhosis ALF is relatively
rare but usually affects younger patients, and has a high mortality rate and major
resource implications (160).
The poor prognosis of ALF not only reflects an imbalance between hepatocyte death
and regeneration, but also the development of secondary extra-hepatic complications
(161). In a recent series 30% of listed patients not surviving to liver transplantation
had intra-cranial hypertension and 95% had multi-organ failure (162). While some
advances have been made in our understanding of and treatment options for hepatic
encephalopathy in this setting, renal dysfunction has received little scientific interest.
Renal failure is common. More than 40% of patients with severe encephalopathy
have been reported to demonstrate a serum creatinine rise to greater than 400 pmol/1
(163). Furthermore, renal failure is associated with increased mortality, emphasised
by the inclusion of serum creatinine in the Kings College Hospital (KCH) prognostic
criteria (164,165). It is well recognised that AKI has implications for distant organ
function in other disease processes. Via immunomodulation AKI itself may drive
cardiac, lung, and brain, as well as liver injury (166,167,168). Therefore, it follows
that the minimisation of renal dysfunction in patients with ALF could alter the
outcome of patients not suitable for liver transplantation, and in those listed could
impact on survival to transplantation and post transplant outcomes.
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The pathophysiology of the haemodynamic and renal derangement that accompanies
ALF remains unclear. Some authors postulate that the hyperdynamic state mirrors
the circulatory dysfunction of cirrhosis with portal hypertension
(105,169,170,171,172). However, ALF has distinct clinical features and the
pathogenesis, particularly in hyperacute liver failure, may be more in keeping with
sepsis (173,174). Both infected and non infected patients with ALF have high
circulating levels of cytokines and demonstrate the systemic inflammatory response
syndrome (SIRS) (175,176). Moreover, SIRS is linked with progression of hepatic
encephalopathy and mortality (175,176,177). Interestingly, in early unpublished
work when liver biopsies of patients with and without renal failure were compared
no difference in the proportion of surviving hepatocytes could be demonstrated
(178). Significant inter-individual differences in the systemic inflammatory response
to infection and other forms of injury have been observed, which may be genetically
predetermined (179,180). Thus, it seems possible that AKI in patients with ALF is
not solely governed by the degree of liver injury but also by the systemic
inflammatory response.
The systemic circulation in acute liver failure
In ALF, patients consistently demonstrate a low systemic vascular resistance and
high cardiac output state (170,171,172,181). However, the regional haemodynamic
changes have been poorly reported and the specific vascular beds to undergo
dilatation remain unknown. Is there widespread vasodilatation as occurs in sepsis or
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localised splanchnic vasodilatation with cerebral, femoral, brachial and renal
vasoconstriction as demonstrated by patients with cirrhosis (11,12,182,183)?
• Hepatic blood flow
Rats with ALF have a marked increase in total hepatic blood flow, and an increase in
the hepatic arterial to portal venous flow and oxygen delivery ratios (184). The
increase in hepatic blood flow is not determined by cardiac output, consistent with
local regulation. This replicates observations in animal models of sepsis
(184,185,186). In humans reported data is also suggestive of an increase in total
hepatic blood flow (181,187). Contrary to findings in the rat model, hepatic arterial
resistance index measured using ultrasound Doppler is elevated and may reflect the
severity of liver failure (186,188).
Portal hypertension is a feature in most, but not all patients. The hepatic venous
pressure gradient is elevated correlating with the degree of reticulin collapse, and
there is an increase in the longitudinal diameter of the spleen (172,188). Those with
ascites have a higher hepatic venous pressure gradient than those without. In fact,
80% of patients with ascites have a hepatic venous pressure gradient greater than 12
mmHg, compared with only 30% of patients with no ascites (172). Moreover, portal
hypertension is present in the majority of patients classified as subfulminant liver
failure and infrequent in more acute disease (172).
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• Cerebral blood flow
Reported cerebral blood flow values are highly variable reflecting confounding
factors and timing of measurements (189,190,191,192). Studies assessing the
response of cerebral blood flow to altered partial pressure of carbon dioxide (C02)
and systemic arterial pressure are consistent with impaired autoregulation, favouring
a relatively vasodilated state (193,194,195). Intra-cranial pressure is critically
determined by cerebral blood flow (192,196,197).
• Peripheral blood flow
Peripheral vasodilatation is generally assumed to be present by experienced
intensivists and hepatologists (169). A surgical model of ALF in pigs has suggested
reduced hind leg vascular resistance (198,199). However, in an uncontrolled study of
patients lower extremity blood flow was said to be similar to previously reported
values for healthy volunteers, although no adjustment was made for systemic
haemodynamics (200).
• Renal blood flow
As in sepsis, but in contrast to hepatorenal syndrome, renal blood flow measurements
in animal models have yielded conflicting results (183). In one study, renal vascular
resistance was increased and renal blood flow reduced compared to controls (201).
Renal blood flow correlated with portal pressure and intra-hepatic porto-systemic
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shunting but not arterial blood pressure (202). On the other hand, in another model a
relative reduction in renal vascular resistance and no change in renal blood flow
compared to shams were demonstrated (199). Authors attributed these apparent
contradictory findings to different stages of the disease, postulating that generalised
vasodilatation occurs early and renal vasoconstriction late (199). Circulatory
resuscitation and the animal model used are additional likely influential factors.
Human studies from the 1970s and 80s demonstrated reduced renal plasma flow and
GFR in the presence of severe hepatic encephalopathy (171,203).
The spectrum of renal dysfunction in acute liver failure
The spectrum of renal dysfunction in ALF has not been well described. Wilkinson et
al observed that 50% of patients with ALF of mixed aetiology and severe
encephalopathy without renal failure had sodium retention and impaired free water
clearance (203). This group had a slightly reduced renal plasma flow and GFR
compared to patients with normal renal tubular function. Transudative ascites
occurred in one case series in 75% of patients with subfulminant liver failure, and
only 33% with fulminant liver failure (172). Exudative ascites has also been
described in viral hepatitis and occurs in the absence of portal hypertension (172).
Anecdotally, ascites is not seen in hyperacute liver failure such as following
paracetamol overdose. Once renal failure has developed 30-65% of patients have
been reported to have urinary features of acute tubular necrosis, and this has been
observed chronologically after functional renal impairment (164,204).
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Additional factors that may contribute to the development of renal dysfunction in
ALF include dehydration secondary to vomiting, infection, disseminated
intravascular coagulation and nephrotoxic drugs (178,205,206,207,208). Paracetamol
has been shown to induce renal tubular cell necrosis and apoptosis in vitro and there
are case reports of isolated renal failure following paracetamol overdose in the
absence of hepatic injury (209,210,211).
Data is currently lacking to confirm the spectrum of renal dysfunction in ALF.
However, clinical observations and Navasa's portal hypertension study suggest that
the slower onset forms of ALF may have haemodynamic and renal changes with
parallels to the circulatory changes of cirrhosis and portal hypertension (172).
However, in fulminant liver failure differing mechanisms may be key.
The systemic inflammatory response to acute liver failure
SIRS is the clinical sequelae of a massive inflammatory cascade that results from
systemic cytokine release (212). The illness that characterises SIRS is considered a
continuum of clinical and pathophysiological severity with multi-organ dysfunction
at the extreme end (212). SIRS is most commonly associated with infection, when it
is termed sepsis. However, SIRS is also present in a variety of non-infectious disease
processes such as acute pancreatitis, trauma, haemorrhagic shock, and burns (212). In
ALF patients frequently demonstrate SIRS even in the absence of clinical sepsis
(175,176). Multi-organ dysfunction is present in the majority of listed patients who
do not survive to transplantation, and SIRS has been linked with organ dysfunction
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and outcome (162,175,176,177). It therefore seems probable that SIRS plays a role in
the haemodynamic and renal complications of ALF.
• Current hypothesis for the inflammatory response to injury
It is postulated that the inflammatory response to injury is dictated by the balance of
pro- and anti-inflammatory mediators (213,214,215). At the initial site of injury or
infection macrophages, polymorphonuclear phagocytes, endothelial cells and
complement are activated with the release of pro-inflammatory mediators to destroy
damaged tissue and antigens, and to promote wound healing. Anti-inflammatory
agents attempt to down regulate this effect and prevent further tissue damage.
If the primary event is sufficiently severe the inflammatory response may spill out
into the systemic circulation to allow recruitment of neutrophils, T and B cells,
platelets and coagulation factors and, hence, limit the local injury. The inflammatory
and compensatory anti-inflammatory systemic responses occur simultaneously and
maintain homeostasis, though one process may be favoured over another. When pro-
and anti-inflammatory responses go unchecked SIRS and the compensatory anti¬
inflammatory response syndrome (CARS) may manifest, respectively. CARS is
characterised by relative immunosuppression and an increased susceptibility to
infection. The balance between SIRS and CARS determines outcome. Persistent
imbalance, termed immunological dissonance, may result in death from
overwhelming inflammation, or from failure to clear infection and to promote organ
recovery.
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• The systemic inflammatory response in sepsis and other multiple
organ dysfunction syndromes
In sepsis, bacterial products trigger the systemic inflammatory response via pattern
recognition receptors (PRRs) on innate immune cells (460,461). It is this apparently
critical initial step that promotes the release of inflammatory mediators, including
cytokines such as IL-1, IL-6, TNF-a, IL-12, interferons, chemokines, adhesion
molecules, growth factors, tissue-degrading enzymes such as metalloproteinases, and
enzymes that generate cyclooxygenase-2 and iNOS (466). Examples of PRRs include
Toll-like receptor (TLR)4 that detects lipopolysaccharide, and TLR2 that detects
multiple microbial products from bacteria, fungi and viruses (461). The importance
of the TLRs in sepsis is demonstrated by TLR deficient animal models, and genetic
polymorphisms in humans have been linked with an augmented susceptibility to
infection (461).
The systemic pro-inflammatory and anti-inflammatory response follows
simultaneously, although in early sepsis the former predominates (462). The severity
of the response is determined by multiple pathogen and host factors (462). Some
patients will experience an overwhelming rapidly fatal pro-inflammatory cascade, as
seen in meningococcal septicaemia and toxic shock syndrome (462,463). The
majority, however, progress to a protracted anti-inflammatory or immunoparesis
phase when there may be failure to clear the infection, development of secondary
infections and a high risk of death (463). At autopsy a continued septic focus is
almost universally present (464). Interestingly, despite apoptosis and necrosis being
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detected in most organs, the extent of cell death is not considered enough to explain
organ failure (465). It is speculated therefore that cell "hibernation" contributes to
organ dysfunction in these patients.
A similar syndrome occurs in patients with tissue injury without sepsis, such as in
acute pancreatitis, trauma, major haemorrhage and burns (212). Here, endogenous
products of cell injury called damage-associated molecular patterns (DAMPs) are the
TLR ligands (461,466,467). DAMPs include nucleic acids, histones, uric acid
crystals, adenosine triphosphate, cytochrome C, SI00 molecules, and high-mobility
group box-1 protein (HMGB1) (461). HMGB1 has received particular attention, and
anti-HMGBl neutralising antibody has been shown to attenuate organ damage in
experimental models of acute pancreatitis, haemorrhage, trauma and hepatic
ischaemia-reperfusion injury (468,469,470,471). The downstream events after
DAMP-TLR interaction are not identical to those initiated by pathogens in sepsis
(466). Nevertheless, the clinical picture of an initial primarily pro-inflammatory
multiorgan dysfunction followed by delayed immunosuppression is comparable
(472).
It should be mentioned that endotoxaemia is frequently observed in sepsis and other
inflammatory conditions, and correlates with the development of multiorgan failure
(473,474,475,476). The gut is especially vulnerable to ischaemia-reperfusion injury
during haemodynamic instability. The "gut hypothesis" suggests that disruption of
the mucosal barrier resulting in bacterial translocation, and the release of
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nonbacterial gut-derived factors, plays a key role in distant organ injury and
dysfunction in multiple organ dysfunction syndrome (477).
• Evidence for the systemic inflammatory response in acute liver failure
Patients with ALF demonstrate increased levels of circulating pro- (TNF-a, IL-1, IL-
6 and IL-8) and anti-inflammatory cytokines (IL-10)
(216,217,218,219,220,221,222,223). Moreover, systemic levels of the acute phase
protein c-reactive protein are increased, and al anti-trypsin and fibrinogen levels are
greater than expected (216,218,223). However, cytokine concentrations are highly
variable and correlation with mortality is less consistent (216,220,221,222,223). This
disparity may reflect diverse study populations or methodological difficulties
(216,220,221,223,224). Importantly, immunoassays detect only free, circulating
inflammatory mediators and not those bound to cells receptors (179). In addition,
cytokine release has circadian periodicity and the inflammatory response is dynamic
and of variable duration: in the majority of studies inflammatory mediators were
measured at a single time point (179).
Sheron et al performed serial measurements of IL-6 and TNF in a group comprised
mainly of paracetamol-induced liver failure and commented that no underlying trend
was demonstrated over time (221). Frequency of measurements was not documented
and data not shown. Nagaki et al demonstrated serial TNF-a, IL-6 and IL-10 levels in
a small and variable number of patients with predominantly viral-induced liver injury
treated with plasma exchange (220). Again no relationship was seen.
55
TNF-a has two specific receptors that may be shed following binding and circulate
as soluble ligand-receptor complexes (225). Soluble TNF receptors I (p55) and II
(p75) have a far longer half-life than free TNF-a and, consequently, may be more
sensitive indicators of the inflammatory response (226). In ALF soluble TNF
receptor I and II levels are increased compared to healthy controls, and elevated
soluble TNF receptor I levels correlate with non survival (217,219,220). The soluble
TNF receptors, by competing with cell surface receptors, may play an anti¬
inflammatory role or, alternatively, may act as a 'slow release reservoir' and
augment the effects of TNF-a (227). Keane et al observed reduced TNF-a
neutralization capacity of plasma from patients with ALF in vitro despite increased
levels of soluble TNF receptors (217).
The ratio of pro- to anti-inflammatory mediators may be more relevant than absolute
values. Sekiyama et al found that the ratio of IL-1 receptor antagonist to IL-ip at
time of hospitalisation was threefold lower in non survivors than in survivors (216).
• Evidence for immune cell dysfunction in acute liver failure
A hallmark of CARS is immune cell dysfunction (213,214). In addition to an
increase in circulating anti-inflammatory mediators, T-cell anergy and monocyte
deactivation has been described in sepsis, burns and trauma (214,224,228). T-cell, B-
cell and dendritic cell apoptosis is seen in sepsis and acute pancreatitis, which
induces further anergy and anti-inflammatory cytokine release (214,229).
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In ALF research has focussed on monocyte dysfunction. Circulating monocytes in
vitro from patients with ALF demonstrate similar spontaneous but reduced
lipopolysaccharide stimulated IL-6 production when compared with controls (218).
TNF production has been reported to be normal or increased depending on aetiology
and almost certainly timing (218,230,231). However, in paracetamol-induced liver
failure both reduced spontaneous and stimulated production of TNF is associated
with poor outcome (218,230). An expansion of IL-10 producing monocytes and an
increase in IL-10 secretion following endotoxin stimulation supports the concept of a
shift toward anti-inflammatory monocyte activity (215,232,233). The HLA-DR
molecule is a key antigen-presenting surface molecule and reduced HLA-DR
expression by monocytes is a feature of sepsis, predicting poor outcome (234).
Similarly, ALF patients demonstrate a decrease in HLA-DR expression that is more
marked in non-survivors (224).
Neutrophil dysfunction consisting of reduced production of superoxide and hydrogen
peroxide, and impaired phagocytosis has been described (235,236). The
administration of granulocyte colony-stimulating factor (G-CSF) in vitro and in vivo,
which is known to induce neutrophil proliferation, maturation and increase
superoxide production, improved neutrophil phagocytosis and killing (236,237).
Endogenous G-CSF levels demonstrate no association with mortality (238).
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Source of the systemic inflammatory response to acute liver failure
The trigger for the systemic inflammatory response to ALF remains unclear.
However, the observation that hepatectomy results in haemodynamic stabilisation
and reduced intracranial pressure is in agreement with the concept of the liver as the
driving force (478). 'Spill over' of inflammatory mediators from the necrotic liver
may occur, or necrotic cells may enter the circulation and cause immune stimulation
(213,214).
Echoing other non-infectious inflammatory conditions, there is a growing body of
evidence to support a critical role for DAMPs. Levels of HMGB1 are increased in
the circulation of animals and humans with acute liver injury (479,480,481,482).
Moreover, anti-HMGBl has been shown to attenuate liver damage, reduce plasma
cytokines levels and improve survival in D galactosamine induced-ALF in rats (479).
Of note, although HMGB1 is initially passively secreted by cells undergoing
necrosis, it is also later released as an inflammatory mediator by monocytes and
macrophages in a hyper-acetylated form (482). Circulating acetylated HMGB1
levels, representing activation of the immune response, have been found to be
elevated in patients who died or were transplanted, but not in spontaneous survivors
of ALF (482). Other products of cell death that have been demonstrated in the
systemic circulation in ALF include DNA fragments, mitochondrial products,
keratin-18 and nucleosomes (480,481,483).
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Several DAMP receptors that are known to be involved in innate immune cell
activation have been examined as potential stimuli of the systemic inflammatory
response to ALF. TLR4 expression is increased in the liver and serum monocytes in
experimental models, and TLR4 knockout/antagonism is accompanied by less liver
injury, a delayed onset of hepatic encephalopathy, less lung and renal injury, and
superior survival (484,485,486,487). Similarly, blockage of TLR9 and formyl
peptide receptor 1 (FPR1) results in an attenuated systemic inflammatory response,
and protects against liver and distant organ damage (489). In humans with acute liver
injury, the PRR pentraxin 3 is elevated in plasma, and the liver has been confirmed
as a potential source (488). Furthermore, pentraxin 3 levels correlate with circulating
cytokine levels, organ dysfunction including brain and kidney, and outcome (488).
The "gut hypothesis" is also likely applicable. Endotoxaemia certainly is common,
perhaps in part reflecting impaired hepatic clearance, and has been correlated with
worse survival (205,490). Inhibition of endotoxin in a surgical model of ALF blunted
the rise in circulating TNF and IL-6 (239).
Finally, impaired metabolism of cytokines is probably important. Inadequate hepatic
metabolism of inflammatory mediators has been suggested as a factor in patients
with hepatic insufficiency (179). The kidneys remove both pro- and anti¬
inflammatory cytokines possibly explaining some of the association between renal
dysfunction and death (240).
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• Genetic predisposition to the systemic inflammatory response to acute
liver failure
There are significant inter-individual differences in the systemic inflammatory
response to infection and other forms of injury, which may be genetically
predetermined (179,180). The TNF genotype B1B1 has been negatively associated
with the development of severe encephalopathy in paracetamol-induced liver failure
(241). Large scale studies are required to examine the relationship between genetic
polymorphisms and outcome measures.
The role of the systemic response to acute liver failure in the aetio-
pathogenesis of acute kidney injury
Given the overwhelming evidence of a systemic inflammatory response to ALF it
seems probable that this plays an important and potentially critical role in the
pathogenesis of the circulatory and renal dysfunction in these patients.
In sepsis, the haemodynamic derangement is primarily attributed to endothelial
dysfunction (213). Inflammatory cytokines induce endothelial cell activation with a
loss of vascular integrity and a shift towards a pro-thrombotic, pro-inflammatory
state. Secondary upregulation of nitric oxide via iNOS, prostaglandins via COX-2,
and endothelins occurs mainly in the underlying smooth muscle. The pattern of these
vasoactive mediators determines vascular response and, thus, organ dysfunction
(242). In ALF, serum IL-6 levels correlate with low mean arterial pressure, low
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systemic vascular resistance and oxygen consumption (221). Nitric oxide and ET-1
and -3 levels are elevated (243,244). Attenuation of the systemic inflammatory
response to ALF in rats prevented the fall in mean arterial pressure (239). Moreover,
the therapeutic application of hypothermia in patients is accompanied by an
improvement in systemic haemodynamic measurements (197,245).
The pathogenesis of AKI in sepsis involves both haemodynamic and non
haemodynamic factors (183). Firstly, there is a reduced glomerular filtration pressure
resulting in a fall in GFR. Whether this reflects reduced renal blood flow or
intrarenal haemodynamic alterations remains unknown. It has been postulated that
there may be relative efferent arteriole vasodilatation with preserved or even
increased total renal blood flow (183,206). Secondly, there is evidence of direct renal
tubular cell death. Post-mortem kidney biopsies from patients who died of septic
shock demonstrate as well as acute tubular necrosis an intense leukocyte infiltration
of glomeruli and interstitial capillaries, and the presence of tubular cell apoptosis
(246). Endotoxin, either directly or via systemic cytokine release, may induce renal
tubule and glomerular endothelial apoptosis in experimental models (247). TNF-a
especially appears to be an important player in the renal injury of sepsis
(183,206,247). Supporting the hypothesis that AKI in ALF shares similar
mechanisms the only study to examine circulating inflammatory mediators and their
association with renal dysfunction found a positive correlation between plasma TNF,
and soluble TNF receptors, and serum creatinine (221).
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Management of acute kidney injury in acute liver failure
The management of AKI in ALF is supportive. RRT is often instituted early and in
the absence of oliguria based on the premise that the removal of inflammatory and
other mediators may act to stabilise circulatory dysfunction and minimise organ
injury (169,247). Continuous venovenous haemodiafiltration is the method of choice
to avoid haemodynamic instability and rapid electrolyte and fluid shifts, which may
increase the risk of cerebral oedema (169). Controlled hypothermia may also be
beneficial (197). In contrast to cirrhotic liver disease, terlipressin worsens cerebral
hyperaemia and intracranial hypertension and should be avoided (248).
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1.4 Renal dysfunction after liver transplantation
Liver transplantation is the definitive treatment for portal hypertension-related renal
dysfunction in cirrhosis, and AKI in ALF. Yet, liver transplantation itself is
complicated by renal disease. During the peri-operative period approximately one
third of all liver transplant recipients develop AKI, and one quarter require RRT
(249,250). Thereafter, chronic kidney dysfunction is common with a 5-year
cumulative incidence of stage 4/5 CKD as high as 18% (8). AKI and CKD are major
causes of morbidity and mortality in liver transplant recipients.
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Peri-operative acute kidney injury
AKI immediately after liver transplantation is multi-factorial in origin, although pre¬
existing renal dysfunction plays an important role. CKD is a consistent risk factor for
AKI in other settings, possibly as a result of haemodynamic dysfunction and altered
renal autoregulation, and an increased pre-disposition to renal injury (251). Liver
transplant patients demonstrate a spectrum of renal dysfunction. In liver
transplantation for cirrhosis the overall reported prevalence of ascites and
hyponatraemia is 80% and 30%, respectively (252,253). The frequency of intrinsic
renal disease in less clear, although many patients have liver disease that may cause
co-existent renal injury, and diabetes mellitus and hypertension are common (8). In
one series of unselected patients who underwent renal biopsies at the time of
transplantation universal glomerular abnormalities were observed (254). Several
studies have confirmed that an increased pre transplant serum creatinine is a
predictor of post operative AKI (249,255,256).
Intra-operative events also play a key role. The type of transplant surgery is relevant
as the piggyback technique, which preserves venous continuity, has been associated
with a reduced incidence of acute renal dysfunction (257,258). Intra-operative
hypotension and need for inotropes are common predictors of AKI (249,250). The
greatest intra-operative haemodynamic derangement typically occurs at the time of
graft reperfusion and patients with post reperfusion syndrome, the extreme
manifestation, have a marked increase in the frequency of severe renal impairment
(259). Similarly, blood transfusion requirements have been related to AKI in many
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observational studies possibly reflecting the severity of surgical haemorrhage
(250,260). Alternatively, excessive transfusion may be causal and increase blood
losses. When a low central venous pressure is maintained during the pre-anhepatic
phase via the avoidance of plasma transfusion and the use of intra-operative
phlebotomy less renal dysfunction is observed (261).
Post-operatively, intra-abdominal hypertension demonstrates a relationship with
kidney dysfunction, possibly as a result of reduced renal blood flow, intra-renal
redistribution of blood, or renal congestion (260,262). The administration of a
calcineurin inhibitor (CNI) further compromises renal perfusion and function.
Tacrolimus and cyclosporine cause acute, dose-dependent, renal vasoconstriction and
a fall in GFR (263). Such effects have been attributed to an imbalance between
vasoactive substances including endothelin and prostaglandins that are also
implicated in the pathogenesis of hepatorenal syndrome (4,263). It has therefore been
postulated that the greater haemodynamic and neuro-humoral derangement of
cirrhotic patients may result in an increased susceptibility to the nephrotoxic effects
(264). Delayed and lower dose peri-operative tacrolimus has been demonstrated to be
beneficial for short term post transplant renal function (265).
• Clinical relevance of acute kidney injury after liver transplantation
The well recognised initial clinical consequences of AKI are electrolyte and acid
base disturbance, and fluid overload. Liver transplant recipients with AKI have a
prolonged intensive care stay and hospitalisation. Moreover, AKI is an independent
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risk factor for mortality in Critical Care (266). The direct and indirect financial
burden ofAKI is significant (267).
Beyond the peri-operative period, AKI has important ramifications for renal function
(251). In non transplant populations, such as patients undergoing major vascular
surgery, the occurrence of perioperative AKI is associated with an increased risk of
CKD (268). Furthermore, patients requiring dialysis for AKI who are dialysis-free at
the time of hospital discharge are 3 times more likely to develop end-stage renal
failure (269). Similar observations have been made in liver transplant recipients (8).
Animal models have confirmed that AKI can cause permanent structural damage,
with progressive tubulo-interstitial fibrosis and lasting implications for renal function
(270). Increasing severity of AKI is associated with greater long term mortality in a
graduated manner (271). Therefore, in a time of increasing graft longevity
necessitating a shift of focus to nongraft related complications, AKI is likely a
potentially modifiable factor involved in late post transplant morbidity and mortality.
Chronic kidney disease after liver transplantation
The development of CKD after liver transplantation can be predicted by multiple
patient factors. Pre-transplant renal function is consistently associated with renal
outcome. With increasing severity of renal impairment there is an increased risk of
CKD (8). Moreover, as previously discussed, the duration of renal dysfunction is
important probably reflecting the onset of secondary acute tubular necrosis in
hepatorenal syndrome or intrinsic kidney disease (156,157). The vast majority of
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patients requiring RRT prior to transplantation for less than 30 days are removed
from dialysis post transplant, compared to only 10% of those requiring it for more
than 3 months (272).
Other pre transplant risk factors include older age, female gender, white ethnicity,
hepatitis C and diabetes mellitus (8,273). Confirming the multi-factorial nature of
CKD after liver transplantation Pilleboute found vascular lesions in 65% of renal
biopsies performed a mean of 5 years post surgery, tubulointerstitial lesions
attributed to hydroxyethyl starch in 61%, thrombotic microangiopathy likely
secondary to interferon alpha therapy for hepatitis C in 50%, CNI toxicity in 46%
and diabetic lesions in 34%. Two patients out of 26 were diagnosed with IgA
nephropathy. Lesions belonging to multiple categories were present in most cases
(274).
On the whole liver transplant recipients demonstrate a steep decline in GFR during
the first post operative weeks with relative stabilisation thereafter, and 6 and 12
month post transplant GFR are invariable predictors of chronic renal dysfunction
(8,264,275,276,277,278). Such a dramatic loss of renal function is attributed to peri¬
operative AKI and the CNIs (263,264,279,280). In addition to the acute
haemodynamic consequences of cyclosporine and tacrolimus the CNIs cause chronic
renal damage with tubulo-interstitial fibrosis, an effect that is considered dose-
independent (263). Patients receiving cyclosporine in the non transplant setting for
autoimmune uveitis demonstrate an almost identical change in renal function over
time (281). Despite no change in renal plasma flow the uveitis cohort had a
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progressive decline in GFR with irreversible glomerular and tubulointerstitial lesions
(281). Not unsurprisingly, in liver transplant patients the CNI troughs levels do not
generally demonstrate a relationship with CKD, although a higher 1 month
cyclosporine trough level and a greater daily and cumulative dosage were associated
with chronic renal dysfunction in one study (277). Cyclosporine is associated with a
greater risk of CKD than tacrolimus for unclear reasons (8,263).
• Clinical relevance of chronic kidney disease after liver transplantation
Liver transplant recipients with CKD have increased mortality. Stage 4/5 disease has
been reported to have a 5 times relative risk of death (8). The association of CKD
with cardiovascular mortality is well established (282,283). More recently, a large
observational study in the non transplant setting has confirmed increased non
cardiovascular death relating to pulmonary disease, cancer and infection (284).
However, it is not only mortality that is a relevant measure of worse outcome in
CKD. Patients with chronic renal dysfunction also have much greater morbidity,
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• Prevention of chronic kidney disease after liver transplantation
At present the management of CKD in the liver transplant population is focussed on
CNI minimising strategies. Evidence to support this approach once renal dysfunction
is present remains limited and is hampered by heterogeneity between trials with
regards type of CNI, trough targets, baseline renal function and time since
transplantation, not to mention small patient numbers (Tables 1.2 and 1.3).
Cyclosporine conversion to tacrolimus was associated with no benefit, but no
deterioration in renal function in a single uncontrolled study (286). On the other
hand, low dose or elimination of CNI with mycophenolate mofetil overall appears to
result in some improvement in renal function, and is well tolerated (Table 1.2). The
most recent and only negative trial was hampered by significantly different GFRs at
baseline between the treatment and control arms (290). An alternative approach has
been elimination of CNI with sirolimus (Table 1.3). Yet, Abdelmalek's large study
demonstrated no difference in change in renal function 12 months after conversion,
and the sirolimus patients had higher rates of biopsy-proven acute rejection and
adverse events (294).
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In view of the persistence of significant renal dysfunction when CNI minimisation is
adopted, interest has shifted towards prevention of renal injury. Four large
randomised controlled trials have been published in the last 10 years comparing
standard dose with delayed and/or low dose tacrolimus from the immediate peri¬
operative period (Table 1.4). All of these studies have failed to maintain adequately
low CNI trough levels in the treatment arms. Nevertheless, some conclusions can be
drawn. Firstly, delayed introduction followed by standard dose tacrolimus with
daclizumab cover for the initial post-operative days probably offers no advantage
over immediate administration (265,295,296). Although a statistically significant
difference was observed in the ReSpECT trial baseline GFR was slightly less in the
delayed CNI group (295). Secondly, and encouragingly, long term lower dose
tacrolimus from day 1 post transplant does result in less renal function loss (297).
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A further 2 trials have examined the benefits of CNI minimisation from 4-12 weeks
after transplantation, via the addition of a mammalian target of rapamycin (mTOR)
inhibitor (Table 1.5). Tacrolimus elimination with an mTOR inhibitor alone was
associated with an increased rate of acute cellular rejection that caused premature
termination of the treatment arm (298). However, patients receiving a combination of
mTOR inhibitor with reduced dose CNI or mycophenolate mofetil had superior renal
function by 12-months post transplant and acceptable rejection rates (298,452).
Subsequently published followup data confirms maintained renal benefit to 2-years
after transplantation (453). It should be noted that in both the mTOR trials, in
contrast to CNI minimisation with mycophenolate mofetil, patients were more likely
to discontinue the study drug because of intolerable adverse effects (297,298,452).
This is despite a relatively low dose of sirolimus compared to other studies (Table
1.3) (452).
To summarise, CNI minimisation from early post liver transplantation is
accompanied by less renal function loss. Nevertheless, 25% of patients still develop
CKD (297). Once renal dysfunction occurs it is frequently irreversible. Thus,
prevention of post transplant CKD should be a key focus of care, and additional
strategies are necessary.
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1.5 Conclusion
Renal dysfunction is common and continues to have devastating consequences in
patients with all aspects of liver disease. In cirrhosis and ALF, management remains
primarily supportive and does not impact on prognosis. Only liver transplantation
offers survival benefit, but is a finite resource. Moreover, liver transplantation itself
is complicated by both AKI and CKD.
To allow Physicians to help their patients, scientific progress is desperately needed in
our understanding of the underlying mechanisms of, and risk factors for, renal
dysfunction in liver disease. Only by developing knowledge will preventative
strategies and treatment options become available that impact ofpatient outcome.
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1.6 Aims and hypotheses
The principle aim of this thesis is to derive a better understanding of renal
dysfunction in liver disease. By doing so, my intention is to move one step closer to
improving patient morbidity and mortality in this setting.
The following hypotheses will be addressed:
• In patients with cirrhosis increased activity of endogenous ET-1 is involved
in the pathophysiology of renal dysfunction through renal vasoconstriction,
and ET-1 antagonism will reverse these effects (Chapter 2).
• In ALF the systemic inflammatory response syndrome is associated with the
development of AKI (Chapter 3).
• Estimated GFR is superior to serum creatinine in predicting prognosis in
patients on the liver transplant waiting list (Chapter 4).
• Given potentially different pathophysiological mechanisms underlying renal
dysfunction, patients transplanted for ALF have comparatively better long
term renal outcomes than patients transplanted for CLD (Chapter 5).
• Modifiable patient factors are associated with the long term decline in renal
function after liver transplantation (Chapter 6).
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CHAPTER 2
Renal dysfunction in cirrhosis: A randomised controlled physiological
study of endothelin-1 receptor antagonism in patients with advanced
cirrhosis and refractory ascites
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2.1 Introduction
Patients with portal hypertension have a spectrum of renal dysfunction that first
becomes evident in early compensated cirrhosis, and evolves in parallel with
advancing neuro-humoral and circulatory derangement (4). In pre-ascitic cirrhotics
there is impaired renal sodium metabolism, with reduced natruiresis in the standing
position and following a saline load (61,62). Later, sodium excretion is reduced
further, there is a positive sodium balance, and ascites develops (9,64). Finally, a
progressive fall in total renal blood flow is eventually accompanied by a fall in GFR
when intra-renal compensatory mechanisms fail (88,102). Renal dysfunction is an
important prognostic marker in this setting; ascites, low urinary sodium,
hyponatraemia and hepatorenal syndrome are consistent predictors of short term
mortality in cirrhotic patients (64,299,300).
Endothelin-1 physiology
ET-1 is a potent vasoactive 21 amino acid peptide that has been implicated in the
pathophysiology of the renal dysfunction of portal hypertension (301). The
endothelin family comprises three isopeptides that are predicted by three separate
genes and have distinct tissue distributions, with ET-1 having the principle
cardiovascular effects (302,303,304). ET-1 is produced mainly by the endothelium.
Other sources of ET-1 include vascular smooth muscle cells, leucocytes,
cardiomyocytes, fibroblasts, activated hepatic stellate cells and cholangiocytes, and
mesangial cells, podocytes and tubular epithelial cells of the kidney (304,305,306).
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The gene product, prepro-ET-1, is cleaved to the precursor molecule, big ET-1, from
which ET-1 is generated via the action of endothelin-converting enzyme (ECE)
(301,302). Gene transcription of ET-1 is increased by several factors relevant to
CLD, including low sheer stress, angiotensin II, adrenaline and inflammatory
cytokines, and reduced by nitric oxide, prostaglandins and natriuretic peptides (304).
ET-1 acts in an autocrine and paracrine manner on 2 distinct G-protein-coupled-
receptor subtypes, Endothelin-A (ET-A) and Endothelin-B (ET-B) (307,308,309).
The binding of ET-1 to ET-A, and to a lesser extent ET-B, receptors of the vascular
smooth muscle mediates vasoconstriction, whilst in the endothelium ET-1 via ET-B
receptors mediates vasodilatation through the release of nitric oxide and prostacyclin
(304). Vascular ET-B receptors also act as an important route of clearance of ET-1
from the circulation (310,311,312). Hence, ET-B receptor antagonism is associated
with an elevated plasma concentration of ET-1, which may in turn increase ET-A
receptor activation (311,312).
Systemic haemodynamic effects of endothelin-1
In healthy humans, brachial artery infusion of phosphoramidon, an inhibitor of ECE,
and BQ-123, a selective ET-A receptor antagonist, causes local vasodilatation
supporting a role for ET-1 in the maintenance of basal vascular tone (313). Systemic
ET-1 blockade is associated a reduction in peripheral vascular resistance and blood
pressure (314). Such effects are similar following BQ-123 infusion and combined
ET-A and B receptor antagonism confirming that the physiological consequence of
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ET-1 is predominantly mediated via the ET-A receptor (315). ET-B receptor
antagonism with BQ-788 causes an increase in systemic vascular resistance (315).
Therefore, the overall effect of ET-B receptor activation on the circulation in health
appears to be that of vasodilatation (315).
Renal haemodynamic effects of endothelin-1
The kidney has a high concentration of ET-1 and contains abundant ET-1 receptors
(316,317,318). In humans, the ET-B receptor subtype predominates with an ET-B to
ET-A ratio of 2:1 (319). ET-A receptors are localised to vascular smooth muscle of
the arcuate arteries, arterioles, glomeruli and vasa recta (319). ET-B receptors are
found on the endothelium of large arteries at the cortio-medullary junction and
microvasculature, plus the epithelial cells lining the renal tubule especially the
collecting duct (319). Via these receptors ET-1 modulates renal blood flow and intra-
renal haemodynamics, and tubular function, and has pro-inflammatory and pro-
fibrotic effects.
Exogenous ET-1 results in an increase in renal vascular resistance, fall in total renal
blood flow and reduction in GFR (312,320,321). These changes are abolished by co-
infusion of BQ-123, thereby implying that renal vasoconstriction is largely mediated
by the ET-A receptor subtype (321). The renal microcirculatory effects in humans
are not currently known. Animal models suggest that ET-1 administration is
associated with arteriole vasoconstriction, which is more pronounced in the afferent
than efferent arterioles. Afferent vasoconstriction is mediated by both ET-A and ET-
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B receptor activation. In the efferent arteriole ET-B receptors are more prominent,
but their overall contribution to resting tone is less clear and may be model specific.
Within the glomerulus itself, ET-1 may influence the GFR through mesangial cell
contraction via ET-A, and potentially by cytoskeletal remodelling in podocytes
(322).
Human antagonist studies do not support a role for ET-A receptors in the
maintenance of renal vascular tone in health. B-123 infusion has no effect on renal
haemodynamics or GFR (312,315,321,323,324,325,326). Combined ET-A and ET-B
receptor antagonism with BQ-123 and BQ-788 similarly did not alter total renal
blood flow or renal vascular resistance, although the administration of the mixed ET-
A/B receptor antagonist SB 209670 precipitated an increase in total renal plasma
flow (315,327). BQ-788 infusion alone is associated with renal vasoconstriction and
a fall in total renal blood flow suggesting that ET-1 via ET-B receptor mediated
vasodilatation is relevant to the maintenance of renal vascular tone (315).
Renal tubular effects of endothelin-1
ET-1 is also important in modulating sodium and water reabsorption within the renal
tubule. Although the predominant effects are in the collecting duct, ET-1 is
expressed and has actions in other regions. In the proximal tubule the effects appear
to be mainly via the ET-B receptor, which both stimulates and inhibits sodium
transport processes depending on ET-1 concentrations and degree of acidosis. In the
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thick ascending limb only ET-B receptors have been detected and their activation
results in reduced sodium and chloride reuptake (322).
The collecting duct, and in particular the inner medullary collecting duct, is the main
site of ET-1 synthesis in the kidney (328,329). Here, production is increased in
response to extra-cellular fluid volume expansion, as well as other factors such as
local hypoxia, IL-1 (3 and transforming growth factor-(3, and reduced by lower pH and
interferon-y (322). Moreover, the collecting duct is the major site of ET-1 receptor
expression with the ET-B receptor being the principal isoform (318,330,331,332). In
vitro and knock out murine models provide strong evidence that ET-1 is an important
inhibitor of collecting duct sodium reabsorption (333,334,335,336). ET-1 inhibits
sodium uptake via the epithelial sodium channel, involving both ET-B receptor
mediated mitogen activated-protein kinase (MAPK) activation and nitric oxide (322).
In addition, ET-B receptor activation inhibits collecting duct water reabsorption
through inhibition of arginine vasopressin-stimulated osmotic water permeability
(322). The role of the ET-A receptor in sodium and water transport in the collecting
duct remains unclear.
Despite well documented ET-1 induced natriuresis in experimental models, selective
ET-A, selective ET-B and combined ET-A/B receptor antagonism in healthy
volunteers has not been associated with any change in urinary sodium excretion or
fractional excretion (315,337). However, in the setting of angiotensin-converting
enzyme inhibition, BQ-123 infusion resulted in an ET-B receptor dependent
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natriuresis that was mediated by nitric oxide and, to a lesser degree, prostanoids
(325).
The role of endothelin-1 in the pathophysiology of renal disease
There is compelling animal data supporting a role for ET-1 in the pathophysiology of
acute and chronic renal disease (338,339). In humans with CKD, acute selective ET-
A receptor antagonism was associated with renal vasodilatation with an increase in
total renal blood flow, although no change in GFR. The fall in effective filtration
fraction (EFF) and proteinuria suggested a greater effect on efferent arteriole tone
and reduced glomerular pressure. Selective ET-B receptor antagonism resulted in
renovasoconstriction and decreased GFR, but combined ET-1 receptor blockade had
no renal haemodynamic effects. No changes in urinary sodium excretion or fractional
excretion were observed (315). In another study of patients with non diabetic
proteinuric CKD, ET-A receptor inhibition produced a marked natruiresis (340).
Longer term, selective ET-A receptor antagonism has been found to reduce the EFF,
GFR and proteinuria in non diabetic CKD, and to reduce proteinuria in diabetics
(340,341,342). Finally, in patients with chronic renal insufficiency undergoing
cardiac angiography combined ET-1 blockade resulted in an increased incidence of
radiocontrast nephrotoxicity supporting a protective effect (343).
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Evidence supporting a role for endothelin-1 in the pathophysiology of portal
hypertension
Patients with cirrhosis demonstrate elevated plasma ET-1 levels, and concentrations
increase with rising Child Pugh score, and are higher in patients with ascites
compared with compensated disease, and in patients with hepatorenal syndrome
compared with those with maintained renal function (344,345). The parallel increase
in plasma big ET-1 concentration is consistent with an increase in ET-1 synthesis
(346). Greater hepatosplanchnic release has been observed suggesting that the liver is
a primary source (347). Moreover, ET-1 expression is markedly enhanced in human
cirrhotic liver tissue with activated hepatic stellate cells being identified as the major
site of synthesis (348). Other apparent important sources of increased ET-1
production in these patients are the spleen and kidney (346,349). Reduced hepatic
clearance of ET-1 also contributes (350). Splanchnic vasodilatation, regional
hypoxia, increased circulating vasoactive mediators and endotoxin are likely
mechanisms underlying the increased ET-1 release (304,351).
ET-1 has been implicated in the pathophysiology of portal hypertension. In cirrhosis,
activated hepatic stellate cells, which are known to regulate sinusoidal resistance to
blood flow, demonstrate increased expression of ET-A and ET-B receptors
(352,353). ET-1 stimulates contraction of stellate cells and the hepatic sinusoid, and
has been shown to increase intrahepatic portal vascular resistance (354,355,356,357).
ET-A receptor antagonism and ET-B receptor antagonism in cirrhotic rats resulted in
sinusoidal dilatation and reduced portal pressure, and sinusoidal constriction and
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increased portal pressure, respectively (358). Combined antagonism reduced portal
pressure (358). Therefore, it is postulated that the hepato-splanchnic production of
ET-1 contributes to portal hypertension by mediating intrahepatic stellate cell
contraction and an increase in hepatic sinusoidal tone (358).
The systemic infusion of ET-A, ET-B and non selective ET-1 receptor antagonists in
humans has not been demonstrated to alter the hepatic venous pressure gradient,
perhaps as a consequence of competing effects on intrahepatic, collateral and
splanchnic circulations (359,360). Nevertheless, forearm haemodynamic studies do
support the presence of an activated ET-1 system with a greater contribution to the
maintenance of peripheral basal vascular tone via the ET-A receptor in preascitic
cirrhosis than healthy controls (361,362). Interestingly, Vaughan et al found that in
patients with ascites local ET-1 infusion was associated with forearm vasodilatation
rather than constriction, raising the possibility that the ET-B receptor plays a more
prominent role in these patients (363). Yet, there were significant methodological
problems with the study that limit its interpretation (364).
Evidence supporting a role for endothelin-1 in the pathophysiology of portal
hypertension-related renal dysfunction
Given the described observations in non cirrhotic experimental and clinical studies,
and the evidence for increased activity in portal hypertension, ET-1 is an attractive
candidate to explain the altered renal haemodynamic and tubular function of portal
hypertensive-related renal dysfunction.
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In support of this hypothesis, plasma ET-1 levels correlate negatively with creatinine
clearance and effective renal plasma flow (ERPF) (345,365). Furthermore, an acute
rise in portal pressure by TIPSS occlusion is accompanied by an acute increase in
arterial ET-1 concentration and renal ET-1 production, and a dramatic reduction in
renal plasma flow (366). Therefore, ET-1 may be a mediator of the hepato-renal
reflex. In patients with hepatorenal syndrome, liver transplantation is associated with
a rapid decrease in ET-1 concentrations and subsequent improvement in renal
function, suggesting a causal role (367).
There are currently no ideal animal models of portal hypertensive renal dysfunction.
Galactosamine-induced hepatoxicity resembles acute hepatic failure and is associated
with functional renal impairment. In this model, ET-A receptor expression was
increased in the renal cortex, and a non selective ET-1 receptor antagonist prevented
the development of renal failure in the absence of any effect on total renal blood flow
or renal vascular resistance (201). Nevertheless, the results may not be applicable to
hepatorenal syndrome because the renal dysfunction of acute liver failure and portal-
hypertensive renal dysfunction may not be comparable. Rats with carbon-
tetrachloride-induced cirrhosis have upregulation of ET-B receptors in the inner-
medullary collecting duct, and combined ET-1 receptor blockade resulted in
decreased water excretion that was not observed in controls (368). However, the
renal dysfunction in this setting likely represents direct drug-induced nephrotoxicity
(369). Most recently, in a non cirrhotic model of portal hypertension that was
associated with a reduction in renal perfusion pressure, no change in ET-1 receptor
expression was noted (370).
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In patients, there are no placebo controlled studies examining the role of ET-1 in the
pathophysiology of portal hypertensive renal dysfunction. Soper observed in 3
patients with alcoholic cirrhosis, and reduced renal plasma flow and GFR, an
increase in both parameters following BQ-123 infusion (371). On the other hand,
combined ET-A and ET-B receptor antagonism in 5 patients with cirrhosis and type
2 hepatorenal syndrome was not accompanied by any improvement in renal function.
Instead, 4 patients demonstrated a rise in serum creatinine and there was a
statistically significant fall in 24-hour urinary volume (372). No conclusions can be
drawn from these observational studies and the question remains whether ET-1




We hypothesised that the increased activity of endogenous ET-1 is involved in the
pathophysiology of renal dysfunction in patients with advanced liver disease through
renal vasoconstriction, and that ET-1 antagonism would reverse these effects,
increase renal blood flow and improve renal function. The aim of this study was to
examine the systemic haemodynamic and renal effects of ET-1 antagonism in
patients with advanced cirrhosis and refractory ascites and/or hepatorenal syndrome.
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2.3 Methods
This was a randomised, double-blind, placebo-controlled crossover study. Five
patients with advanced cirrhosis and refractory ascites were recruited. Four patients
attended for 3 separate study periods: (A) selective ETA receptor antagonism; (B)
combined ETA/B receptor antagonism; (C) saline placebo. The fifth patient
withdrew after participating in 1 study period only.
The studies were performed in a quiet temperature-controlled room with the subject
recumbent throughout in the Royal Infirmary of Edinburgh Clinical Research
Facility between April 2007 and October 2008. The study protocol was approved by
the Local Research Ethics Committee and all subjects provided written informed
consent. The investigations conformed to the principles outlined in the Declaration of
Helsinki.
Subjects
Patients had advanced cirrhosis and refractory ascites as defined by the International
Ascites Club (4). Suitable inpatients and outpatients were recruited from the Centre
for Liver and Digestive Disorders at The Royal Infirmary of Edinburgh. The
exclusion criteria were as follows: below the age of consent or mentally or legally
incapacitated; enrolled in another trial; malignancy; TIPSS in situ; pre-existing renal
disease other than hepatorenal syndrome; significant comorbidity (diabetes mellitus,
heart or lung disease, peripheral vascular disease, musculoskeletal or other condition
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that prevents the subject from lying supine for prolonged time periods); taking
vasoactive medications; on anti-coagulant medications; prothrombin >17 seconds
and/or platelets <50 xl09/l; active sepsis or other SIRS such as acute alcoholic
hepatitis. Prior to the study patients had underwent full clinical assessment including
blood and urine chemistry and renal ultrasonnography to exclude intrinsic kidney
disease.
Healthy control data was provided by Goddard et al from a study of ET receptor
antagonism in health and CKD (315). In this study, with an identical study protocol
performed by grant co-applicants and members of the present study group, 8 healthy
volunteers were recruited. The exclusion criteria included the use of any medications
within the preceding 2 weeks.
Primary outcome measures
The primary outcome measures were effective renal blood flow (ERBF) and GFR
measured by standard para-aminohippurate sodium (PAH) and inulin clearance
techniques, respectively.
Drugs
BQ-123 (Clinalfa AG and American Peptide Company, see Limitations Chapter), a
selective ETA receptor antagonist (373), was infused at 100 nmol/1 for 15 minutes
and at 1000 nmol/1 for 15 minutes 90 minutes later. These doses were selected from a
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previous study as having a threshold and maximum haemodynamic effect in healthy
controls (374). BQ-788 (Clinalfa AG and American Peptide Company, see
Limitations Chapter), a selective ETB receptor antagonist (375), was infused at 30
and 300 nmol/1 for 15 minutes, doses shown to be haemodynamically active in a
previous systemic dose ranging study (376). Drugs were dissolved in physiological
saline (0.9%; Baxter Healthcare Ltd) and infused intravenously at a constant rate of 1
ml/min. Saline was administered as placebo.
PAH (Clinalfa AG and Merck, see Limitations Chapter) and inutest (Serb) were
dissolved in dextrose 5% (Baxter) and administered as a bolus loading dose of 0.4 g
PAH and 3.5 g inutest in 100 ml dextrose over 15 minutes followed by a
maintenance infusion of 792 mg PAH (13.2 mg/min) and 1200 mg inulin (20
mg/min) administered in 120 ml dextrose/hr.
All drugs were prepared by a research nurse unconnected with the study.
Assays
At prespecified time points, venous blood was collected into Lithium heparin tubes
for measurement of PAH and inulin, and EDTA tubes for haematocrit (Hct).
Similarly, urine was collected in universal containers for the measurement of PAH
and inulin.
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Hct was measured on whole blood with a Coulter counter. All other blood samples
were centrifuged immediately at 1000 xg (2500-3000 rpm) at 4 °C for 20 minutes
and subsequently stored along with the urine in a -80 °C freezer to allow batch
processing at a later stage.
Inulin was determined by spectrophotometry after hydrolysis to fructose, and PAH
was determined by high-performance liquid chromatography.
Pre study conditions
Subjects were requested to adhere to a low sodium diet (100 ml/day) to standardise
salt intake and to avoid caffeine, nicotine and alcohol for 72 hours prior to each
study. They fasted from midnight the night before and during the study, other than a
light breakfast that was provided on arrival in the Clinical Research Facility. Diuretic
medications were omitted on the days of participation.
Study protocol
Subjects each attended for 3 study periods in a randomised manner: (A) selective
ETA receptor antagonism with BQ-123 100 nmol/min and 1000 nmol/min; (B)
combined ETA/B receptor antagonism with BQ-123/BQ-788 100/30 nmol/min and
1000/300 nmol/min; (C) saline placebo. The study periods were separated by at least
7 days because previous studies with the same doses of BQ-123 and BQ-788 have
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demonstrated that haemodynamic changes return to baseline after 4 hours, to ensure
complete washout of the study drugs (374,376).
The study protocol is outlined in Figure 2.1. On each study day, an 18 gauge cannula
was sited into an antecubital vein in each arm and a urinary catheter was inserted.
Diuresis was induced by 500 ml of 5% dextrose over 30 minutes through the left arm
cannula followed by 130 ml/hr maintenance infusion. Fifteen minutes later, through
the same cannula, the bolus loading dose of PAH and inulin was co-administered in
100 ml 5% dextrose over 15 minutes followed by the maintenance dose co¬
administered in 120 ml/hr 5% dextrose. The maintenance infusions were continued
to study end. After a minimum 2-hour equilibration period (the equilibration period
was extended if the last 2 urinary flow rates were not within 25% of each other), 2
sets of baseline measurements were performed. The low dose ET-1
antagonist/placebo was then administered through the right antecubital cannula, and
the high dose ET-1 antagonist/placebo administered 90 minutes later.
Systemic haemodynamic measurements (heart rate; blood pressure; cardiac index)
were performed at 15 minute intervals from one hour prior to administration of the
low dose study drug until study end using validated non-invasive automated
techniques (377,378). Urinary flow rate (UFR)s were determined from 30 minute
urine collections following catheter insertion. Urine was collected for sample
analysis from -30 minutes (PAH, inulin). Blood was sampled at the mid point of each
collection (PAH, inulin, Hct).
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Statistical analyses
Blood pressure at each time point was calculated as the mean of 2 recordings and
represented as mean arterial pressure (MAP=diastolic blood pressure +1/3 pulse
pressure). Bioimpedance data at each time point was calculated as the mean of 4
recordings, each the average of 15 consecutive heart beats. Data was corrected for
body surface area to give cardiac index, for direct comparison between subjects
(cardiac index=cardiac output/body surface area). Systemic vascular resistance index
(SVRI) was calculated by dividing MAP by cardiac index and expressed in dyne.s
m2/ cm5. ERPF and GFR were calculated from PAH and inulin clearances,
respectively (379). GFR was adjusted for body surface area. ERBF was calculated by
dividing ERPF by (1-Hct), effective renal vascular resistance (ERVR) by dividing
MAP by ERBF, and EFF by dividing GFR by ERPF x 100%.
Baseline data were calculated as the mean of the 2 time points that immediately
preceded administration of the first study drug. Statistical analysis was performed on
untransformed data. Two comparisons of interest were preidentified as placebo
versus BQ-123 and placebo versus BQ-123/788. Responses were examined by
repeated-measures ANOVA with Bonferroni correction was used to assess
significance at specific time points. P<0.05 was considered statistically significant.
Data was analysed using the SPSS 18 package. All values are expressed as mean +/-
standard error of the mean (SEM).
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2.4 Results
Baseline demographics of the patients are outlined in table 2.1. All four patients had
advanced liver cirrhosis with a mean Child Pugh score of 11 and Model for End-
stage Liver Disease (MELD) score of 15. All had refractory ascites and had
undergone large volume paracentesis within the preceding 4 weeks. The mean serum
sodium was 134 mmol/1 and the mean serum creatinine was 90 pmol/1.
No patient was receiving vasoactive medications at the time of participation in the
study. The mean spironolactone dose and frusemide dose was 200 (range 100-300)
mg and 20 (range 0-40) mg, respectively.
Baseline systemic haemodynamics and renal function
Baseline systemic haemodynamics and renal function are outlined in table 2.2.
Patients demonstrated the typical circulatory changes of portal hypertension. When
compared to healthy controls, patients had a lower mean MAP (p=0.003) and SVRI
(p<0.001), and higher mean cardiac index (p<0.001) and heart rate (p<0.001).
Patients had a similar mean ERBF (p=0.621) and ERVR (p=0.400) to controls (315).
Mean GFR (p=0.003) and EFF (p<0.001) were lower in the patient group.
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MDRD 6 eGFR (ml/min/1,73m2)
























Values expressed as mean +/- standard error of the mean (range).
Abbreviations: MDRD 6 eGFR, Modification of Diet in Renal Disease 6-variable estimated
glomerular filtration rate; MELD, Model for End Stage Liver Disease; UKELD, UK score for
Patients with End-Stage Liver Disease
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Patient1 Patient2 Patient3 Patient4
85 85 77 77
1428 1027 1308 1304
4.8 6.7 4.7 4.9
65 91 90 73
61 75 43 31
825 722 590 459
104 118 136 168
11.1 14.1 10.4 8.7
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Systemic haemodynamic and renal effects of placebo
In patients, placebo was not associated with any change in MAP (83 (4) vs 85 (5)
mmHg; mean (SEM); p=0.284), SVRI (1318 (82) vs 1391 (150) dyne.s m2/cm5;
mean (SEM); p=0.576), cardiac index (5.1 (0.4) vs 5.0 (0.4) 1/min/m2; mean (SEM);
p=0.816) or heart rate (80 (7) vs 75 (5) bpm; mean (SEM); p=0.284) from baseline to
study end.
Placebo was associated with an increase in ERVR (132 (16) vs 180 (26)
mmHg.min/1; mean (SEM); p=0.024) and reduction in ERBF (659 (102) vs 500 (81)
ml/min; mean (SEM); p=0.016), although no change in GFR (50 (9) vs 47 (8)
ml/min/1.73m ; mean (SEM); p=0.668). There was a trend towards an increase m
EFF (10.3 (0.9) vs 12.7 (0.8) %; mean (SEM); p=0.050). There was no effect on
UFR (3.4 (0.7) vs 3.6 (0.6) ml/min; mean (SEM); p=0.712), therefore negating any
waning effect of diuretic therapy.
Placebo had similar systemic haemodynamic effects in healthy controls (315).
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Systemic haemodynamic effects of endothelin-1 receptor antagonism
In patients, the administration of BQ-123 and BQ-123/788 had no statistically
significant effect on MAP, SVRI, cardiac index or heart rate (Table 2.3, Figure 2.2).
In healthy controls, BQ-123 and BQ-123/788 reduced MAP (BQ-123 -4+/-1 mmHg,
p<0.01; BQ-123/788 -4+/-2 mmHg, p<0.01; peak mean placebo-corrected change
from baseline) and SVRI (BQ-123 -591+/-104 dyne.s m2/ cm5, p<0.01; BQ-123/788
-498+/-159 dyne.s m2/ cm5, p<0.01), and was associated with an increase in cardiac
index (315).
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Figure 2.2: Systemic haemodynamics after ET-1 receptor antagonism. Values
expressed as mean placebo-corrected % change from baseline +/- SEM. Grey line,
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Abbreviations: CI, cardiac index; ET-1, endothelin-1; HR, heart rate; MAP, mean arterial
pressure; SEM, standard error of the mean; SVRI, systemic vascular resistance index.
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Renal effects of endothelin-1 receptor antagonism
BQ-123 alone did not result in any statistically significant change in patient renal
function (Table 2.3, Figure 2.3). BQ-123/788 reduced GFR in a non-dose dependent
manner (-11 ml/min/1.73m2, p=0.012; peak mean placebo-corrected change from
baseline), but had no effect on ERBF or ERVR.
When individual patient data was considered, the UFR of Patient 2 was observed to
swing dramatically and could not be explained physiologically (placebo +470 %;
BQ-123 +270 %' BQ-123/788 +716 %; peak % change from baseline) (Figure 2.4).
The statistical analysis of renal function following ET-1 receptor antagonism was
therefore repeated excluding Patient 2 (Table 2.4, Figure 2.5). In this reanalysis, BQ-
123 did not result in any statistically significant change in renal function. BQ-
123/788 did not alter ERBF or ERVR, but reduced GFR (-8 ml/min/1.73m2,
p=0.016; peak mean placebo-corrected change from baseline), EFF (-2.1 %,
p=0.029) and UFR (-1.3 ml/min, p=0.009).
Neither BQ-123 nor BQ-123/788 altered renal function of healthy controls (315).
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Figure 2.3: Renal function after ET-1 receptor antagonism. Values expressed as
mean placebo-corrected % change from baseline +/- SEM. Grey line, BQ-123; black
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Abbreviations: EFF, effective filtration fraction; ERBF, effective renal blood flow; ERVR,
effective renal vascular resistance; ET-1, endothelin-1; GFR, glomerular filtration rate; SEM,
standard error of the mean.
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Figure 2.4: Individual patient UFR following placebo and ET-1 receptor antagonism.
Grey broken line, Patient 1; grey solid line, Patient 2; black broken line, Patient 3;
black solid line, Patient 4.
Placebo BQ-123 BQ-123/788
Abbreviations: ET-1, endothelin-1; UFR, urinary flow rate.
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Table 2.4: Peak placebo-corrected change from baseline following ET-1 receptor
antagonism (patient 2 excluded from analysis).
GFR ERBF ERVR EFF UFR
(ml/min/1.73 (ml/min) (mmHg.min/l) (%) (ml/min)
m2)
BQ-123 -6 -143 +54 +2.4 -1.9
% -13.6 -22.5 +39.1 +27.6 -48.3
P value 0.149 0.095 0.238 0.107 0.060
BQ-123/788 -8 -76 +25 -2.1 -1.3
% -16.7 -13.7 +18.7 -23.4 -33.0
P value 0.016 0.415 0.196 0.029 0.009
Abbreviations: EFF, effective filtration fraction; ERBF, effective renal blood flow; ERVR,
effective renal vascular resistance; ET-1, endothelin-1; GFR, glomerular filtration rate; UFR,
urinary flow rate.
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Figure 2.5: Renal function after ET-1 receptor antagonism (excluding Patient 2).
Values expressed as mean placebo-corrected % change from baseline +/- SEM.












Abbreviations: EFF, effective filtration fraction; ERBF, effective renal blood flow; ERVR,




This is the first placebo controlled study of the renal effects of ET-1 antagonism in
patients with advanced cirrhosis and manifestations of portal hypertension-related
renal dysfunction. We have shown that in patients with refractory ascites, acute
combined ET-A and ET-B receptor blockade resulted in a fall in GFR despite no
change in systemic haemodynamics or total renal blood flow, and a marked reduction
in UFR. These findings negate our hypothesis and are consistent with a reno-
protective role for ET-1 in portal hypertension-related renal dysfunction.
The fall in GFR was in the setting of a reduction in EFF, thus suggesting that non
selective ET-1 receptor antagonism had a greater effect on efferent arteriole tone
with a fall in glomerular pressure. Given that these observations were only made in
the presence of ET-B receptor antagonism, we postulate that ET-B mediated efferent
arteriole vasoconstriction is important in maintaining glomerular perfusion pressure
in these patients. In agreement, several in vitro animal models have demonstrated a
significant vasoconstrictor function of ET-B receptors in the post glomerular
arteriole (380,381,382). During ET-A receptor blockade a progressive increase in
ET-1 dose precipitated initial vasodilatation, followed by vasoconstriction (96).
Therefore, it has been speculated that ET-B receptor mediated efferent arteriole
vasoconstriction is only evident at higher concentrations because of relatively low
affinity ligand binding (381). Such concentrations might be expected in the activated
ET-1 system of portal hypertension.
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In healthy humans, ET-1 infusion resulting in an increase in renal vascular resistance
and fall in total renal blood flow was associated with a 36% increase in EFF (383).
Moreover, when co-infused with an ET-A receptor antagonist at a dose that
abolished the rise in renal vascular resistance exogenous ET-1 remained associated
with a greater EFF relative to baseline. This supports the concept of ET-1 playing a
role in preserving glomerular perfusion pressure, either via the ET-B receptor or
indirectly via the action of other vasoactive mediators (384). In patients with CKD
acute ET-A, but not combined ET-1, receptor antagonism caused renal vasodilatation
and a fall in EFF while ET-B blockade did the opposite (315). Equally, long standing
ET-A receptor antagonism in proteinuric CKD did not affect total renal blood flow
but was associated with a lower EFF at the end of treatment (340). In this group,
therefore, there is also evidence of preferential efferent arteriole vasoconstriction,
although this may be mediated by the ET-A receptor.
In portal hypertension the apparent importance of increased tone in the efferent
arteriole for maintaining glomerular perfusion pressure is echoed in studies of
angiotensin II receptor blockade. The administration of captopril to patients with
cirrhosis has had variable effects on total renal blood flow, but has consistently been
found to reduce the EFF (385,386,387). Of potential relevance is that the RAAS and
ET-1 systems are known to interact and haemodynamic synergism has been
demonstrated in health (325,388). Only in the presence of angiotensin-converting
enzyme inhibition did ET-A receptor antagonism cause renal vasodilatation and
reduced EFF (325). Therefore, ET-1 and angiotensin II may act synergistically on the
efferent arteriole (325). In CKD these vascular effects may promote proteinuria and
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worsen renal outcomes (340). Conversely, in portal hypertension-related renal
dysfunction they may be beneficial and serve to maintain glomerular perfusion
pressure and GFR. Interestingly, cirrhotic patients with ascites who have a reduced
GFR in the setting of preserved renal plasma flow but reduced EFF have evidence of
inappropriately low systemic generation of angiotensin II (90). Relative under¬
activity of the RAAS may thus also be relevant to our findings.
The most striking observation of this study was the dramatic fall in UFR with ET-1
antagonism that was disproportionate to the fall in GFR. The effect was dose-
dependent and only statistically significant following combined ET-A and ET-B
receptor blockade. This is consistent with in vitro and animal models that provide
strong evidence that ET-1 via the ET-B receptor is an important inhibitor of
collecting duct sodium and water reabsorption (322,333,334,335,336). To our
knowledge this is the first study in healthy humans or patients to demonstrate renal
tubular effects of ET-1 receptor blockade in the absence of angiotensin-converting
enzyme inhibition. ET-A receptor antagonism in healthy humans pretreated with
enalapril increased sodium excretion markedly (325).
In contrast to in health, CKD and less advanced cirrhosis, we did not demonstrate
any systemic haemodynamic effects of selective or combined ET-1 blockade
(315,359). Although this may reflect small patient numbers no clear trends were
seen. Furthermore, the lack of circulatory changes echoes the findings in Wong's non
placebo controlled study of combined ET-1 receptor antagonism in patients with
advanced liver disease (372). An alternative explanation is the competing effects of
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the ET-A and ET-B receptors, particularly if ET-B mediated vasoconstriction has a
greater role. This may also underpin our failure to demonstrate any dose-related renal
haemodynamic changes.
An additional interesting observation that should be mentioned is the renal
haemodynamic changes of the placebo arm. Patients demonstrated a dramatic
increase in ERVR from baseline to study end, and fall in ERBF. GFR was
maintained in the face of an increase in EFF. The immediate effect of a 500ml bolus
of dextran 40 in cirrhotic patients with ascites is a rise in cardiac output and renal
blood flow, and fall in renal resistance (454). Our 'baseline' measurements were
performed 3 hours following a 600ml 5% dextrose bolus, with 250ml per hour
maintenance thereafter. Dextrose is not an effective plasma expander and is rapidly
lost from the intravascular compartment (455). Therefore, it seems possible that the
rise in ERVR reflects a homeostatic response to fluid redistribution, with increased
activity of the RAAS and SNS, and more subtle systemic haemodynamic changes
that could not be identified with the methodology. Unfortunately readings were not
taken prior to volume filling, but we speculate that the lower ERBF and higher
ERVR may be closer to the normal resting values for these individuals.
We examined the effects of ET-1 receptor antagonism in patients with refractory
ascites. Only 1 patient fulfilled the diagnostic criteria for type 2 hepatorenal
syndrome and it could be argued that our results cannot be extrapolated to this group
specifically (105). However, portal hypertension-related renal dysfunction should be
considered as a spectrum (4). Moreover, the limitations of serum creatinine as a
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marker of renal function in cirrhosis are well recognised (389). All 4 patients had a
reduced GFR and half had a GFR of less than 60 ml/min/1.73m2 (389). Despite
relatively well preserved total renal blood flow the EFF was reduced and comparable
to patients with hepatorenal syndrome (90). Therefore, the recruited patients had
severe portal-hypertension-related renal dysfunction at time of inclusion
characterised by failure of intra-renal compensatory mechanisms. Our findings are
also similar to the renal effects demonstrated when Wong administered a non
selective ET-1 receptor antagonist to patients with type 2 hepatorenal syndrome
(372).
The main other limitation of this study is the small number of patients recruited.
Nevertheless, we have demonstrated statistically significant effects of ET-1 receptor
blockade in accordance with previous results. Furthermore, the principle factor
limiting the number of potential participants was the numerous exclusion criteria.
This has allowed an uncontaminated examination of ET-1 receptor antagonism in
portal hypertension and refractory ascites to be performed. The small patient
numbers is compounded by the wide swings in UFR demonstrated by patient 2
necessitating her exclusion from the analysis. A peak change of 700% from baseline
is difficult to explain physiologically. However, all patients had a urinary catheter
and careful attention was paid throughout the studies to ensure good drainage. The
baseline parameters of patient 2 were somewhat different from the other participants
with a lower SVRI and higher cardiac index, higher GFR and lower UFR. In
retrospect, she may have had an element of superimposed acute alcoholic hepatitis,
which could possibly alter the haemodynamic and renal response to ET-1.
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2.6 Conclusion
In conclusion, in this double-blind placebo-controlled crossover study we have
demonstrated for the first time that in patients with advanced cirrhosis and refractory
ascites acute combined ET-A and ET-B receptor blockade caused a fall in GFR
despite no change in systemic haemodynamics or total renal blood flow, and a
marked reduction in UFR. Selective ET-A receptor antagonism had no
haemodynamic or renal tubular effects suggesting that the ET-B receptor plays a key
role in this setting. These findings are consistent with a reno-protective role for ET-1
in portal hypertension-related renal dysfunction.
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CHAPTER 3
Renal dysfunction in acute liver failure: The systemic inflammatory
response syndrome and its association with acute kidney injury in
patients with acute liver failure
Published by Leithead JA, Ferguson JW, Bates CM, Davidson JS, Lee A, Bathgate
AJ, Hayes PC, Simpson KJ. The SIRS is predictive of renal dysfunction in patients
with non-paracetamol-induced acute liver failure. Gut 2009;58(3):443-9.
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3.1 Introduction
Renal failure is a common complication of ALF that occurs in 43% of patients with
grade IV hepatic encephalopathy (163). It is associated with increased mortality,
emphasised by the inclusion of serum creatinine in the KCH prognostic criteria
(164,165). Despite the clinical burden of renal dysfunction in this setting, the
aetiological mechanisms and risk factors remain unclear. Consequently, treatment
options without liver transplantation are limited and potential prophylactic measures
are unknown.
Current hypothesis suggests that the renal dysfunction of ALF and hepatorenal
syndrome of cirrhosis share similar pathophysiology (105,169). Supporting this
argument, the circulatory dysfunction of ALF, which is characterised by reduced
systemic vascular resistance and high cardiac output, appears to parallel that of CLD
(170,171,172,184). The marked reduction in renal blood flow and GFR that is
associated with renal failure mirrors the renal perfusion changes of advanced
cirrhosis (171). Flowever, ALF has distinct haemodynamic features that indicate that
the renal dysfunction of ALF and cirrhosis may not be comparable. Firstly, clinically
significant portal hypertension is not always present in patients with ALF and renal
dysfunction (172). Moreover, the degree of portal hypertension rarely equates with
that of hepatorenal syndrome in cirrhosis: the mean reported hepatic venous pressure
gradient for patients with ALF and renal dysfunction is 14 mmHg compared with 21
mmHg for patients with hepatorenal syndrome (109,148,172). Secondly, animal
studies imply that the systemic vasodilatation may be more generalised and not
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limited to the splanchnic circulation as occurs in cirrhosis (198,199). Pigs with ALF
demonstrate reduced hind leg and renal vascular resistance, which contrasts with the
femoral and renal vasoconstriction of hepatorenal syndrome (11,12,198,199).
Vasodilatation within these vascular beds is more in keeping with the hyperdynamic
syndrome of sepsis than of advanced cirrhosis (182,183). Recently it had been
demonstrated that the SIRS is often present in patients with ALF (175,176). SIRS is
associated with progression of hepatic encephalopathy suggesting that the systemic
inflammatory response may be involved in its pathogenesis (175,176). Following on
from this, we postulate that the systemic inflammatory response may play a role in
the pathogenesis of renal dysfunction in these patients.
Additional factors that may contribute to renal dysfunction in ALF include
hypovolemia, nephrotoxic drugs, infection and disseminated intravascular
coagulation (163,206,207,208). Paracetamol has been shown in animal models to
have a direct nephrotoxic effect and in humans there are case reports of renal failure
following paracetamol overdose in the absence significant hepatic injury
(209,210,211). Nevertheless, the frequency of renal dysfunction in patients with




At present there is a poor understanding of the pathogenesis and risk factors for renal
dysfunction in ALF. The primary aim of this study was to examine whether SIRS is
associated with renal dysfunction in a large cohort of patients with ALF. The




This was a retrospective study of 442 patients admitted to a single tertiary referral
centre with ALF between November 1992 and June 2007. One hundred and seven
patients who were ventilated prior to admission were excluded from the analysis
because of the influence of sedation and mechanical ventilation on SIRS (175,176).
A further 6 patients who received RRT but did not fulfil the definition for renal
dysfunction, and 21 patients who did not have a peak serum creatinine available,
were also not assessed. Therefore, the study cohort comprised 308 patients.
ALF was defined as severe liver injury with hepatic encephalopathy in which the
onset of encephalopathy was within 8 weeks of the first symptoms of illness, and in
the absence of pre-existing liver disease (159). A patient was considered to have
significant renal dysfunction if they fulfilled the RIFLE criteria (acronym indicating
Risk of renal dysfunction, Injury to the kidney, Failure of kidney function, Loss of
kidney function and End-stage renal disease) for AKI: peak serum creatinine >2
times the baseline level (390). The baseline serum creatinine was unavailable and
therefore estimated from the Modification of Diet in Renal Disease (MDRD) Study
4-variable equation
eGFR = 186 x creatinineOng/dl)'1154 x age(years)"0 203 x 1.2 1 2(if black) x 0.742(if
female)
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with an assumed GFR at the lower end of normal (75 ml/min/1.73m2), as outlined by
the Acute Dialysis Quality Initiative (ADQI) workgroup (390). Serum creatinine may
theoretically overestimate GFR in patients with ALF. Therefore, we chose the
criteria for AKI rather than Acute Kidney Failure to allow detection of significant
renal dysfunction with greater sensitivity (390).
Data was collected prospectively and entered into a dedicated database. The
following variables were recorded at the time of hospital admission; temperature,
pulse, white cell count (WCC), neutrophil count, platelet count, international
normalised ratio (INR), serum electrolytes, serum bilirubin, alanine aminotransferase
(ALT), albumin, and arterial hydrogen ion (H+), bicarbonate (HCO3 ), PaC02, and
lactate. Peak creatinine and peak INR were documented. SIRS was defined as 2 or
more of temperature <36°C or >38°C, heart rate >90 beats per minute, WCC
<4><109/L or >12x109/L, and PaCo2 <4.3 kPa (212). Regular alcohol intake prior to
admission was recorded; alcohol excess was defined for women as >112 grams/week
and for men >168 grams/week as per the UK guidelines (391). The presence of the
following variables at any point during admission were documented; ventilation,
treatment for increased intra-cranial pressure (ICP), hypotension (systolic blood
pressure <90mmHg), need for inotropes (nor-adrenaline/adrenaline), hypoglycaemia,
prognosis assessed using the KCH criteria, and infection (positive cultures and/or
ascitic fluid polymorphonuclear count >250/mm3 and/or radiological evidence of
infection) (165). All patients had cultures (sputum/stool/ascites/intra-vascular
catheter where appropriate) and a chest X-ray performed routinely on admission, and
repeat cultures if clinically indicated. Spontaneous survival and death were defined
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as survival without liver transplantation and death without liver transplantation
respectively: patients who received a liver transplant were excluded from all survival
analyses.
Statistical analyses
Normally distributed continuous variables and non-parametric continuous variables
were compared using the Student's t-test and Mann-Whitney test respectively. Chi-
squared analysis was used for comparison of categorical data. Stepwise backwards
logistic regression models, verified with forwards models, were used to determine
the factors independently associated with death and AKI. Patients who received a
liver transplant were excluded from all survival analyses. Only those variables with
P<0.10 were included in the multivariate analyses. P<0.05 was considered
significant. Data was analysed using the SPSS 15 package.
All values are expressed as mean and standard deviation (SD), and median and inter¬




The mean age was 39.7 (SD 14.7) years and the male to female ratio was 1:1.3. The
causes of ALF were paracetamol overdose (217 patients), seronegative hepatitis (39
patients), idiosyncratic drug reaction (23 patients), hepatitis B (5 patients),
autoimmune (5 patients), alcoholic hepatitis (5 patients), Budd-Chiari (5 patients),
acute fatty liver ofpregnancy (3 patients), hepatitis A (2 patients), Wilsons disease (2
patients) and non-paracetamol drug overdose (2 patients). One hundred and twelve
patients died, 112 survived and 83 underwent liver transplantation.
Prevalence of acute kidney injury
At the time of admission to hospital the median serum creatinine was 149 (IQR 96-
256) pmol/1, and 133 patients (43%) fulfilled the criteria for AKI. Thereafter, most
patients demonstrated a decline in renal function: 196 patients (64%) had a 10% or
greater increase in serum creatinine, 106 patients (34%) had no change in serum
creatinine and 6 patients (2%) had a 10% or greater improvement in serum
creatinine. The median peak serum creatinine was 288 (IQR 135-392) p.mol/1. Two
hundred and eight patients (67%) fulfilled the criteria for AKI at any point during
their illness, of whom, 70% underwent RRT.
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Prevalence of systemic inflammatory response syndrome
Seventy percent of patients had SIRS. SIRS was more prevalent in patients with
paracetamol-induced ALF compared with patients with non-paracetamol-induced
ALF (77% vs. 54%, p<0.001). The frequency of SIRS was not affected by the
presence of infection (infected 70%: non-infected 70%, p=0.880). SIRS was not
more common in patients who achieved KCH poor prognostic criteria (achieved
72%; not achieved 67%, p=0.344), although a greater proportion of patients who
were hypoglycaemic (hypoglycaemic 78%, non-hypoglycaemic 65%, p=0.040) or
required treatment for increased ICP (treatment 79%, no treatment 66%, p=0.032)
demonstrated SIRS.
Acute kidney injury, systemic inflammatory response syndrome and mortality
Patients with AKI had a prolonged hospital admission (AKI 11;7-20 days: non-AKI
6;4-10 days, median and IQR, p<0.001) and reduced spontaneous survival (AKI
36%; non-AKI 84%, p<0.001, Figure 3.1). There was no relationship between AKI
and liver transplantation (AKI 25%; non-AKI 33%, p=0.118). However, the
transplanted patients who had AKI pre-operatively had a longer post-operative
hospital stay (AKI 26;20-33 days: non-AKI 15; 13-20 days, median and IQR range,
p<0.001) and a trend towards reduced survival to hospital discharge (AKI 67%; non-
AKI 85%, p=0.064).
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Figure 3.1: Spontaneous survival in patients with ALF subdivided based on the
presence or absence of AKI. Patients who received a liver transplant were excluded
from the survival analysis.
Log-rank p < 0.001




Number of patients at risk
No acute kidney injury
67 28 8
Acute kidney injury
156 84 32 15
T
6
Abbreviations: AKI, acute kidney injury; ALF, acute liver failure.
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The presence of SIRS was also associated with reduced spontaneous survival (SIRS
42%; non-SIRS 60%, p=0.035). Nevertheless, a similar proportion of patients with
and without SIRS received a liver transplant (26% vs. 32%, p=0.386) and there was
no association between SIRS and survival following transplantation (SIRS 70%;
non-SIRS 71%, p=0.957).
Other variables associated with spontaneous survival are outlined in Table 3.1. On
multivariate analysis AKI, and not SIRS, was independently associated with
mortality.
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Table 3.1: Factors predictive of mortality on univariate and multivariate analysis in
patients with ALF*.
Univariate OR p value Multivariate OR p value
(95% CI) (95% CI)
Age (years) 1.04(1.02-1.06) <0.001 1.06(1.03-1.09) <0.001
Hypoglycaemia 6.20(3.40-11.27) <0.001 4.97(2.27-10.91) <0.001
Treatment for increased ICP 5.17(2.54-10.55) <0.001 6.72(2.56-17.67) <0.001
SIRS 2.00(1.04-3.85) 0.037
AKI 9.18(4.45-18.94) <0.001 5.48(2.20-13.64) <0.001
Reference group (relative risk 1.00): no hypoglycaemia, no treatment for increased ICP, no
SIRS, no acute kidney injury, male gender, non-paracetamol-induced ALF, no infection.
"Variables not associated with mortality: female gender (p=0.502), paracetamol-induced ALF
(p=0.129), infection (p=0.547).
Abbreviations: ALF, acute liver failure; OR, odds ratio; CI, confidence interval; ICP, intra¬
cranial pressure; SIRS, systemic inflammatory response syndrome; AKI, acute kidney injury.
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Relationship between acute kidney injury and the aetiology of acute liver
failure
Patients who developed AKI were more likely to have ALF as a result of
paracetamol ingestion than those who did not have AKI (80% vs. 51%, p<0.001).
The median peak serum creatinine for patients with paracetamol-induced ALF was
300 (IQR 183-413) pmol/1 and for patients with non-paracetamol-induced ALF was
149 (IQR 99-322) pmol/1 (p<0.001). Seventy-six percent of patients with
paracetamol-induced ALF and 46% of patients with non-paracetamol-induced ALF
fulfilled the criteria for AKI (p<0.001).
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Relationship between acute kidney injury and the severity of acute liver
failure
Clinical and biochemical characteristics of the AKI and non-AKI patients on
admission to hospital are outlined in table 3.2. Patients with AKI had a higher ALT
level (p<0.001), INR (p=0.001) and lactate (p=0.007), and were more likely to be
acidotic (31% vs. 0%, p<0.001).
By definition all patients became encephalopathic. However, the AKI group were
more likely than the non-AKI group to be ventilated (77% vs. 56%, p<0.001) and a
greater proportion required treatment for increased ICP (AKI 34%, non-AKI 14%,
p<0.001). In addition, patients with AKI were more likely to demonstrate
hypoglycaemia (AKI 50%, non-AKI 18%, p<0.001) and to fulfil KCH poor
prognostic criteria (AKI 64%, non-AKI 37%, p<0.001).
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Table 3.2: Clinical and biochemical characteristics on admission of patients with
ALF who did/did not develop AKI.
Variable AKI (no:208) Non-AKI (no: 100) p value
Age (years) 41.0+/-14.0 36.9+/-15.7 0.020
Male:Female 1:1.2 1:1.4 0.439
Alcohol excess (%) 88(52) 30(38) 0.043
Temperature (°C) 36.4+/-1.1 36.8+/-0.8 0.001
Heart rate (bpm) 107(92-120) 96(80-110) <0.001
WCC (x109/l) 12.8(9.4-18.0) 11.0(6.9-13.7) 0.001
Neutrophil count (x109/l) 11.2 (7.6-16.5) 8.8(5.9-12.2) <0.001
Lymphocyte count (x109/l) 0.7(0.5-1.2) 1.0(0.7-1.5) 0.002
Platelet count (x109/l) 115(55-162) 158(99-237) <0.001
INR 4.9(3.0-7.1) 3.7(2.5-5.6) 0.001
Sodium (mmol/l) 134(129-138) 136(133-138) 0.007
Potassium (mmol/l) 4.1(3.6-5.0) 3.6(3.3-4.2) <0.001
Urea (mmol/l) 7.7(5.0-12.5) 4.1(2.7-7.4) <0.001
Creatinine (pmol/l) 221(138-298) 92(74-113) <0.001
Bil (pmol/l) 96(68-139) 140(88-433) <0.001
ALT (U/l) 5856(2105-10000) 2655(957-6775) <0.001
Albumin (g/l) 32.9+/-8.2 32.9+/-7.2 0.946
H+ (nmol/l) 41(35-50) 33(31-37) <0.001
PaC02 (kPa) 4.0(3.2-4.6) 4.2(3.8-4.8) 0.033
HC03" (mmol/l) 18.1 (13.7-22.8) 24.0(20.9-26.9) <0.001
Lactate (mmol/l) 4.2(2.6-8.4) 2.7(2.0-4.5) 0.007
Any encephalopathy (%) 125(61) 68(68) 0.253
SIRS (%) 136(78) 43(53) <0.001
Abbreviations: ALF, acute liver failure; AKI, acute kidney injury; WCC, white cell count; INR,
international normalised ratio; ALT, alanine aminotransferase; SIRS, systemic inflammatory
response syndrome.
130
Relationship between acute kidney injury and systemic inflammatory
response syndrome
Patients who developed AKI had evidence of a greater systemic inflammatory
response. At the time of hospital admission they were more likely to have a
temperature <36°C (AKI 34%, non-AKI 12%, p=0.010), had a faster heart rate
(p<0.001), a higher WCC (p=0.001) and a lower PaC02 (p=0.033) (table 3.2).
Furthermore, a greater proportion of those with AKI developed hypotension (AKI
63%, non-AKI 13%, p<0.001) and required inotropic support (AKI 56%, non-AKI
9%, pO.OOl).
Seventy-eight percent of the AKI patients had SIRS compared with 53% of the non-
AKI patients (p<0.001). An increasing number of components of SIRS was
associated with an increased probability of renal dysfunction: 47%, 60%, 69%, 79%
and 81% of the patients with 0, 1, 2, 3 and 4 components of SIRS at admission
respectively developed AKI (p=0.047). The AKI group were more likely to
demonstrate infection (AKI 56%, non-AKI 38%, p=0.003). Nevertheless, in both
those with infection (AKI 74%, non-AKI 57%, p=0.062) and those without infection
(AKI 82%, non-AKI 50%, p<0.001) SIRS was more common in the AKI patients.
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Independent risk factors for the development of acute kidney injury in acute
liver failure
A multivariate analysis was performed to identify the factors that are independently
associated with renal dysfunction (Table 3.3). This revealed that the severity of ALF,
the systemic inflammatory response to ALF, and superimposed factors may all be
relevant. The variables independently associated with AKI were age (p=0.024),
fulfilled KCH poor prognostic criteria (p<0.001), hypotension (p<0.001), SIRS
(p=0.017), superimposed infection (p=0.077) and paracetamol as the cause of ALF
(p<0.001).
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Table 3.3: Factors predictive of AKI on univariate and multivariate analysis in all
patients with ALF.
Variable Univariate OR p value Multivariate OR p value























Reference group (relative risk 1.00): non-paracetamol-induced ALF, did not achieve KCH
prognostic criteria. No hypoglycaemia, no treatment for increased ICP, no hypotension, no
SIRS, no infection.
Abbreviations: AKI, acute kidney injury: ALF, acute liver failure; OR, odds ratio; CI,
confidence interval; ICP, intra-cranial pressure; SIRS, systemic inflammatory response
syndrome.
133
In view of the strong association of paracetamol with AKI the entire cohort was then
subdivided into two groups: paracetamol-induced ALF and non-paracetamol-induced
ALF based on the presence or absence of paracetamol-induced liver injury
respectively. The associations between the severity of ALF and AKI, and SIRS and
AKI, were reassessed.
Acute kidney injury in paracetamol-induced acute liver failure
In the paracetamol-induced ALF subgroup, patients with AKI had evidence of more
severe liver injury when compared with patients with no AKI (Table 3.4): they were
more likely to be hypoglycaemic (p<0.001), to require treatment for increased ICP
(p=0.003) and to fulfil KCH poor prognostic criteria (p<0.001). In contrast, the AKI
patients were not more likely to demonstrate SIRS (p=0.373) and were not more
likely to have infection (p=0.287). However, they did have a lower admission
temperature (p<0.001), higher WCC (p=0.043), trend towards a lower PaC02
(p=0.070), and were more likely to have 3 or more systemic inflammatory response
components (AKI 43%, non-AKI 27%, p=0.055). On multivariate analysis the
factors associated with AKI in patients with paracetamol-induced ALF were age (OR
1.03; 95% CI 1.00-1.06, p=0.059), treatment for increased ICP (OR 2.74; 95% CI
1.05-7.15, p=0.039) and hypotension (OR 11.38; 95% CI 4.19-30.91, p<0.001).
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Table 3.4: Univariate analysis of variables as predictors of AKI in patients with
paracetamol-induced ALF and non-paracetamol-induced ALF.
Variable Paracetamol-induced ALF Non-paracetamol-induced ALF
AKI (no: 166) Non-AKI (no:51) AKI (no:42) Non-AKI (no:49)
Peak creatinine (pmol/l) 341(294-454) 109(86-140) 329(258-474) 99(86-113)
Renal replacement therapy (%) 124(75) 0 22(52) 0
Age (years) 39.5+/-13.1 33.6+/-14.2 b 47.4+/-15.5 40.3+/-16.6"
Male:Female 1.1.0 1:1.2 1:2.0 1:1.7
Alcohol excess (%) 80(57) 22(54)
Jaundice-enceph time (days) 11(2-25) 12(2-23)
Temperature OA (°C) 36.4+/-1.1 37.0+/-0.9° 36.3+/-1.3 36.6+/-0.6
Heart rate OA (bpm) 109(92-120) 102(86-120) 100(90-120) 90(80-100)"
WCC OA (x109/l) 13.0(9.4-18.0) 11.5(6.9-14.3)8 12.0(9.4-18.0) 10.7(7.0-12.8)'
Neutrophil count OA (x109/l) 11.5(8.2-16.5) 10.5(5.9-12.7) 9.6(7.0-14.9) 7.7(5.5-10.4)"
Platelet count OA(x109/l) 112(47-157) 154(92-220)" 136(77-182) 164(113-284)"
INR OA 5.3(3.6-7.7) 4.6(3.1-6.6)' 2.4(1.9-4.3) 2.7(2.0-4.2)
Peak INR 7.9(5.0-10.7) 6.4(4.3-9.3) 4.3(2.2-5.1) 3.2(2.3-5.1)
Bilirubin OA (pmol/l) 89(62-116) 100(74-124) 325(110-531) 438(241-524)
ALT OA (U/l) 6949(3884-10925) 6547(4373-8790) 613(171-2712) 1050(365-2228)
Albumin OA (g/l) 34.3+/-8.1 36.5+/-6.1 28.1+/-6.7 29.2+/-6.4
H+ OA (nmol/l) 41(35-50) 33(30-38)c 41(34-45) 34(31-36)"
PaC02 (kPa) 4.0(3.2-4.6) 4.2(3.7-4.8) 4.0(3.4-5.1) 4.4(3.8-4.7)
HC03" OA (mmol/l) 18.0(13.0-22.4) 23.0(20.0-26.9)c 20.3(15.1-24.7) 24.6(21.8-27.0)'
Lactate OA (mmol/l) 4.7(2.8-9.0) 3.0(2.1-5.3) 3.7(2.3-7.0) 2.5(1.7-4.0)
Hypotension (%) 102(63) 5(10)° 27(64) 8(17)'
Inotropes (%) 98(60) 4(8)' 18(43) 5(10)'
Hypoglycaemia (%) 89(55) 11(22)' 13(31) 7(15)
Treatment for increased ICP(%) 59(36) 7(14)" 10(24) 7(15)
Infection (%) 89(55) 23(46) 26(63) 15(31)"
SIRS (%) 110(79) 28(72) 26(76) 15(36)'
KCH poor prognosis (%) 105(63) 0(0)' 29(69) 37(76)
Spontaneous survival (%) 48(37) 47(92)° 8(30) 10(63)'
a p<0.05,b p<0.01,c p<0.001 versus no acute kidney injury group
Abbreviations: AKI, acute kidney injury; ALF, acute liver failure; OA, on admission to hospital; WCC,
white cell count; INR, international normalised ratio; ALT, alanine aminotransferase; ICP, intra-cranial
pressure; SIRS, systemic inflammatory response syndrome; KCH, Kings College Hospital.
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Acute kidney injury in non-paracetamol-induced acute liver failure
In the non-paracetamol-induced ALF subgroup, patients with AKI did not have
evidence of more severe liver injury relative to patients with no AKI (table 3.4).
Despite a trend towards an association between AKI and hypoglycaemia (p=0.062),
patients with renal dysfunction were not more likely to require treatment for
increased ICP (p=0.285) or to achieve KCH poor prognostic criteria (p=0.491).
Nevertheless, there was a strong relationship between AKI and SIRS (p<0.001,
Figure 3.2). Patients with AKI were more likely to have infection (p=0.002), and in
both infected (AKI 78%, non-AKI 40%, p=0.017) and non-infected patients (AKI
73%, non-AKI 33%, p=0.037) the prevalence of SIRS was greater in those with AKI.
On multivariate analysis the factors associated with AKI in patients with non-
paracetamol-induced ALF were hypotension (OR 8.63; 95% CI 2.63-28.3, p<0.001)
and SIRS (OR 6.98; 95% CI 2.13-22.83, p=0.001).
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Figure 3.2: Boxplot of peak change in serum creatinine (peak serum
creatinine/baseline serum creatinine) in patients with ALF subdivided based on
aetiology, and the presence or absence of the SIRS. A peak change in serum
creatinine >2, represented by the horizontal line, is the definition of AKI.
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We have shown for the first time that in ALF renal dysfunction is associated with
SIRS. On univariate analysis patients with AKI were more likely to be hypothermic,
had a faster heart rate, a higher WCC and a lower PaC02. Multivariate analysis
confirmed that SIRS was a risk factor for the development of AKI. Importantly, this
association was independent of the presence of infection and of severity of liver
injury as assessed by the KCH prognostic criteria. A further novel finding of our
study is the strikingly increased risk of AKI demonstrated by patients with
paracetamol-induced ALF. This relationship supports in vitro animal data and
clinical suspicion that paracetamol has a direct nephrotoxic effect. Drug induced
renal injury could mask any relationship between SIRS and renal dysfunction.
Therefore, a key finding of our study is the strong association between SIRS and
AKI in the subgroup of patients with non-paracetamol-induced ALF.
To our knowledge this is the first study to examine the prevalence of SIRS in ALF
using all 4 components of the systemic inflammatory response (212). Previous
groups have excluded the respiratory component because of the influence of
mechanical ventilation (175,176,177). Using similar methodology to the earlier
studies the prevalence of SIRS in our cohort was comparable (50%: Rolando et al
57%: Vaquero et al 34%: Schmidt et al 55%). However, when all 4 components
were applied the prevalence of SIRS rose to 70%. The diagnosis of SIRS was based
on parameters at time of admission to our unit. Therefore, additional patients may
have developed SIRS at a later stage.
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The observation that SIRS may be present in patients with ALF even in the absence
of infection confirms previous findings (175,176). In fact, the prevalence of SIRS
was similar in infected and non-infected groups. We acknowledge that occult
infection may have influenced our results. However, our unit actively seeks infection
with cultures performed routinely on admission, and repeated thereafter if clinically
indicated. SIRS is the clinical sequelae of a massive inflammatory cascade that
results from systemic cytokine release (179). SIRS not only occurs in infected
patients but also in a variety of other conditions including trauma and acute
pancreatitis (179). In ALF, non-infected patients similarly demonstrate high
circulating levels of cytokines (216,219,220,392). The source of the systemic
cytokines in this setting remains unclear although release from the necrotic liver, or
secondary to endotoxaemia, or impaired hepatic cytokine metabolism are possible
(179,205,239).
The findings of our study suggest that the systemic inflammatory response plays a
role in the pathogenesis of renal dysfunction in ALF. Consequently, the renal
dysfunction of sepsis may be a more accurate parallel than the hepatorenal syndrome
of cirrhosis. In sepsis renal dysfunction probably occurs as a result of haemodynamic
and non-haemodynamic factors (183). There is reduced glomerular filtration
pressure, which reflects altered intra- and extra-renal vascular activity (183,206).
Furthermore, the systemic inflammatory response may contribute directly to renal
tubular dysfunction by stimulating apoptotic death of tubular cells (183,393). Most
research has focused on TNF-a. This cytokine appears to play a major role in the
pathogenesis of the circulatory dysfunction and renal injury of sepsis (183,206,394).
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In ALF TNF-a and IL-6 levels have been shown to correlate with the development of
renal failure and circulatory failure respectively (395). Therefore, we propose that in
ALF, as in sepsis, cytokines responsible for the systemic inflammatory response are
central to the development of renal dysfunction.
The systemic inflammatory response has also been implicated in the pathogenesis of
the circulatory and renal dysfunction of cirrhosis (143,396). These patients
demonstrate endotoxaemia in the absence of infection and have increased systemic
cytokine levels, which correlate with the severity of disease
(32,116,117,119,397,398). Furthermore, prophylactic antibiotics reduce the
incidence of hepatorenal syndrome and improve survival in patients with
decompensated cirrhosis, independent of the prevention of infection (123).
Nevertheless, portal hypertension remains the primary event (105,399). Moreover,
the frequency of SIRS in patients with cirrhosis, even when renal dysfunction is
present (41%), is much less than we have demonstrated in ALF (AKI 78%, non-AKI
53%) (396). Patients with subfulminant ALF are more likely to have clinically
significant portal hypertension than those with fulminant ALF, and may develop
ascites (172). Therefore, in subfulminant ALF renal dysfunction may share
similarities with hepatorenal syndrome of cirrhosis. However, in fulminant hepatic
failure the systemic inflammatory response may be the key mediator of renal
dysfunction.
We were unable to demonstrate a relationship between the severity of ALF, as
assessed by the KCH prognostic criteria, and SIRS. It is well recognised that there
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are significant inter-individual differences in the systemic inflammatory response to
infection and other forms of injury, which may be genetically predetermined
(179,180). Therefore, it is likely that some individuals will be more at risk of the
circulatory and renal complications of the systemic inflammatory response to ALF
than others.
Paracetamol as the cause of ALF was an independent predictor of AKI consistent
with the clinical suspicion that paracetamol has a direct nephrotoxic effect. The mode
of paracetamol related nephrotoxicity remains undefined, although case reports of
isolated renal failure following paracetamol overdose indicate that it is independent
of hepatic injury (209,211). It is postulated that a locally produced toxic metabolite
of paracetamol induces proximal tubular cell necrosis (209,210,400). Functional
renal effects may also contribute as alterations in renal plasma flow and GFR have
been demonstrated in the absence of structural and hepatic dysfunction (210).
Our study has some potential limitations. We chose to use Trey and Davidson's
definition of ALF and include all patients with encephalopathy in the study. Grade I
encephalopathy is difficult to diagnose and previous similar papers have included
patients with severe encephalopathy only (163,164,171). However, our cohort was
comparable to the described populations with regards to severity of liver injury and
outcome, and the diagnosis of encephalopathy was made by a small number of
physicians indicating relative consistency of opinion. Secondly, we did not have
details of co-morbidities and, in particular, pre-existing renal disease or nephrotoxic
medications that may have influenced our results. The patients studied were of a
141
young age and it is therefore assumed that pre-existing renal function was normal.
Our unit avoids nephrotoxic drugs when managing patients with ALF although this
does not preclude exposure prior to transfer.
The identification of modifiable risk factors for the development of AKI in ALF has
important implications for patient management. As in sepsis, early and aggressive
optimisation of haemodynamics with fluid therapy, central venous pressure
monitoring and inotrope administration may significantly reduce the occurrence of
renal dysfunction (206,401,402). Furthermore, manipulation of the systemic
inflammatory response itself is likely to be advantageous. Prompt diagnosis and
treatment of superimposed infection is essential (401,402). In addition, removal of
cytokines and other inflammatory mediators by haemofiltration or albumin dialysis
(MARS) may be beneficial (403,404,405). Finally, pentoxifylline, by down




In conclusion, in this large single-centre retrospective study we have examined the
relationship between SIRS and AKI in ALF. We have shown that the SIRS is
strongly associated with renal dysfunction and we hypothesise that the inflammatory
cascade plays a key role in its pathogenesis. Given the reduced spontaneous survival
of patients with AKI we suggest that the early administration of therapies that target
the systemic inflammatory response and limit the development of AKI may have a
favourable effect on patient morbidity and mortality.
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CHAPTER 4
Renal dysfunction as a prognostic indicator: Estimated glomerular
filtration rate (eGFR) as a prognostic indicator in patients listed for liver
transplantation
Published by Leithead JA, MacKenzie SM, Ferguson JW, Hayes PC. Is estimated
GFR superior to serum creatinine in predicting prognosis on the waiting list for liver
transplantation? Transplant International 2011;24:482-488.
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4.1 Introduction
Cirrhosis is associated with a progressive functional renal impairment characterised
by increased tubular sodium reabsorption, impaired free water clearance and pre¬
renal azotemia (4). This spectrum of renal dysfunction evolves in parallel with
advancing disease and consequently the clinical manifestations of renal dysfunction,
ascites, hyponatraemia and hepatorenal syndrome, are important prognostic markers
(80,105,299,408). Serum creatinine as a continuous variable is an independent
predictor of mortality following the transjugular intrahepatic portosystemic shunt
procedure and in those on the liver transplant waiting list (409,410). It is a
component of the MELD score, which is used to prioritise graft allocation.
However, serum creatinine is not solely influenced by glomerular filtration and is not
an accurate estimator of renal function (411). Creatinine production is proportional to
muscle mass, and is greater in males than females, in younger than older individuals
and in blacks than whites, despite similar GFR (282). In addition, in cirrhosis
reduced creatine production by the liver, muscle wasting and increased renal tubular
secretion of creatinine may result in a falsely low serum creatinine level (412,413).
The effect of gender, age and race on serum creatinine is of particular concern in the
MELD era of organ allocation. UNOS data has demonstrated that women listed for
liver transplantation are less likely to survive to transplantation than men, supporting
a systematic bias of the scoring system (414,415,416). Similarly, an inherent
discrimination against older patients could explain the independent association of
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increasing age with waiting-list mortality (417). It follows that a scoring system with
an alternative measure of renal function may be preferable to MELD.
The gold standard measure of GFR, inulin clearance, has recently been shown to be
superior to serum creatinine in predicting liver transplant waiting-list mortality (418).
Unfortunately, inulin clearance is time consuming, impractical and costly and is not a
useful test if repeated measures are required (412,413). Calculated GFR is a possible
alternative and has been evaluated as an absolute measure of renal function, although
not as a prognostic marker, in this setting (419).
The most accurate calculated GFR for cirrhotic patients is provided by the MDRD
equations, which are creatinine based estimates modified for age, gender and race
(419,420,421). The MDRD 4-variable calculated GFR is readily available, at
minimal cost, with routine reporting advocated in several countries, and is an
attractive measure of renal function (422,423). The MDRD 5-variable and 6-variable
calculated GFRs, in addition, adjust for blood urea nitrogen, and blood urea nitrogen
and serum albumin, respectively, and could be superior prognostic indicators.
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4.2 Aims
The aim of this study was to examine whether the MDRD calculated GFR is superior
to serum creatinine in predicting prognosis on the liver transplant waiting list. In a
subgroup of patients measured creatinine clearance was also available and was
examined as a prognostic indicator.
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4.3 Methods
This was a single-centre retrospective study of consecutive adults listed for first liver
transplantation between November 1992 and June 2007. Patients listed for ALF,
hepatocellular carcinoma, or joint liver/kidney transplantation, or who had
documented intrinsic renal disease were not assessed. Those removed from or still
active on the waiting list were also not included.
The following variables at time of liver transplant assessment were recorded: gender,
age, race, aetiology of liver disease, presence of ascites or hepatic encephalopathy,
and laboratory data (serum sodium, creatinine, bilirubin, albumin and INR). eGFR
was calculated from the relevant parameters using the MDRD study 4-variable
(eGFR(MDRD4)), 5-variable (eGFR(MDRD5)) and 6-variable (eGFR(MDRD6))
equations (420,421).
eGFR(MDRD4) = 186 x creatinine(mg/dl)"'154 x age(yrs)"0'203 x (0.742 if female) x
(1.210 ifblack))
eGFR(MDRD5) = 270 x creatinine(mg/dl)"1007 x age(yrs)"0180 x blood urea
nitrogen(mg/dl)"°-169 x (0.755 if female) x (1-178 ifblack)
eGFR(MDRD6) _ 170 x creatinine(mg/dl)"°999 x age(yrs)"0176 x blood urea
nitrogen(mg/diy° i70 x albumin(g/dl)+0-318 x (0.762 if female) x (1.180 if black)
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The MELD score was determined as previously described (424). The UKELD, a
recently devised scoring system that incorporates serum sodium in addition to the
MELD variables, was also calculated (425).
In a subgroup of patients transplanted between May 2000 and June 2007 measured
creatinine clearance (CrCl) was available. This was determined from a 24-hour
urinary collection performed routinely during the in-patient assessment period.
Failure to obtain a CrCl was, in most cases, secondary to poor patient compliance.
Statistical analyses
Normally distributed continuous variables and non-parametric continuous variables
of males and females were compared using the Student's t-test and Mann-Whitney
test respectively. Chi-squared analysis was used for the comparison of categorical
variables. Survival modelling was performed using cox proportional hazards
regression. Data was censored at the time of liver transplantation and to lessen the
influence of extreme values all continuous laboratory variables were transformed
into their natural logarithms. To allow the comparison of MELD or UKELD with a
similar model with logeGFR or logeCrCl substituted for logecreatinine the regression
coefficients of MELD or UKELD were initially adjusted for our patient population.
Regression coefficients were then recalculated in the presence of logeGFR instead of
logecreatinine. Receiver-operating characteristic (ROC) curves were generated to
assess the accuracy of models in predicting 3-month waiting-list mortality.
Concordance statistics were compared using the method described by Hanley and
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McNeil (426). All patients censored prior to the specified time point were excluded
from these analyses. p<0.05 was considered statistically significant at all times. Data
was analysed using the SPSS 15 package.
Values are expressed as mean and standard deviation (SD), and median and inter¬




The mean age of the patients (number 427) at time of listing for liver transplantation
was 55.3 (SD 11.6) years and the male to female ratio was 1:1. The main indications
for transplantation were primary biliary cirrhosis (119 patients, 27.9%), alcoholic
liver disease (103 patients, 24.1%), sclerosing cholangitis (62 patients, 14.5%),
hepatitis C cirrhosis (37 patients, 8.9%) cryptogenic cirrhosis (36 patients, 8.4%),
and autoimmune hepatitis (33 patients, 7.7%). The median listing MELD score was
16 (IQR 13-20) and the median listing UKELD score was 56 (IQR 54-60).
Sixty patients (14.1%) died prior to liver transplantation. The median time from
listing to death was 50 (IQR 26-101) days. For patients who were transplanted the
median waiting-time was 68 (IQR 27-142) days. Two hundred and twelve patients
(49.6%) were transplanted and 44 patients (10.3%) died within 3 months of listing.
The median listing serum creatinine was 89 (IQR 77-107) pmol/1, the median listing
serum sodium was 136 (IQR 132-139) mmol/1, and 60.6% of patients had ascites.
The median eGFR(MDRD4), eGFR(MDRD5) and eGFR(MDRD6) was 69 (IQR 57-
83) ml/min/1.73m2, 71 (IQR 56-86) ml/min/1.73m2, and 73 (IQR 57-89)
ml/min/1.73m2, respectively.
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Comparison of MDRD eGFR equations as predictors of waiting list mortality
Logecreatinine (OR 14.12; 95% CI 3.76-53.13, p<0.001), logeGFR(MDRD4) (OR
0.18; 95% CI 0.06-0.53, p=0.002), logeGFR(MDRD5) (OR 0.16; 95% CI 0.06-0.44,
p<0.001), and logeGFR(MDRD6) (OR 0.14; 95% CI 0.05-0.39, p<0.001)
demonstrated an association with 3-month waiting-list mortality.
ROC curves for logecreatinine, logeGFR(MDRD4), logeGFR(MDRD5) and
logeGFR(MDRD6) as predictors of 3-month waiting list mortality are shown in
Figure 4.1. When all eGFR equations were compared logeGFR(MDRD6) had the
greatest concordance statistic (logeGFR(MDRD4) 0.648; 0.548-0.749:
logeGFR(MDRD5) 0.683; 0.587-0.780: logeGFR(MDRD6) 0.695; 0.601-0.789,
logecreatinine 0.696; 0.598-0.793, c-statistic and 95% confidence interval).
LogeGFR(MDRD6) statistically outperformed logeGFR(MDRD4) (p=0.054), and
was comparable to logeGFR(MDRD5) (p=0.614) and logecreatinine (p=0.981).
Following on from this, all further analyses comparing eGFR with serum creatinine
were performed using the eGFR MDRD 6-variable equation.
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Figure 4.1: ROC curves of log serum creatinine (logecreatinine), log eGFR
calculated using the MDRD 4-variable equation (logeGFR(MDRD4)), log eGFR
calculated using the MDRD 5-variable equation (logeGFR(MDRD5)) and log eGFR
calculated using the MDRD 6-variable equation (logeGFR(MDRD6)) for predicting 3-
month liver transplant waiting list mortality.








Abbreviations: eGFR, estimated glomerular filtration rate; MDRD, Modification of Diet in
Renal Disease; ROC, receiver-operating characteristic.
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Does substitution of eGFR(MDRD6) for serum creatinine improve the
prognostic accuracy of MELD and UKELD?
ROC analysis was used to determine whether the substitution of logeGFR(MDRD6)
for logecreatinine improved the accuracy of the existing prognostic models, MELD
and UKELD (Table 4.1). The regression coefficients for each model were initially
adjusted for our study population (MELD(adj)/UKELD(adj)), and thereafter
recalculated in the presence of logeGFR(MDRD6) instead of logecreatinine
(MELD(eGFR)/UKELD(eGFR)).
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Table 4.1: AUC for ROC curves for prediction of 3-month liver transplant waiting-list
mortality in all patients.
Model c-statistic 95% CI
MELD (adj) 0.841 0.773-0.909
MELD (eGFR) 0.846 0.777-0.915
UKELD (adj) 0.859 0.790-0.928
UKELD (eGFR) 0.864 0.795-0.933
Abbreviations: CI, confidence interval; c-statistic, concordance statistic; eGFR, estimated
glomerular filtration rate; MELD, Model for End Stage Liver Disease; MELD(adj), MELD
score with regression coefficients adjusted for our model; MELD(eGFR), MELD score with
logeGFR substituted for logecreatinine; ROC, receiver-operating characteristic; UKELD, UK
score for patients with End-stage Liver Disease ;UKELD(adj), UKELD score with regression
coefficients adjusted for our model; UKELD(eGFR), UKELD score with logeGFR substituted
for logecreatinine.
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LogeGFR(MDRD6) substituted for logecreatinine did not change the concordance
statistic for MELD as a predictor of 3-month waiting-list mortality (MELD(adj) vs
MELD(eGFR), p=0.825). Furthermore, logeGFR(MDRD6) substituted for
logecreatinine did not alter the concordance statistic for UKELD as a predictor of
death by 3 months (UKELD(adj) vs UKELD(eGFR), p=0.781).
In view of the concern that the MELD and UKELD scoring systems are systemically
bias and may discriminate against female and older patients the concordance
statistics of individual patient groups were also determined (table 4.2). There was no
statistically significant difference in the concordance statistics of the MELD score or
UKELD score between genders (MELD, p=0.718; UKELD, p=0.645) and age
groups (MELD, p=0.099; UKELD, p=0.216). LogeGFR(MDRD6) substituted for
logecreatinine did not change the concordance statistic for MELD or UKELD as
predictors of 3-month waiting-list mortality in females, males, older or younger
patients (p values not shown).
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Does substitution of CrCI for serum creatinine improve the prognostic
accuracy of MELD and UKELD?
Measured creatinine clearance (CrCI) was available in 139 of the 256 patients
(54.3%) listed for liver transplantation between May 2000 and June 2007. The CrCI
patients were comparable to patients who did not have a recorded CrCI (table 4.3). In
this cohort of 139, 31 patients (22.3%) died prior to transplantation. The median time
from listing to death was 49 (IQR 19-88) days. The median waiting-time to
transplantation was 85 (IQR 35-179) days. Fifty five patients (39.6%) were
transplanted and 25 patients (18.0%) died within 3-months of listing.
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Table 4.3: Comparison of listing variables in patients listed for liver transplantation
between May 2000 and June 2007 who did and did not have CrCI available.
Variable No CrCI CrCI p value
(no:117) (no: 139)
Age (years) 54.0(12.3) 55.3(11.4) 0.374
Male gender 62(53.0) 85(61.2) 0.188
Noncholestatic disease 71(60.7) 83(59.7) 0.874
INR 1.4(1.2-1.6) 1.3(1.1-1.6) 0.553
Bilirubin (gmol/l) 76(42-139) 84(46-156) 0.526
Albumin (g/l) 28.9 (5.4) 29.0 (5.4) 0.876
Encephalopathy 36 (43.9) 35(42.7) 0.875
Ascites 60(60.6) 70(60.3) 0.969
Sodium (mmol/l) 135(132-138) 136(131-139) 0.591
Creatinine (gmol/l) 91(78-106) 91(79-106) 0.795
eGFR(MDRD6) 73(58-90) 76(60-87) 0.997
MELD 17(14-20) 16(14-21) 0.771
UKELD 57(54-61) 57(54-61) 0.936
Values expressed as mean (standard deviation), median (inter-quartile range) and number
(percent) where appropriate.
Units for eGFR(MDRD6) = ml/min/1,73m2.
Abbreviations: CrCI, measured creatinine clearance: eGFR(MDRD6), estimated glomerular
filtration rate derived from 6-variable MDRD equation; INR, international normalised ratio;
MELD, Model for End stage Liver Disease; MDRD, Modification of Diet in Renal Disease;
UKELD, UK score for patients with End-stage Liver Disease.
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The median listing serum creatinine, serum sodium, eGFR(MDRD6) and CrCl was
91 (IQR 79-110) pmol/1, 136 (IQR 131-139) mmol/1, 75 (60-87) ml/min/1.73m2, and
72 (51-95) ml/min, respectively. CrCl demonstrated a greater correlation with
eGFR(MDRD6) (0.615, p<0.001) than with serum creatinine (-0.452, p<0.001).
Logecreatinine (OR 7.77, 95% CI 1.33-45.51, p=0.023) and logeCrCl (OR 0.22, 95%
CI 0.07-0.67, p=0.008) were associated with 3-month waiting-list mortality. ROC
curves for logecreatinine and logeCrCl are shown in Figure 4.2. Logecreatinine and
logeCrCl had similar concordance statistics for the prediction of death by 3 months
(logecreatinine 0.660; 0.532-0.788: logeCrCl 0.718; 0.604-0.831, c-statistic and 95%
confidence interval, p=0.353).
As before, ROC analysis was used to determine whether the substitution of logeCrCl
for logecreatinine improved the accuracy of the existing prognostic models, MELD
and UKELD (Table 4.4). LogeCrCl substituted for logecreatinine did not change the
concordance statistic for MELD (MELD(adj) vs MELD(CrCl), p=0.249) or UKELD
(UKELD(adj) vs UKELD(CrCl), p=0.198) as a predictor of 3-month waiting-list
mortality.
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Figure 4.2: ROC curves of log serum creatinine (logecreatinine) and log creatinine












Abbreviations: CrCI, measured creatinine clearance: ROC, receiver-operating characteristic.
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Table 4.4: AUC for ROC curves for prediction of 3-month liver transplant waiting-list
mortality.
Model c-statistic 95% CI
MELD (adj) 0.809 0.708-0.910
MELD (CrCI) 0.845 0.765-0.926
UKELD (adj) 0.849 0.756-0.942
UKELD (CrCI) 0.881 0.808-0.954
Abbreviations: CI, confidence interval; CrCI, measured creatinine clearance; c-statistic,
concordance statistic; MELD, Model for End stage Liver Disease; MELD(adj), MELD score
with regression coefficients adjusted for our model; MELD(CrCI), MELD score with logeCrCI
substituted for logecreatinine; ROC, receiver-operating characteristic; UKELD, UK score for
patients with End-stage Liver Disease; UKELD(adj), UKELD score with regression




Our study has examined for the first time eGFR, calculated using the MDRD
equations, in the prediction of mortality on the liver transplant waiting list. We have
demonstrated that decreasing eGFR, as a continuous variable, was associated with an
increased risk of death within 3 months of listing. This reiterates the well recognised
spectrum of renal dysfunction that occurs in the setting of cirrhosis and reflects the
underlying circulatory derangement of advanced disease. Of the three MDRD
equations, the eGFR derived from the 6-variable equation was the better prognostic
indicator. On univariate analysis, eGFR(MDRD6) was comparable, but not superior,
to listing serum creatinine for prediction of 3-month waiting-list mortality. When
substituted for serum creatinine eGFR(MDRD6) did not improve the prognostic
accuracy of the existing MELD and UKELD models.
Although a negative study, the finding that eGFR(MDRD6) is not superior to serum
creatinine in the prediction of waiting-list mortality is an important observation.
Several studies have previously highlighted the prognostic inadequacies of serum
creatinine in patients with end stage liver disease (414,415). Concerns have been
raised that scoring systems for graft allocation that incorporate serum creatinine may
disadvantage some individuals. In searching for alternative measures of renal
function the next step is to use creatinine-based estimates of GFR that adjust for
patient factors potentially conferring systemic bias. The MDRD eGFR is well
validated in the non liver setting, is calculated from readily available variables
including age, gender and race, and has been shown to be the most accurate eGFR in
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cirrhotic patients (282,419,420,421). Our negative results support the need for further
research to identify more precise non creatinine-based measures of renal function in
these patients.
An explanation for the failure of eGFR(MDRD6) to improve the MELD and
UKELD scoring systems is that the equation does not take into account disease-
related factors such as nutritional status. Consequently, eGFR(MDRD6) is not an
accurate measure of absolute renal function with one third of patients demonstrating
an MDRD estimate outwith 30% of the measured GFR (419). The Cockcroft-Gault
eGFR adjusts for body weight and, although a less precise estimator of glomular
filtration rate in this population, it's ability to predict survival remains unknown
(419,427). Notably, the difficulty obtaining an accurate dry weight in patients with
significant ascites and peripheral oedema makes the Cockcroft-Gault eGFR a less
attractive option (412,413).
Other possible weaknesses of eGFR for predicting mortality on the liver transplant
waiting list are as follows. Similar to ascites and serum sodium concentration, eGFR
may be influenced by diuretic use and could theoretically be subject to manipulation
(299). Furthermore, a reduced eGFR may reflect intrinsic renal disease, which may
not confer the same prognostic significance. All patients with evidence of renal
impairment should have renal pathology excluded with urinalysis and renal imaging
(105). Creatinine assays are not currently standardised and there is significant
variability in serum creatinine levels using different methods (428). Therefore, the
prognostic significance of eGFR may not be echoed in all centres.
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The association of measured creatinine clearance with mortality in patients listed for
liver transplantation was a further novel finding of this study. Decreasing measured
creatinine clearance, as a continuous variable, was associated with an increased risk
of death within 3 months of listing. Mirroring the findings of eGFR(MDRD6)
measured creatinine clearance was a comparable, but not superior, prognostic
indicator to serum creatinine. When substituted for serum creatinine measured
creatinine clearance increased the accuracy of MELD and UKELD by 3.6% and
3.2%, respectively, although statistical significance was not achieved. The negative
result may reflect a relatively small patient subgroup, but probably reflects the
inaccuracy of measured creatinine clearance as a measure of absolute renal function
(429).
Despite the large population assessed in this single-centre study, we recognise some
potential limitations. Firstly, due to the retrospective nature we cannot ensure that all
patients with intrinsic renal disease were excluded from the analysis. In our unit
patients assessed for liver transplantation routinely undergo urine testing and renal
ultrasonnography, and those with significant renal impairment are considered for
renal biopsy. As a result, most patients with intrinsic renal disease should have been
identified. Secondly, biochemical values were based on a single measurement and
may not have been a true representation of the steady state in all. However, during
the 5-day liver transplant assessment our patients are relatively stable and less likely
to be subject to diuretic-induced or sepsis-related acute renal impairment. Thirdly,
the patients included in the study were listed over a 15 year period during which
advances have been made in the management of CLD, such as the widespread use of
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terlipressin and albumin for hepatorenal syndrome. Therefore, there may be a small
time effect that could not be factored into the statistical analysis. Finally, the
indications for transplantation in this cohort differ somewhat from the typical
transplant centre with a greater proportion of patients listed for primary biliary
cirrhosis and less for viral hepatitis. The MELD score has shown to have comparable
3-month mortality risk prediction in a diverse range of liver diseases, both cholestatic
and non-cholestatic (410). Consequently, we do not believe that the somewhat
atypical spread of aetiologies should have influenced our findings.
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4.6 Conclusion
Clinically applicable, precise measures of renal function are not currently available
in cirrhotic patients. Serum creatinine remains the most widely used parameter and
despite its limitations has some clinical relevance. A change in serum creatinine may
indicate haemodynamic decompensation or intrinsic renal disease, and serum
creatinine is an important prognostic indicator (409,410). In this study we have
demonstrated that listing eGFR(MDRD6) was comparable, but not superior, to
listing serum creatinine for prediction of 3-month waiting-list mortality, and when
substituted for serum creatinine eGFR(MDRD6) did not improve the prognostic
accuracy of the existing MELD and UKELD models. Our findings support the need
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5.1 Introduction
Renal dysfunction is a common complication of ALF with two thirds of patients
manifesting AKI, and almost half requiring RRT. Many have postulated that the
pathogenesis is similar to the hepatorenal syndrome of cirrhosis (105,169). However,
a growing body of evidence supports a systemic inflammatory response to ALF, and
the SIRS is an independent predictor of AKI in ALF patients (175,215). It follows
that the renal dysfunction of sepsis may be a more accurate parallel than the
hepatorenal syndrome. Additional factors that may contribute to renal dysfunction in
ALF but are less likely in stable cirrhotic patients include hypovolemia, nephrotoxic
drugs particularly paracetamol, infection and disseminated intravascular coagulation
(163,206,207).
Despite the contrasting peri-operative clinical condition of patients transplanted for
ALF and CLD, post liver transplant renal outcomes have not been examined
specifically in this group. Pre-transplant GFR, pre-transplant renal failure requiring
RRT, and acute renal injury are consistent predictors of chronic renal dysfunction
after elective liver transplantation (8,430). Given the greater baseline circulatory and
neuro-humoral derangement of ALF it seems possible that the acute haemodynamic
effects of the CNIs administered immediately following transplantation are
exaggerated (263,264,279,280). On the other hand, the differing patho-physiological
mechanisms could offer relative reno-protection and a reduced risk of CKD.
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The clarification of the impact of liver transplantation for ALF on post transplant
renal function has important implications for patient management. Chronic renal
dysfunction is a major cause of patient morbidity and mortality and the minimisation
of renal injury has emerged as a priority for transplant physicians (8,273,282,284).
Simultaneous liver-kidney transplantation is not an option in patients transplanted for
ALF because of the medical urgency, but the identification of prognostic variables




The aims of this study were firstly to describe the incidence and risk factors for
chronic renal dysfunction following liver transplantation for ALF and secondly to




This was a retrospective single-centre study of consecutive patients who underwent
super-urgent liver transplantation for ALF (UK Transplant Super Urgent Scheme
Category 1-7) between December 1992 and July 2007 (431). Eight patients had
inadequate documentation available and were excluded from the analysis. A further 1
patient was lost to follow-up. Therefore, the study cohort comprised 101 patients.
ALF was defined as severe liver injury with hepatic encephalopathy in which the
onset of encephalopathy was within 8 weeks for the first symptoms of illness, and in
the absence of pre-existing liver disease (159).
Data was collected on the following pre-operative variables at the time of listing:
age, gender, race, liver disease aetiology, additional co-morbidity, smoking status,
INR, serum bilirubin, albumin, serum creatinine, serum sodium (hyponatraemia;
sodium <135 mmol/1), and presence of ascites (on ultrasound). SIRS was defined as
>2 of temperature <36°C or >38°C, heart rate >90 beats per minute, WCC <4xl09/l
or >12x109/1, and PaC02<4.3kPa at the time of admission (212). Documented peri¬
operative variables were peak pre-operative serum creatinine, pre-operative RRT,
post-operative RRT, inotropes (noradrenaline/adrenaline), bacterial sepsis and fungal
sepsis. Immunosuppression was noted and CNI trough levels at 1-week, 1-month and
12-months (a comparable 12-month value for the linear regression analysis was
obtained for all patients regardless of CNI by expressing the trough as relative to the
median value). Renal function was recorded at 1-month, 6-months, 12-months, and
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2-, 3-, 4- and 5-years following transplantation. Patients still receiving RRT at 1-
month were given an arbitrary serum creatinine of 350 pmol/1 and an eGFR of 15
ml/min/1.73m2.
A patient was considered to have significant renal dysfunction pre-operatively if they
fulfilled the RIFLE criteria for AKI: peak serum creatinine >2 times the baseline
level (390). The baseline serum creatinine was unavailable for most patients and was
estimated as previously described (390). Following transplantation the main measure
of renal function was eGFR, determined using the MDRD Study 4-variable equation
(421).
eGFR = 186 x creatinine(mg/dl)"1154 x age(years)"0 203 x 1.2 1 0(if black) x 0.742(if
female
CKD was defined as eGFR <60 ml/min/1.73m2 on at least 2 occasions from 6
months post transplant onwards: stage 3, stage 4 and stage 5 CKD were defined as
eGFR 30-59 ml/min/1.73m2, 15-29 ml/min/1.73m2, and <15 ml/min/1.73m2 or on
dialysis, respectively (282).
To examine whether the renal dysfunction of ALF has a different renal prognosis
after transplantation to the renal dysfunction of CLD a control group of patients
transplanted for CLD was identified. These patients were age-matched (to within 5
years) and sex-matched to the original cohort. The relatively young age of the
patients transplanted for ALF meant that only 71 patients could be appropriately
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matched. The causes of CLD were primary biliary cirrhosis (18 patients, 25.4%),
alcohol (10 patients, 14.1%), chronic active hepatitis (9 patients, 12.7%), sclerosing
cholangitis (9 patients, 12.7%), cryptogenic cirrhosis (9 patients, 12.7%), hepatitis C
(5 patients, 7.0%) and other (11 patients, 15.5%). Three patients (4.2%) were
transplanted for hepatocellular carcinoma. None of the control patients had intrinsic
renal disease prior to transplantation and no patient underwent combined liver-
kidney transplantation.
Immunosuppression was similar for patients transplanted for ALF and for CLD, and
consisted of a CNI, azathioprine and prednisolone in most cases. Midway through
the specified time period the unit policy for CNI changed from cyclosporine to
tacrolimus. Prednisolone was usually discontinued by 3 to 6 months post transplant
unless otherwise indicated. Deviation from the protocol occurred only in the setting
of adverse event or graft rejection. Acute rejection was usually managed with lg of
methyl-prednisolone intravenously for 3 days followed by re-introduction of oral
steroids with or without increased dose of, or switch to, alternative CNI. Chronic
rejection was managed with the latter and in a small number of patients azathioprine
was changed to mycophenolate. IL-2 receptor antagonist induction therapy was not
administered to any of the patients.
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Statistical analyses
Cumulative incidence of CKD was estimated using the Kaplan-Meier method.
Survival was estimated using Kaplan-Meier plots with log-rank test for differences,
and age-adjusted survival was determined using Cox proportional hazards analyses.
Normally distributed continuous variables and non-parametric continuous variables
were compared using the Student's t-test and Mann-Whitney test, respectively. Chi-
squared analysis or Fisher's exact test were used for comparison of categorical data.
A multivariate linear regression analysis was performed to explore the relationship
between peri-operative renal dysfunction and long term renal function following
transplantation. Clinically relevant factors were included simultaneously with 12-
month eGFR as the dependent variable. Cox proportional hazards analysis was then
used to identify variables predictive of CKD by 5-years post transplant. Three
multivariate models were constructed with all clinically relevant factors entered
simultaneously. Variables entered into Model 1 were age, gender, pre-transplant
diagnosed hypertension, category of ALF (paracetamol-induced vs non-paracetamol-
induced), SIRS, CNI at time of hospital discharge and pre-transplant AKI. In Models
2 and 3 AKI was replaced by the other measures of peri-operative renal dysfunction,
peak pre-operative change in serum creatinine and immediate post transplant RRT,
respectively. All 3 measures of peri-operative renal dysfunction were not included in
the same model because of collinearity. None of the multivariate models were
adjusted for the presence of pre-transplant diabetes mellitus secondary to small
patient numbers. P<0.05 was considered statistically significant unless otherwise
stated. Data was analysed using the SPSS 15 package.
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All values are expressed as mean and standard deviation (SD), and median and inter¬




The causes of ALF were paracetamol (46 patients, 45.5%), seronegative hepatitis (27
patients, 26.7%), idiosyncratic drug reaction (11 patients, 10.9%), autoimmune
hepatitis (7 patients, 6.9%), hepatitis B (4 patients, 4.0%), Budd-Chiari (3 patients,
3.0%), Wilsons disease (2 patients, 2.0%) and hepatitis A (1 patient, 1.0%).
The median jaundice to encephalopathy time for patients with non-paracetamol-
induced ALF was 14 (IQR 11-31) days. In patients with paracetamol-induced ALF
the median time from overdose to listing for liver transplantation was 69 (IQR 54-72)
hours. Patient characteristics at the time of listing are outlined in Table 5.1. The
median time from listing to transplantation was 1 (IQR 1-2) day. The estimated 1-
month, 12-month and 5-year post transplant patient survival was 83%, 75% and 68%,
respectively.
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Type I diabetes mellitus 2(2.0)




Seronegative hepatitis 27 (26.7)
Idiosyncratic drug reaction 11 (10.9)
Autoimmune hepatitis 7 (6.9)
Hepatitis B 4 (4.0)
Budd-Chiari 3 (3.0)
Wilsons disease 2 (2.0)
Hepatitis A 2(1.0)









Grade lll/IV encephalopathy 57(59.4)
Inotropes 36(37.9)
Values expressed as mean (standard deviation), median (inter-quartile range) and number (percent)
where appropriate.
Abbreviations: ALF, acute liver failure; INR, international normalised ratio; MELD, Model for End-stage
Liver Disease; SIRS, systemic inflammatory response syndrome.
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Peri-operative renal function
Actual baseline renal function was available in 21 patients: the median baseline
serum creatinine was 75 (IQR 60-93) pmol/1 and the mean baseline eGFR was 106
(SD 45) ml/min/1.73m2.
During the immediate pre-operative period the median peak serum creatinine of the
entire cohort was 203 (IQR 102-362) pmol/1. Fifty-four patients (53.5%) fulfilled the
criteria for AKI, of whom 72.2% underwent RRT. A further 5 patients were
commenced on haemofiltration in the absence of a creatinine rise. Following
transplantation 64.9% (n=63) received RRT. By 1-month post transplant the median
serum creatinine was 97 (IQR 83-136) pmol/1 and the mean eGFR was 67 (SD 40)
ml/min/1.73m2. Four of the surviving patients (4.8%) were still on RRT at this time
point.
When patients with and without paracetamol-induced ALF were compared the
former were more likely to demonstrate peri-operative renal dysfunction.
Paracetamol-induced ALF patients had a greater median peak pre-operative serum
creatinine (paracetamol-induced-ALF, 332 (217-415) pmol/1, n=47; non-
paracetamol-induced-ALF, 108 (86-187) pmol/1, median (IQR), n=54; p<0.001), a
greater frequency of AKI (paracetamol-induced-ALF, 83%; non-paracetamol-
induced-ALF, 28%; p<0.001), and a greater frequency of pre- (paracetamol-induced-
ALF, 74%; non-paracetamol-induced-ALF, 15%; p<0.001) and post-operative RRT
(paracetamol-induced-ALF, 95%; non-paracetamol-induced-ALF, 38%; p<0.001). At
1-month post transplant mean eGFR was similar for the two groups (paracetamol-
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induced-ALF, 57 (30) ml/min/1.73m2, n=36; non-paracetamol-induced-ALF, 74 (44)
ml/min/1.73m2; mean (SD), n=48; p=0.053).
Post-operative renal function
In most patients renal function demonstrated maximal recovery by 6- to 12-months
following transplantation. The mean 12-month eGFR was 70 (SD 21)
ml/min/1,73m2, and 21.1% (n=16) of patients had stage 3-5 CKD by this time point.
In those patients with follow up to 5 years after transplantation the mean eGFR
remained stable at 70 (SD 20) ml/min/1.73m2, and the prevalence of stage 3-5 CKD
was 29.5% (n=13). Twelve month eGFR demonstrated a close correlation with 5-
year eGFR (r=0.809, p<0.001). The cumulative incidence of stage 3-5, and stage 4-5
CKD by 5-years was 41.5% and 2.6%, respectively.
Figure 5.1 demonstrates the mean listing and 1-month, 6-months and 12-months after
transplantation eGFR of patients surviving to 12-months, subdivided based on
paracetamol as the cause for ALF compared with other aetiologies. Beyond the peri¬
operative period, there was no difference in the mean eGFR of the paracetamol-
induced ALF and non-paracetamol-induced ALF groups (p value <0.013 considered
significant). The cumulative incidence of stage 3-5 CKD by 1- and 5-years post
transplant was 8.6% and 27.4% for paracetamol-induced ALF patients respectively,
and 29.3% and 50.9% respectively for non-paracetamol-induced ALF patients
(p=0.021).
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Figure 5.1: Mean eGFR and 95% confidence intervals at the time of listing for liver
transplantation and at 1, 6 and 12 months following transplantation in all patients
surviving to 12 months subdivided into paracetamol-induced and non-paracetamol-
induced ALF groups. P value <0.013 considered significant.




Paracetamol-induced 27.2 56.6 74.4 75.7
(n:35)
P value <0.001 0.026 0.429 0.032
Abbreviations: ALF, acute liver failure; eGFR, estimated glomerular filtration rate.
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Relationship between peri-operative renal dysfunction and post transplant
mortality
ALF patients who fulfilled the criteria for AKI prior to transplantation had greater
mortality post transplant (log-rank p=0.061: age-adjusted HR 2.09; 95% CI 1.01-
4.34, p=0.048) (Figure 5.2). Similarly, patients who required post operative RRT
demonstrated an increased risk of death (age-adjusted HR 6.22; 95% CI 2.01-19.26,
p=0.002).
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Figure 5.2: Kaplan-Meier plot of the probability of survival following liver
transplantation for ALF subdivided based on the presence or absence of pre¬
operative AKI.
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Abbreviations: AKI, acute kidney injury; ALF, acute liver failure.
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Relationship between peri-operative renal dysfunction and post transplant
renal function
To explore the relationship between peri-operative renal dysfunction and long term
renal function following transplantation for ALF a multiple linear regression analysis
was performed, therefore, allowing adjustment for other relevant clinical factors such
as age, gender and immunosuppressive therapy. Given the close correlation between
12-month eGFR and 5-year eGFR, 12-month eGFR was used as the dependent
variable (Table 5.2). The analysis revealed no significant association between pre-
transplant AKI and 12-month post transplant eGFR (p=0.098). Instead, increasing
age (p=0.012), female gender (p=0.005), pre-operative SIRS (p=0.041) and
cyclosporine as primary immunosuppression (p=0.021) were associated with worse
renal function. Patients with paracetamol-induced ALF had a higher 12-month eGFR
compared with patients with non-paracetamol-induced ALF (p=0.027).
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Table 5.2: Multivariate linear regression analysis of variables associated with eGFR
12-months following liver transplantation for ALF.
B (95% CI) p p value
Age (years) -0.516 -0.916, -0.116 -0.318 0.012
Female gender -14.500 -24.358, -4.643 -0.332 0.005
Past medical history: hypertension -20.354 -59.134, 18.426 -0.123 0.297
Paracetamol-induced ALF 16.176 1.889, 30.463 0.371 0.027
Pre-operative SIRS -12.780 -24.991, -0.570 -0.270 0.041
Pre-operative acute kidney injury -10.204 -22.369, 1.960 -0.235 0.098
CNI: cyclosporine -12.465 -22.947, -1.983 -0.263 0.021
12-month CNI trough 0.583 -7.662, 8.832 0.016 0.887
Reference group (relative risk 1.00): male gender, past medical history: no hypertension,
non-paracetamol-induced ALF, no pre-operative SIRS, no pre-operative acute kidney injury
CNI: tacrolimus (at time of 12-month eGFR).
Abbreviations: ALF, acute liver failure; B, unstandardised regression coefficient; p,
standardised regression coefficient; CNI, calcineurin inhibitor; eGFR, estimated glomerular
filtration rate; SIRS, systemic inflammatory response syndrome.
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Predictors of chronic kidney disease following transplantation
Recognising the significant morbidity and mortality of CKD, as well as concerns
regarding the influence of early deaths after transplantation on the 12-month data,
cox regression was then performed to identify peri-operative variables predictive of
post transplant CKD. Variables associated with the development of CKD following
transplantation on univariate analysis are outlined in table 5.3. A subsequent
multivariate regression analysis including all clinically relevant variables
simultaneously (Model 1 table 5.3) identified older age (overall p=0.019), female
gender (p=0.049), pre-transplant diagnosed hypertension (p=0.031) and cyclosporine
immunosuppressive therapy (p=0.027) to be predictors of CKD after transplantation.
Patients transplanted for paracetamol-induced ALF were at lower risk of CKD than
patients transplanted for non-paracetamol-induced ALF (p=0.039).
Pre-transplant AKI both on univariate analysis (p=0.796), and after adjusting for
confounding factors (p=0.288), was not predictive of post transplant CKD. Similarly,
no relationship was demonstrated between peak pre-operative change in serum
creatinine (univariate analysis, p=0.838; multivariate analysis, p=0.457, Model 2
table 5.3), or RRT during the immediate post transplant period (univariate analysis,
p=0.420; multivariate analysis, p=0.134, Model 3 table 5.3), and chronic renal
dysfunction.
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Comparison of post transplant renal function in patients transplanted for
acute liver failure and age-sex matched patients transplanted for chronic liver
disease
To determine whether ALF per se is associated with renal function following
transplantation age-sex-matched patients transplanted for CLD were introduced into
the statistical analysis. Pre- and peri-operative characteristics of patients with ALF
and with CLD are compared in table 5.4. The median waiting-list time was 1 (IQR 1-
2) day for ALF patients and 52 (IQR 20-136) days for CLD patients (p<0.001).
Median listing serum creatinine was higher (p<0.001), mean listing eGFR lower
(p<0.001) and the frequency of ascites less (p<0.001) in the ALF group.
Furthermore, the ALF patients were more likely to receive pre- (p<0.001) and post¬
operative RRT (p<0.001). The estimated 1-month, 12-month and 5-year survival was
78%, 69%, and 62%, respectively, for ALF patients and 96%, 90% and 79% for
patients with CLD (Figure 5.3, log-rank p=0.029).
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Table 5.4: Pre- and peri-operative clinical characteristics of patients transplanted for
ALF and age-sex-matched patients transplanted for CLD.
ALF (no:71) CLD (no:71) p value
Age (years) 42.2(12.4) 42.5(12.1) 0.918
Male:Female 1:1.3 1:1.3 1.000
Time on waiting list (days) 1(1-2) 52(20-136) <0.001
Comorbidity
Diagnosed hypertension 6(8.5) 2(2.8) 0.137
Type 1 diabetes mellitus 0(0) (0) 1.000
Type II diabetes mellitus 1(1.4) 5(7.0) 0.104
Dyslipidaemia 1(1.4) 4(5.6) 0.183
Hepatitis C 1(1.4) 6(8.5) 0.058
Active smoker 37(56.9) 20(29.4) 0.001
At listing
INR 5.8(2.8-11.1) 1.2(1.1-1.5) <0.001
Bilirubin (pmol/l) 227(81-486) 67(35-172) <0.001
Albumin (g/l) 30.8(11.4) 30.0(5.6) 0.582
MELD score 41(33-52) 16(12-19) <0.001
Creatinine (pmol/l) 148(94-298) 81(71-97) <0.001
eGFR (ml/min/1,73m2) 49(42) 83(30) <0.001
Hyponatraemia 27(38.0) 19(26.8) 0.151
Ascites 18(25.4) 41(57.7) <0.001
Peri-operative
Peak creatinine (pmol/l) 200(99-384)
Pre RRT 30(42.3) 0(0) <0.001
Post RRT 41(61.2) 12(16.9) <0.001
Fungal sepsis 5(7.5) 3(4.2) 0.327
Bacterial sepsis 35(52.2) 25(35.2) 0.044
Super-urgent retransplant 4(5.6) 4(5.6) 0.641
Early acute cellular rejection 17(25.4) 28(39.4) 0.078
CNI on discharge: cyclosporin 16(28.1) 27(39.1) 0.192
Values expressed as mean (standard deviation), median (inter-quartile range) and number (percent) where
appropriate.
Abbreviations: ALF, acute liver failure; CLD, chronic liver disease; CNI, calcineurin inhibitor; eGFR, estimated
glomerular filtration rate; INR, international normalised ratio; MELD, model for end-stage liver disease; RRT, renal
replacement therapy.
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Figure 5.3: Kaplan-Meier plot of the probability of survival following liver












'i.. Chronic liver disease
Acute liver failure
Log-rank p=0.029
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Time (years)
Number of patients at risk:
Chronic liver disease
71 62 56 56 33 13 1 0
Acute liver failure
71 43 32 23 26 11 4 1
Abbreviations: ALF, acute liver failure; CKD, chronic liver disease.
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By 1 month following transplantation the median serum creatinine (ALF, 92 (83-
127) pmol/1; CLD, 88 (79-101) pmol/1, median (IQR); p=0.103) and the mean eGFR
(ALF, 69 (42) ml/min/1.73m2; CLD, 74 (27) ml/min/1.73m2, mean (SD); p=0.451)
were similar in ALF and CLD patients. Figure 5.4 illustrates the mean pre- and post¬
transplantation eGFR in patients with ALF and CLD surviving to 12 months. The
accompanying table (table 5.5) documents relevant pre- and post-transplant clinical
variables of these surviving patients. Despite significantly lower listing eGFR in the
ALF group renal function was similar at all time points in the post-operative period.
The cumulative incidence of stage 3-5 (ALF, 48.7%; CLD, 49.6%; p=0.930) and
stage 4-5 CKD (ALF, 4.1%; CLD, 8.7%; p=0.615) by 5 years was also no different
between ALF and CLD groups.
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Figure 5.4: Mean eGFR and 95% confidence intervals at the time of listing for liver
transplantation and at 1, 6 and 12 months following transplantation in all patients
surviving to 12 months subdivided into ALF and CLD groups. P value <0.013
considered significant. The median time from listing to transplantation for ALF
patients was 1 (IQR 1-2) day and for CLD patients was 52 (20-136) days.
LL
« 30-
0-1 , , , ,
Listing 1 month 6 months 12 months
eGFR (ml/min/1.73m2) compared at time points
Chronic liver disease (n:62) 83.3 74.5 69.2 66.2
Acute liver failure (n:49) 51.1 69.8 69.0 667
p value <0.001 0.468 0.965 0.897
Abbreviations: ALF, acute liver failure; CLD, chronic liver disease; eGFR, estimated
glomerular filtration rate.
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Table 5.5: Relevant pre- and post-transplant clinical characteristics of all patients
transplanted for ALF and patients transplanted for CLD surviving to 12 months after
transplant.
Characteristic
Age at listing (years)
Male:Female
Comorbidity at 12-month post transplant
Diagnosed hypertension
Type II diabetes mellitus
Insulin-dependent diabetes mellitus
CNI on discharge: cyclosporine
1 week CNI trough:
Cyclosporine
Tacrolimus
1 month CNI trough:
Cyclosporine
Tacrolimus
12 month CNI trough:
Cyclosporine
Tacrolimus














Values expressed as mean (standard deviation) and number (percent) where appropriate.
P value <0.017 considered significant.
Abbreviations: ALF, acute liver failure; CLD, chronic liver disease; CNI, calcineurin inhibitor.
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5.5 Discussion
In this large single-centre study we have described for the first time the risk factors
for chronic renal dysfunction following emergency liver transplantation for ALF.
Importantly, we have shown that peri-operative kidney injury does not appear to
have negative consequences for long term renal function in this population. Contrary
to observations in CLD patients pre-transplant AKI and RRT were not associated
with CKD. Only failure to recover renal function, as evidenced by eGFR at 1-month
post transplant, was a predictive factor. Despite marked differences in the peri¬
operative clinical condition of patients transplanted for ALF and CLD long term
renal outcome following transplantation was the same.
The rate of CKD after transplantation for ALF was similar to that reported by Aberg
et al, the single other publication of renal function in this setting (432). Although half
of our patients fulfilled the criteria for AKI pre-transplant, and more than 60%
required RRT during the immediate post-operative period, only 21% had an eGFR
less than 60ml/min/1.73m2 12 months thereafter. This dramatic renal recovery
echoes clinical observations in spontaneous survivors of ALF. By 5-years post
transplant the cumulative incidence of CKD was 42%.
The identical post transplant renal function of ALF and CLD patients was
unexpected when considering our current understanding of the underlying
mechanisms (4,263,264,279,280). Based on the traditional hypothesis of hepatorenal
syndrome one might predict that severe peri-operative renal vasoconstriction would
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exacerbate calcineurin-inhibitor mediated kidney dysfunction (4,263,264,279,280).
Cyclosporine and tacrolimus cause an initially haemodynamic dose-dependent renal
impairment that is feasibly exaggerated in patients with greater baseline circulatory
and neuro-humoral derangement (263,264,279,280). Our results support an
alternative patho-physiological process underlying the renal injury that occurs in
ALF.
In Chapter 3 we demonstrated that SIRS predicts the development of AKI in patients
with non-paracetamol-induced ALF, a relationship that appears to be independent of
the severity of liver injury. Consequently, we have postulated that the renal
dysfunction of sepsis may be a more accurate parallel than the hepatorenal syndrome
of cirrhosis. In fulminant hepatic failure the systemic inflammatory response may be
the key mediator of renal impairment. Patients with subfulminant ALF are more
likely to have clinically significant portal hypertension, and may develop ascites
(172). Therefore, this group may share some of the haemodynamic and neuro¬
humoral features of hepatorenal syndrome. In sepsis, kidney injury may occur in the
setting of preserved or even increased renal perfusion, which is in contrast to the
intense renal vasoconstriction of hepatorenal syndrome (4,183). We propose that
relative renal hyperaemia may help to minimise the renal haemodynamic response to
CNIs and explain the comparable long term post transplant renal function
demonstrated by ALF patients (263).
Alternatively, the failure of peri-operative renal dysfunction to impact on long term
post transplant renal outcomes may reflect the duration of renal impairment. In
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patients transplanted for CLD renal dysfunction duration appears to be a key
determinant of chronic renal impairment. Campbell et al demonstrated that renal
dysfunction duration of greater than 3.6 weeks pre-transplant was an appropriate cut¬
off to identify patients at risk of renal insufficiency 12-months thereafter (433). In
our cohort the renal injury, although more severe, was on the contrary short-lived.
In the non-transplant population AKI is a risk factor for chronic renal dysfunction.
For example, in patients who undergo major vascular surgery the occurrence of peri¬
operative AKI is associated with an increased risk of CKD (268). Furthermore,
patients requiring dialysis for AKI who are dialysis-independent at the time of
hospital discharge are 3 times more likely to develop end-stage renal failure (269).
Animal studies have confirmed that AKI can cause permanent structural kidney
damage with progressive tubulo-interstitial fibrosis and long term implications for
renal function (270). Our failure to show a relationship between peri-operative renal
dysfunction and post transplant CKD is not in accordance with these observations.
AKI is an independent predictor of mortality in patients with ALF, and following
transplantation for ALF. Yet, our findings suggest that beyond hospital discharge
acute renal impairment, if short-lived, does not impact particularly on chronic renal
function.
Paracetamol as the cause of ALF was associated with a higher absolute eGFR at 12-
months following transplantation and a reduced risk of CKD. Paracetamol is an
independent predictor of AKI in patients with ALF and there are case reports of renal
failure following paracetamol overdose in the absence of significant hepatic injury
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(209,211). Animal models support a direct nephrotoxic effect although the
mechanism remains unclear (209). It has been hypothesised that a locally produced
metabolite induces proximal tubular cell necrosis while functional renal effects may
also contribute (209,210,400). Our findings support the reversibility of paracetamol-
induced nephrotoxicity (434,435).
The study has some potential limitations that should be mentioned. Firstly, baseline
renal function was only available in a small number of ALF patients and it is possible
that a proportion could have had undiagnosed intrinsic renal disease. The patients
studied were of a relatively young age and it is assumed that pre-morbid renal
function was normal. Secondly, nephrotoxic medications could have influenced the
severity of peri-operative renal dysfunction. Our unit avoids nephrotoxic drugs, yet,
this does not preclude exposure prior to transfer. Thirdly, although our study consists
of one of the largest single centre cohorts of patients transplanted for ALF it remains
possible that the relatively small numbers may have influenced our results.
With regards the CLD group, only 70% of the ALF patients could be matched
because of the young age range. Furthermore, the pre-transplant eGFR was only
available at the time of listing and not immediately prior to transplantation. Pre-
transplant kidney function may, therefore, have been over represented in the CLD
patients if there was a significant deterioration on the list. Nevertheless, no CLD
patient required pre-operative RRT or reassessment for combined liver-kidney
transplantation and, given the relatively short median waiting-list time of 52 days, it
seems unlikely that this data would have influenced the results. The lack of pre-
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transplant renal impairment in the control arm may also raise some concerns about
it's generalisability for a standard population of liver transplant recipients. This
largely reflects the younger age of the patients. However, those with intrinsic renal
disease or who received a simultaneous liver-kidney transplant were also deliberately
excluded; we wished to examine whether the physiological differences between ALF
and CLD would influence renal outcomes. Of course, it is well recognised that eGFR
is not an accurate measure of renal function in patients listed for elective liver
transplantation, tending to overestimate when the true GFR is reduced (419). Sixty
percent of the CLD patients had ascites and one third had hyponatraemia, indicating
a high prevalence of portal hypertensive-related renal impairment (389). Finally, it is
difficult to ensure retrospectively that ALF and CLD patients received similar
immunosuppressive regimes. However, during the period studied our unit had a
single protocol that was rarely deviated from with CNI administration within 24
hours of transplantation. The similar post transplant CNI trough levels support this
claim.
The findings of our study have important implications for patient management.
Patients who undergo liver transplantation for ALF should not be considered a high
risk group for developing CKD even when peri-operative acute renal impairment is
severe. Consequently, we do not support the routine use of 1L-2 receptor antagonists
and delayed introduction of the CNI in this setting (295). Renal sparing
immunosuppression such as mycophenolate and reduced dose tacrolimus could be




In conclusion, in this large single-centre study of patients transplanted for ALF we
have shown that the severity ofperi-operative renal dysfunction was not predictive of
post transplant CKD. Despite greater peri-operative physiological derangement in
ALF patients when compared with an age-sex-matched cohort transplanted for CLD
renal function following transplantation was the same.
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CHAPTER 6
The late decline in renal function after liver transplantation: Modifiable
patient factors associated with the annualised change in eGFR from 6
months after transplantation
Published by Leithead JA, Ferguson JW, Hayes PC. Modifiable patient factors are
associated with the late decline in renal function following liver transplantation.
Clinical Transplantation 2012; 26(3):E316-23.
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6.1 Introduction
Chronic renal dysfunction is an important complication of liver transplantation,
associated with significant morbidity and mortality (8,273,284). The 5 year
cumulative incidence of severe CKD has been reported to be as high as 18%, and
liver transplant recipients who develop CKD have a 5 times increased risk of death
(8,282). The prevention of chronic renal dysfunction following liver transplantation
has emerged as a priority for transplant physicians.
Early post-operative renal function is an indicator of renal outcome in this setting.
Most patients demonstrate a steep decline in GFR during the first post-operative
weeks with relative stabilisation thereafter, and 6- and 12-month post transplant GFR
are consistent predictors of chronic renal dysfunction (8,264,275,276,277,278).
Consequently, the peri-operative period has become a focus for interventions to
lessen the decline in GFR. Cyclosporine and tacrolimus are considered to play a
critical role in shaping renal function after transplantation (263,264,279,280). Several
randomised controlled trials examining peri-operative minimisation of CNI exposure
have been published (265,295,296). Yet, the results are mixed failing to demonstrate
any convincing long term benefit in unselected patients.
The change in renal function beyond the initial post-operative period has received
less attention. The steady state long-term rate of change in GFR allows individuals at
risk of progression to CKD to be identified (282). Furthermore, by examining the
relationship between rate of change and modifiable risk factors potential therapeutic
201
interventions can be suggested (282). In renal transplant recipients, patients who
receive tacrolimus or non CNI based immunosuppression have a slower rate of
decline in renal function compared to patients prescribed cyclosporine (436). In non-
transplant CKD, hypertension, poor glycaemic control, smoking and possibly
dyslipidaemia have been linked with a faster decline in GFR (282). Renal biopsies of
liver transplant patients with chronic renal failure support a multi-factorial origin
(274). However, the impact of such characteristics on the long-term rate of change in




The aim of this study was to examine the long term change in GFR from 6 months
following liver transplantation, and to identify modifiable factors associated with a
faster rate of decline.
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6.3 Methods
This was a retrospective single-centre case-note study of patients who underwent
elective first liver transplantation between January 1st 1996 and December 31st 2000.
The specified time period allowed the analysis of patients transplanted in an
experienced centre with a follow-up time post transplant of greater than 5 years. This
was an era when peri-operative renal sparing immunosuppression, and aggressive
alteration of immunosuppression in response to moderate post transplant renal
dysfunction, was infrequently practiced in our unit. Furthermore, cardiovascular risk
factors were not as closely monitored. Therefore, variability of management between
patients was less. To allow the analysis of change in renal function in a relatively
homogeneous cohort of patients the records of the following groups were not
reviewed: those listed for ALF (n=39) or joint liver/kidney transplantation (n=7),
those who did not survive for 5 or more years post transplant (n=33) and those who
changed CNI therapy during the follow-up period (n=9). Eighteen patients had
incomplete data available and were also excluded from the analysis. The study group
comprised a total of 97 patients.
Immunosuppression consisted of a CNI, azathioprine and prednisolone in most
patients. Midway through the specified time period the unit policy for CNI changed
from cyclosporine to tacrolimus. Prednisolone was usually discontinued by 3 to 6
months post transplant unless otherwise indicated. Deviation from the protocol
occurred only in the setting of adverse event or graft rejection. Acute rejection was
usually managed with lg of methyl-prednisolone intravenously for 3 days followed
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by re-introduction of oral steroids with or without increased dose of, or switch to,
alternative CNI. Chronic rejection was managed with the latter and in 7 patients
azathioprine was changed to mycophenolate.
Data was collected on the following at the time of listing for liver transplantation:
age, gender, race, aetiology of liver disease, additional comorbidity, smoking status,
MELD score, serum creatinine, serum sodium (hyponatraemia; serum sodium <135
mmol/1), presence of ascites and need for RRT. Post transplantation the following
complications were documented only if occurring during the 5 year follow-up period:
peri-operative RRT, number of acute rejection episodes, chronic rejection, disease
recurrence and re-transplantation. The presence of diabetes, and diagnosed
hypertension and dyslipidaemia were noted if present during the same time period.
All blood pressures, body mass index (BMI) measurements, CNI trough levels and
blood lipid concentrations (non-fasting) taken during routine outpatient appointments
were recorded. These were averaged to provide the average systolic blood pressure,
average diastolic blood pressure, average BMI, average cyclosporine trough level,
average tacrolimus trough level, average cholesterol concentration and average
triglyceride concentration. A comparable calcineurin trough level for the multivariate
models was obtained for all patients regardless of CNI by expressing the trough as
relative to the median value. Obesity was defined as an average BMI greater than or
equal to 30.
GFR was estimated using the MDRD Study 6-variable equation (420).
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eGFR = 170 x creatinine(mg/dl) °"9 x age"0 176 x 1.180(if black) x 0.762(if female) x
serum urea nitrogen"0170 x albumin0138
For each patient the eGFR was calculated from the serum creatinine level taken at
the time of listing for liver transplantation (pre-transplant), and from routine
outpatient clinics at 0.5, 1, 2, 3, 4 and 5 years post transplantation. As per the
National Kidney Foundation CKD was defined as a sustained eGFR of less than 60
ml/min/1.73m2: stage 3, stage 4 and stage 5 CKD were defined as an eGFR of 30 to
59 ml/min/1.73m2, 15 to 29 ml/min/1.73m2, and less than 15 ml/min/1,73m2 or on
dialysis respectively (282).
Statistical analyses
Normally distributed continuous variables were compared using the Student's t-test
and non-parametric continuous variables the Mann-Whitney test. For each patient the
annualized change in eGFR was determined using simple linear regression of all
eGFR measurements available from 6 months post transplantation (282). A negative
annualised change in eGFR represents a decline in eGFR and a positive annualised
change in eGFR represents an improvement in eGFR. The rate of change in eGFR
expected with aging is 1 ml/min/1.73m2 per year (282). Therefore, patients were
described as having a decline in renal function greater than the rate expected with
aging if the annualised change in eGFR was > -1.00 ml/min/1.73m2/year. Patients
with an annualised change in eGFR of between -1.00 and +1.00 ml/min/1.73m2/year
and those with an annualised increase in eGFR of > +1.00 ml/min/1.73m2/year were
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considered to have unchanged renal function and improved renal function
respectively (437).
Logistic regression analyses were used to examine the relationship between the
annualised change in eGFR, and a decline in eGFR greater than the rate expected
with aging, and the development of stage 3-5 CKD. Two separate multivariate
models were constructed with all clinically relevant variables entered
simultaneously. Pre-transplant hypertension was not included in the models because
of small patient numbers. Multivariate linear regression analyses were then used to
determine variables associated with the annualised change in eGFR. Again two
multivariate models were constructed with all clinically relevant variables entered
simultaneously. In model 2 the binary variables insulin dependent diabetes,
diagnosed hypertension and diagnosed dyslipidaemia were replaced with the
continuous variables average glucose, average systolic blood pressure and average
cholesterol in an effort to examine whether modification of these factors might
influence outcome. Age was not included in the models because of collinearity.
Finally, logistic regression analysis was repeated to identify variables associated with
a decline in renal function greater than the rate expected with aging. p<0.05 was
considered statistically significant at all times. Data was analysed using the SPSS 18
package.
The annualised change in eGFR is expressed as the mean with 95% confidence
intervals (95% CI). All other values are expressed as mean and standard deviation




Baseline characteristics of the patients at the time of listing for liver transplantation
are outlined in Table 6.1. The median time from listing to transplantation was 39
(range 2-314) days.
Pre transplant renal function
Pre-transplant the mean eGFR of the entire cohort was 103 (SD 34) ml/min/1.73m2
and the median serum creatinine was 81 (IQR 70-97) pmol/1. Three patients (3.1%)
had an eGFR 30-59 ml/min/1.73m2, 1 patient (1.0%) had an eGFR 15-29
ml/min/1.73m2 and 0 patients had an eGFR <15 ml/min/1,73m2 (Figure 6.1).
Seventeen patients (17.5%) had refractory ascites and 23 (23.7%) had
hyponatraemia.
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Primary biliary cirrhosis 35 (36.1)
Alcoholic liver disease 21 (21.6)
Sclerosing cholangitis 11(11.3)
Cryptogenic cirrhosis 8 (8.2)
Hepatitis C 7 (7.2)
Autoimmune hepatitis 5 (5.1)
Hepatitis B 4(4.1)
Other 6 (6.2)
Hepatocellular carcinoma 7 (7.2)
MELD score 16(5)
Measure of renal function:
Creatinine (pmol/l) 81 (70-97)
eGFR (ml/min/1.73m2) 103(34)
Sodium (mmol/l) 138 (135-140)
Hepatorenal syndrome 2 (2.1)
Renal replacement therapy 0
Ascites 59 (60.8)
Refractory ascites 17 (17.5)
Co-morbidity
Diagnosed hypertension 6 (6.2)
Diagnosed dyslipidaemia 3 (3.1)
Diabetes mellitus 12(12.4)
Insulin dependent diabetes 8 (8.2)
Active smoker 20 (20.6)
Obesity (wet weight) 18(18.8)
Values expressed as mean (standard deviation), median (interquartile range) and number
(percent) where appropriate.
Abbreviations: MELD, for end stage liver disease; eGFR, estimated glomerular filtration rate.
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a* 6-months and 5-years post liver
□ Stage 3 CKD
E9 Stage 4 CKD
I Stage 5 CKD
Change in renal function following transplantation
Eight patients (8.2%) required RRT during the immediate post-operative period.
By six months after transplantation the mean eGFR was 75 (SD 22) ml/min/1.73m2
and the median serum creatinine was 103 (IQR 92-123) pmol/1. Seventeen patients
(17.5%) had stage 3 CKD, 1 patient (1.0%) had stage 4 CKD and no patient had
stage 5 CKD at this time point (Figure 6.1).
During subsequent years there was a progressive increase in the prevalence of renal
dysfunction. At 5 years post transplant 23.7%, 3.1% and 1.0% of patients had stage
3, stage 4 and stage 5 CKD, respectively (Figure 1). The mean 5 year eGFR was 69
(SD 21) ml/min/1.73m2 and the median 5 year serum creatinine was 110 (IQR 98-
129) pmol/1.
eGFR declined at a mean rate of 1.08 ml/min/1.73m2 per year (95% CI 2.13 to 0.03,
p=0.045) from 6 months post transplant. Forty-seven patients (48.5%) demonstrated
a decline in renal function greater than the rate expected with aging. Twenty patients
(20.6%) had no change in renal function and 30 (30.9%) had an improvement in
renal function. Assuming the mean annualised change in eGFR remained constant
the estimated prevalence of stage 3, stage 4 and stage 5 CKD by 10 years post
transplant was 29.9%, 6.2% and 6.2%, respectively.
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Change in eGFR as a predictor of chronic kidney disease by 5 years post
transplant
In patients who developed CKD the mean rate of decline in eGFR from 6 months
post transplant was 2.50 (95% CI -4.03 to -0.97) ml/min/1.73m2 per year compared
with 0.52 (95% CI -1.35 to 0.30) ml/min/1.73m2 per year for patients who did not
(p=0.016). Sixty-seven percent of the CKD group demonstrated a decline in renal
function greater than the rate expected with aging during the preceding years
compared to only 41.4% of the non CKD group (p=0.026).
The annualised change in eGFR from 6 months after transplantation remained an
independent predictor of 5 year CKD in a multivariate model including all clinically
relevant variables simultaneously (table 6.2, p=0.001). Here, the more negative the
change in eGFR (i.e. the greater the decline in eGFR) the greater the likelihood of
CKD. In a similar multivariate model, a decline in renal function greater than the rate
expected with aging was associated with a relative risk of CKD of 6.88 (95% CI
1.75-27.14, p=0.006, adjusted for age, gender, hepatitis C status, pre-transplant
eGFR, refractory ascites and diabetes, peri-operative RRT, and CNI, data not
shown).
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Table 6.2: Univariate and multivariate logistic regression analyses of variables
predictive of CKD by 5 years after liver transplantation.
Univariate Multivariate
OR (95% CI) P
value
OR (95% CI) P
value
Age (years) 1.07(1.02-1.12 0.011 1.09(1.00-1.18) 0.043
Female gender 7.67(2.40-24.52) 0.001 32.11 (3.00-343.71) 0.004
Hepatitis C 2.06 (0.43-9.90) 0.366 31.21 (1.41-688.86) 0.029
Pre-transplant
eGFR (ml/min/1,73m2) 0.97(0.95-0.99) 0.002 0.96 (0.93-0.99) 0.011
Refractory ascites 0.76 (0.23-2.59) 0.663 1.90 (0.21-17.32) 0.571
Diabetes mellitus 0.85 (0.21-3.40) 0.815 5.23 (0.30-91.05) 0.257
Peri-operative RRT 5.08(1.12-22.98) 0.035 33.40 (3.63-307.05) 0.002
CNI: cyclosporine 1.99 (0.78-5.07) 0.151 2.13(0.51-8.96) 0.302
AeGFR 0.86 (0.76-0.98) 0.021 0.63 (0.47-0.84) 0.001
(ml/min/1,73m2/year)
Reference group (relative risk 1.00): male gender, no hepatitis C, no refractory ascites, no
diabetes mellitus, no peri-operative RRT, CNI: tacrolimus.
Abbreviations: CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate;
RRT, renal replacement therapy; CNI, calcineurin inhibitor; AeGFR, mean annualised
change in eGFR from 6 months to 5 years post transplant.
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Factors associated with the change in renal function from 6 months after liver
transplantation
Given the strong association between the decline in renal function from 6 months
post transplant and the development of CKD statistical analyses were then performed
to identify factors that may influence the long term change in eGFR. Clinical
characteristics of the cohort during the follow-up period are outlined in table 6.3.
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Table 6.3: Clinical characteristics of patients after liver transplantation.
Clinical characteristics
Graft dysfunction:
Early acute cellular rejection 33 (34.0)
Late acute cellular rejection 8 (8.2)
Chronic rejection 4 (4.1)
Re-transplant 6 (6.2)
Immunosuppression:
CNI: cyclosporine 29 (29.9)
1 month cyclosporine trough 146(50)
1 month tacrolimus trough 8.1(3.0)
Co-morbidity:
Diagnosed hypertension 46 (47.4)
Diagnosed dyslipidaemia 10(10.3)
Diabetes mellitus 21(21.6)
Insulin dependent diabetes 13 (13.4)
Obesity 33 (34.0)
Average value:
Cyclosporine trough (mmol/l) 137 (20)
Tacrolimus trough (ug/l) 7.7 (1.3)
Systolic blood pressure (mmHg) 142 (15)
Diastolic blood pressure (mmHg) 82 (7.1)
Glucose (mmol/l) 5.8 (5.2-6.9)
Cholesterol (mmol/l, n=91) 5.0 (1.3)
Triglyceride (mmol/l, n=51) 1.6 (1.3-2.7)
Body mass index (BMI) 27.8 (5.1)
Values expressed as mean (standard deviation), median (interquartile range) and number
(percent) where appropriate.
Abbreviations: CNI, calcineurin inhibitor.
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In a multivariate linear regression model adjusting for renal relevant variables, with
the mean annualised change in eGFR as the dependent variable, a higher baseline
eGFR (p<0.001), female gender (p=0.006), diagnosed hypertension (p=0.019) and
diagnosed dyslipidaemia (p=0.034) were associated with a faster rate of decline in
renal function (table 6.4, multivariate model 1). There was no association between
the presence of hepatitis C infection, insulin dependent diabetes or
immunosuppression, and change in eGFR. In a second multivariate model, in which
binary variables were replaced with continuous, average systolic blood pressure was
strongly associated with the change in renal function: for every 10 mmHg increase in
average systolic blood pressure there was a 0.76 ml/min/1.73m2 per year faster
decline in eGFR (p=0.005, table 6.4, multivariate model 2).
Logistic regression analysis was then used to determine variables associated with a
rate of decline in renal function greater than that expected with aging (Table 6.5). In
this multivariate model after adjusting for all clinically relevant variables a higher 6
month eGFR (p<0.001), female gender (p=0.024) and diagnosed hypertension
(p=0.050) were independent risk factors. There was a trend towards an association
between cyclosporine and decline in renal function (p=0.071).
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Table 6.5: Univariate and multivariate logistic regression analysis of variables
associated with a rate of decline in renal function from 6 months post liver
transplantation greater than the rate expected with aging.
Univariate Multivariate
OR (95% CI) P OR (95% CI) P~~
value value
6 month eGFR 1.03(1.01-1.06) 0.002 1.06(1.03-1.10) <0.001
(ml/min/1.73m2)
Female gender 1.47 (0.66-3.29) 0.345 3.94(1.20-12.95) 0.024
Hepatitis C 0.40 (0.07-2.17) 0.288 0.878 (0.11-7.27) 0.904
Peri-operative RRT 0.61 (0.14-2.72) 0.521 1.44 (0.23-8.84) 0.697
CNI: cyclosporine 3.37 (1.34-8.51) 0.010 2.68 (0.92-7.79) 0.071
Average CNI trough 0.832 (0.07-10.05) 0.885 1.10 (0.06-20.44) 0.949
Insulin dependent diabetes 0.89 (0.28-2.90) 0.859 0.86 (0.19-3.86) 0.842
Diagnosed hypertension 1.86 (0.83-4.16) 0.133 2.68(1.00-7.19) 0.050
Diagnosed dyslipidaemia 1.68 (0.44-6.39) 0.444 2.95 (0.56-15.43) 0.200
Reference group (relative risk 1.00): male gender, no hepatitis C, no peri-operative RRT,
CNI: tacrolimus, no insulin dependent diabetes, no diagnosed hypertension, no
dyslipidaemia.




In this single-centre study we have described for the first time the annualised change
in eGFR following liver transplantation. In a homogeneous cohort of patients with
long-term survival we examined the change in eGFR beyond the initial post¬
operative period, and current focus of CKD prevention. By estimating the steady
state change in kidney function our aim was to identify possible modifiable risk
factors for the progression to CKD. We have shown that liver transplant recipients
had a clinically relevant decline in eGFR from 6 months post transplant. Our patients
demonstrated a mean decline in eGFR of 1.1 ml/min/1.73m2 per year, and almost
half had a decline in renal function greater than the rate expected with aging. A
decline in eGFR was a strong and independent predictor for the development of
CKD. Multivariate modelling found a higher baseline eGFR, female gender,
hypertension and dyslipidaemia to be associated with a faster rate of decline in renal
function.
Several factors have been identified that may influence the development of chronic
renal dysfunction following liver transplantation. Increasing age, white race, hepatitis
C, pre-transplant diabetes mellitus, pre-transplant renal impairment and peri¬
operative acute renal failure are independent predictors of CKD (8,273,276,278,438).
These variables highlight at the time of surgery the patients at increased risk of renal
injury in whom preventative measures may be more crucial. However, few are
potentially modifiable and little information has been gained regarding appropriate
strategies to delay or avoid the progression to CKD in high risk individuals. In 2 out
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of 3 large randomised controlled trials of unselected patients delayed peri-operative
administration of tacrolimus did not impact on renal function by 1-year post
transplant (265,295,296). All 3 studies were marred by failure to maintain low
tacrolimus trough levels, and Boudjema et al's trial has confirmed that long-term
reduced CNI exposure is probably more important (297). Reduction or withdrawal of
CNI therapy once CKD has developed results in only a marginal improvement in
kidney function (279,288,289,439,440,441). Therefore, prevention of CKD in liver
transplant patients should be a priority (279).
The key outcome of our study was the observation that hypertension and
dyslipidaemia were associated with the rate of decline in renal function after liver
transplantation. Diagnosed hypertension was independently related to a faster decline
in eGFR, and was a risk factor for a rate of decline greater than the rate expected
with aging. Of course it is always difficult to disentangle the relationship between
hypertension and renal function: high blood pressure can be a consequence as well as
a cause of CKD (282). Even so, echoing findings in non-transplant patients with
CKD and the general population, for every increment increase in average systolic
blood pressure there was a faster rate of decline in GFR (282,442,443). This suggests
that blood pressure control may be of particular importance in limiting the
progression to CKD (459).
Diagnosed dyslipidaemia was also an independent predictor of change in eGFR,
although we were unable to demonstrate a correlation with lipid levels. The diagnosis
of dyslipidaemia was made by primary care or non-transplant hospital physicians,
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and lipid levels were non-fasting and variably performed in the study cohort.
Consequently, the reported lipid levels are probably a poor reflection of the true lipid
profile. In the non-transplant setting the association between dyslipidaemia and a
faster rate of progression of kidney disease is contentious (282). However, many
studies in patients with and without renal dysfunction have linked high cholesterol,
triglyceride and LDL levels, and low HDL levels, with the rate of change in GFR.
Furthermore, lipid-lowering therapy has been shown to slow the decline in renal
function (282,443,444).
In our study female patients had a faster rate of decline in eGFR than males,
mirroring the gender difference demonstrated by renal transplant recipients (437).
Female gender is a risk factor for chronic renal dysfunction following liver, heart and
lung transplantation (8). In contrast, in non-transplant patients male gender is linked
with a faster rate of decline in GFR (282). A possible explanation for this
discrepancy is that females may be more susceptible to CNI mediated renal injury.
The strong association between baseline eGFR and change in eGFR may represent a
statistical phenomenon. Nevertheless, we attempted to minimise 'regression to the
mean' by estimating eGFR slope using a large number of measurements and by
adjusting all analyses for baseline renal function (445,446). We speculate that
patients who had a higher eGFR at 6 months post transplant had greater CNI
exposure than those with renal dysfunction. Moreover, additional potential
contributing factors such as hypertension and dyslipidaemia may have been
monitored less closely in this group.
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The retrospective nature of our study and relatively small patient numbers may
explain the failure to demonstrate a relationship between diabetes, and
immunosuppression, and change in eGFR (282). Furthermore, we did not have urate
levels or urinary protein concentrations available on a sufficient number of patients
to allow analysis (447). On the other hand, an advantage of the population size and
methodology was that it allowed the close observation of risk factors over a
prolonged time period. Additional potential limitations were the precision of the
main outcome measures eGFR and eGFR slope. The former has been shown to be a
less precise measure of GFR in liver transplant recipients than in other groups (419).
However, it is the most widely accepted readily available measure of renal function.
The precision of change in eGFR determined from the slope of eGFR over time
increases with the duration of follow-up (445). All our patients had change in eGFR




In conclusion, our study has shown for the first time that liver transplant recipients
have a clinically relevant decline in eGFR from 6 months following transplantation.
We have identified modifiable factors that may influence the change in eGFR and
increase the risk of progression to CKD. Our study emphasises the multi-factorial
nature of renal dysfunction following liver transplantation. Prospective studies are
required to examine the effects of aggressive blood pressure and lipid control on the
development of CKD in liver transplant patients.
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CHAPTER 7
Renal dysfunction in liver disease: General discussion
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Renal dysfunction is common and continues to have devastating consequences in
patients with all aspects of liver disease. In cirrhosis and ALF, management remains
primarily supportive and does not impact on prognosis. Only liver transplantation
offers survival benefit, but is a finite resource. Moreover, liver transplantation itself
is complicated by both AKI and CKD.
The studies presented in this thesis have helped to further our knowledge of portal
hypertension-related renal dysfunction, AKI in ALF and CKD after liver
transplantation. By doing so, we have moved one step closer to improving patient
morbidity and mortality as a result of renal dysfunction in liver disease.
7.1 Renal dysfunction in cirrhosis
Hypothesis: In patients with cirrhosis increased activity of endogenous
endothelin-1 is involved in the pathophysiology of renal dysfunction through
renal vasoconstriction, and endothelin-1 antagonism will reverse these
effects (Chapter 2).
ET-1 has been implicated in the pathophysiology of portal hypertension-related renal
dysfunction. In this randomised, double-blind, placebo controlled, crossover study of
patients with advanced cirrhosis and refractory ascites, acute combined ET-A and
ET-B receptor blockade caused a fall in GFR despite no change in systemic
haemodynamics or total renal blood flow, and a marked reduction in UFR. Selective
ET-A receptor antagonism had no haemodynamic or renal tubular effects suggesting
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that the ET-B receptor plays a key role in this setting. These findings are consistent
with a reno-protective role for ET-1 in portal hypertension-related renal dysfunction.
7.2 Renal dysfunction in acute liver failure
Hypothesis: In acute liver failure the systemic inflammatory response
syndrome is associated with the development of acute kidney injury (Chapter
3).
Current hypothesis suggests that the renal dysfunction of ALF and the renal
dysfunction ofportal hypertension share similar pathophysiology. However, ALF has
distinct clinical characteristics and the circulatory derangement may be more
comparable with sepsis. In a retrospective study we demonstrated for the first time
that in ALF renal dysfunction is associated with SIRS. On univariate analysis
patients with AKI were more likely to be hypothermic, had a faster heart rate, a
higher WCC and a lower PaC02. Multivariate analysis confirmed that SIRS was a
risk factor for the development of AKI. Importantly, this association was
independent of the presence of infection and of severity of liver injury as assessed by
the KCH prognostic criteria. We propose that the systemic inflammatory cascade
plays a key role in its pathogenesis.
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7.3 Renal dysfunction as a prognostic indicator in liver disease
Hypothesis: Estimated glomerular filtration rate is superior to serum
creatinine in predicting prognosis in patients on the liver transplant waiting list
(Chapter 4).
In cirrhosis the spectrum of renal dysfunction evolves in parallel with advancing
disease. Serum creatinine as a continuous variable is an independent predictor of
mortality in those on the liver transplant waiting-list, and is a component of the
MELD score. However, creatinine is influenced by age, gender and race, and in this
role may disadvantage some individuals. The MDRD eGFR takes into account these
variables and may be a superior measure of renal function. In this study we
demonstrated that listing eGFR was comparable, but not superior, to listing serum
creatinine for prediction of 3-month waiting-list mortality, and when substituted for
serum creatinine eGFR did not improve the prognostic accuracy of MELD. Our
findings support the need for further research to identify more precise non creatinine
based measures of renal function in cirrhosis.
7.4 Implications of renal dysfunction for post liver transplant renal
function
Hypothesis: Given potentially different pathophysiological mechanisms
underlying renal dysfunction, patients transplanted for acute liver failure have
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comparatively better long term renal outcomes than patients transplanted for
chronic liver disease (Chapter 5).
Following on from Chapter 3, we further explored our hypothesis that the renal
dysfunction of ALF and the renal dysfunction of CLD have distinct
pathophysiological mechanisms. In patients super-urgently transplanted for ALF we
found that peri-operative AKI did not appear to have the same long-lasting
consequences for renal function as demonstrated by patients undergoing elective
liver transplantation. Contrary to observations in CLD, pre-transplant AKI and RRT
were not associated with CKD. Despite marked differences in the peri-operative
clinical condition of patients transplanted for ALF and an age-sex-matched cohort
transplanted for CLD long term renal outcomes were the same. Our results support
an alternative pathophysiological process underlying the renal injury that occurs in
ALF.
7.5 The late decline in renal function after liver transplantation
Hypothesis: Modifiable patient factors are associated with the long term
decline in renal function after liver transplantation (Chapter 6).
Strategies to delay or avoid the long-term decline in renal function and progression to
CKD in liver transplant recipients remain unclear. In this final study, we observed for
the first time that liver transplant recipients have a clinically relevant decline in
eGFR from 6 months following transplantation, beyond the initial post-operative
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period and current focus of chronic kidney disease prevention. Our patients
demonstrated a mean decline in eGFR of 1.1 ml/min/1.73m2 per year, and almost
half had a decline in renal function greater than the rate expected with aging. A
decline in eGFR was a strong and independent predictor for the development of
CKD. Multivariate modelling found a higher baseline eGFR, female gender,
hypertension and dyslipidaemia to be associated with a faster rate of decline in renal






8.1 Future directions specific to this thesis
To expand on the presented results and take this thesis forward several important
studies should be performed.
Firstly, the findings in the pilot study of ET-1 receptor antagonism in advanced CLD
described in Chapter 2 require confirmation in a larger cohort of patients. A forearm
study as performed by Helmy but in patients with refractory ascites would elucidate
the relative contributions of the ET-A and ET-B receptors, and perhaps confirm that
the ET-B receptor plays a more prominent role in later disease (361,363). The most
striking renal effect we observed was the dramatic fall in UFR with combined ET-A
and ET-B blockade. We have stored plasma and urine samples that we are soon to
analyse to determine whether this reflected inhibition of natriuresis or free water
clearance. It would be interesting to compare findings with ET-1 receptor
antagonism in patients with diuretic controlled ascites.
Secondly, the studies in Chapters 3 and 5 highlight for the first time the likely
differing pathophysiological mechanisms underlying the renal dyfiinction of ALF.
The next step in pursuing our hypothesis is to perform a prospective observational
study in patients with acute liver injury and ALF to describe the association between
the evolution in the systemic inflammatory response and haemodynamic renal and
tubular dysfunction. In the first instance we intend to perform serial blood sampling
(for DAMPs, cytokines and other inflammatory mediators), systemic and renal
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haemodynamic monitoring and urine sampling (for markers of tubular injury and
function), and to correlate them with clinical outcomes.
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8.2 Summary of ongoing work
During the process of this work I acquired an understanding of renal dysfunction in
liver disease that has allowed me to develop unique hypotheses in as yet
understudied renal processes. As a direct result of these skills and knowledge I am
now a Clinical Lecturer in Hepatology in the Queen Elizabeth Hospital Birmingham
and am developing a programme of research in this field.
My main focus of interest is AKI during the immediate post operative period after
liver transplantation. AKI is a major cause of morbidity and mortality in this setting.
Aetiology is multi-factorial with most studies concentrating on recipient risk factors
such as pretransplant renal function, and immunosuppression. However, there is
mounting evidence to suggest that liver graft injury at the time of transplantation, by
driving a systemic inflammatory response, may play an important role in modifying
both short and long term renal outcomes. It follows that the increased use of
extended criteria grafts may have negative consequences for post transplant renal
function. Furthermore, strategies targeting graft injury may minimise the peri¬
operative renal 'hit' and be beneficial for patient outcomes.
I have observed that AKI is more frequent in donation after cardiac death liver
transplant recipients, and in these patients peak peri-operative aspartate amino¬
transferase, a surrogate marker of hepatic ischaemia reperfusion injury, is the only
variable associated with renal dysfunction (448). Similarly, hepatic ischaemia
reperfusion injury demonstrates a strong relationship with AKI in donation after
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brain death recipients, and the optimal graft quality of split livers is associated with a
reduced frequency of RRT (449,450). More recently, I have confirmed that the
increasing use of extended criteria donors has been associated with an increased
incidence of AKI despite better preoperative optimisation of recipient renal function
and less aggressive immunosuppression (451). Increased donor age, increased donor
BMI, higher donor serum sodium and increasing warm ischaemic time are
independently associated with the development of AKI (451).
My future intention is to characterise the peri-operative evolution of the systemic
inflammatory response in patients undergoing liver transplantation with higher risk
grafts, and to delineate the relationship with haemodynamic and renal derangement.
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8.3 Clinical perspective
We are in an era of increasing organ shortage. I hypothesise that hepatic ischaemia
reperfusion injury and the secondary systemic inflammatory response may play a
critical role in the pathogenesis of AKI after liver transplantation. I believe that my
work is the first step in identifying modifiable disease processes that ultimately may
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The systemic inflammatory response syndrome is
predictive of renal dysfunction in patients with non-
paracetamol-induced acute liver failure
J A Leithead, J W Ferguson, C M Bates, J S Davidson, A Lee, A J Bathgate, P C Hayes,
K J Simpson
ABSTRACT
Background: Although renal dysfunction is a common
complication of acute liver failure (ALF) with significant
prognostic implications, the pathophysiological mechan¬
isms remain unclear. The current hypothesis suggests
that the renal dysfunction may mirror the hepatorenal
syndrome of cirrhosis. However, ALF has distinct clinical
characteristics and the circulatory derangement may be
more comparable with sepsis.
Objectives: To examine the relationship between the
systemic inflammatory response syndrome (SIRS) and
renal dysfunction in ALF, and to identify additional risk
factors for renal dysfunction.
Methods: A single-centre retrospective study of 308
patients with ALF was carried out. Renal dysfunction was
defined according to the RIFLE criteria for acute kidney
injury.
Results: 67% of patients developed renal dysfunction. On
univariate analysis, renal dysfunction patients were more
likely to be hypothermic (p = 0.010), had a faster heart
rate (p<0.001), a higher white cell count (p = 0.001) and
a lower PaC02 (p = 0.033). 78% of renal dysfunction
patients and 53% of non-renal dysfunction patients had
SIRS (p<0.001). On multivariate analysis, the risk factors
for renal dysfunction were age (p = 0.024), fulfilled Kings
College Hospital prognostic criteria (p<0.001), hypoten¬
sion (p<0.001), paracetamol-induced ALF (p<0.001),
infection (p = 0.077) and SIRS (p = 0.017). SIRS
remained an independent predictor of renal dysfunction in
the subgroup of patients with non-paracetamol-induced
ALF (n = 91, p = 0.001). In contrast, in patients with
paracetamol-induced ALF (n = 217), no relationship
between SIRS and renal dysfunction was demonstrated
(p = 0.373).
Conclusion: SIRS is strongly associated with the
development of renal dysfunction in patients with non-
paracetamol-induced ALF. It is proposed that the systemic
inflammatory cascade plays a key role in its pathogenesis.
Renal failure is a common complication of acute
liver failure (ALF) that occurs in 43% of patients
with grade IV hepatic encephalopathy.1 It is
associated with increased mortality, emphasised
by the inclusion of serum creatinine in the Kings
College Hospital (KCH) prognostic criteria.2 3
Despite the clinical burden of renal dysfunction
in this setting, the aetiological mechanisms and
risk factors remain unclear. Consequently, treat¬
ment options without liver transplantation are
limited and potential prophylactic measures are
unknown.
The current hypothesis suggests that the renal
dysfunction of ALF and hepatorenal syndrome of
cirrhosis share similar pathophysiology.4 5
Supporting this argument, the circulatory dysfunc¬
tion of ALF, which is characterised by reduced
systemic vascular resistance and high cardiac out¬
put, appears to parallel that of chronic liver
disease.6-9 The marked reduction in renal blood
flow and glomerular filtration rate that is asso¬
ciated with renal failure mirrors the renal perfusion
changes of advanced cirrhosis.7 However, ALF has
distinct haemodynamic features that indicate that
the renal dysfunction of ALF and cirrhosis may not
be comparable. First, clinically significant portal
hypertension is not always present in patients
with ALF and renal dysfunction.' Moreover, the
degree of portal hypertension rarely equates with
that of hepatorenal syndrome in cirrhosis: the
mean reported hepatic venous pressure gradient for
patients with ALF and renal dysfunction is 14 mm
Hg compared with 21 mm Hg for patients with
hepatorenal syndrome.9-11 Secondly, animal studies
imply that the systemic vasodilatation may be
more generalised and not limited to the splanchnic
circulation as occurs in cirrhosis.1213 Pigs with ALF
demonstrate reduced hind leg and renal vascular
resistance, which contrasts with the femoral and
renal vasoconstriction of hepatorenal syndrome.12-
15 Vasodilatation within these vascular beds is more
in keeping with the hyperdynamic syndrome of
sepsis than of advanced cirrhosis.1617 Recently it
had been demonstrated that the systemic inflam¬
matory response syndrome (SIRS) is often present
in patients with ALF.1819 SIRS is associated with
progression of hepatic encephalopathy, suggesting
that the systemic inflammatory response may be
involved in its pathogenesis.1819 Following on from
this, we postulate that the systemic inflammatory
response may play a role in the pathogenesis of
renal dysfunction in these patients.
Additional factors that may contribute to renal
dysfunction in ALF include hypovolaemia, nephro¬
toxic drugs, infection and disseminated intravas¬
cular coagulation.1 20-22 Paracetamol has been
shown in animal models to have a direct nephro¬
toxic effect, and in humans there are case reports of
renal failure following paracetamol overdose in the
absence of significant hepatic injury.23-25
Nevertheless, the frequency of renal dysfunction
in patients with paracetamol-induced ALF has not
been shown to be higher than in other aetiologies.1
At present there is a poor understanding of the
pathogenesis and risk factors for renal dysfunction
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in ALF. The primary aim of our study was to examine whether
SIRS is associated with renal dysfunction in a large cohort of
patients with ALF. Our secondary aim was to identify
additional risk factors for the development of renal dysfunction
in ALF.
PATIENTS AND METHODS
This was a retrospective study of 442 patients admitted to a
single tertiary referral centre with ALF between November 1992
and June 2007. One hundred and seven patients who were
ventilated prior to admission were excluded from the analysis
because of the influence of sedation and mechanical ventilation
on SIRS.1819 A further 6 patients who received renal replacement
therapy but did not fulfil the definition for renal dysfunction,
and 21 patients who did not have a peak serum creatinine
available, were also not assessed. Therefore, the study cohort
comprised 308 patients.
The mean age was 39.7 (SD 14.7) years and the male to
female ratio was 1:1.3. The causes of ALF were paracetamol
overdose (217 patients), seronegative hepatitis (39 patients),
idiosyncratic drug reaction (23 patients), hepatitis B (5
patients), autoimmune (5 patients), alcoholic hepatitis (5
patients), Budd-Chiari (5 patients), acute fatty liver of
pregnancy (3 patients), hepatitis A (2 patients), Wilson disease
(2 patients) and non-paracetamol drug overdose (2 patients).
One hundred and twelve patients died, 112 survived and 83
underwent liver transplantation.
ALF was defined as severe liver injury with hepatic
encephalopathy in which the onset of encephalopathy was
within 8 weeks of the first symptoms of illness, and in the
absence of pre-existing liver disease.26 A patient was considered
to have significant renal dysfunction if they fulfilled the RIFLE
criteria (acronym indicating Risk of renal dysfunction, Injury to
the kidney, Failure of kidney function, Loss of kidney function
and End-stage renal disease) for acute kidney injury (AKI): peak
serum creatinine >2 times the baseline level.27 The baseline
serum creatinine was unavailable and therefore was estimated
from the Modification of Diet in Renal Disease formula with an
assumed glomerular filtration rate at the lower end of normal
(75 ml/min/1.73 m2), as outlined by the Acute Dialysis Quality
Initiative (ADQI) workgroup.27 Serum creatinine may theoreti¬
cally overestimate the glomerular filtration rate in patients with
ALF. Therefore, we chose the criteria for AKI rather than acute
kidney failure to allow detection of significant renal dysfunction
with greater sensitivity.27
Data were collected prospectively and entered into a
dedicated database. The following variables were recorded at
the time of hospital admission: temperature, pulse, white cell
count, neutrophil count, platelet count, international normal¬
ised ratio (INR), serum electrolytes, serum bilirubin, alanine
aminotransferase (ALT), albumin, arterial hydrogen ion (H+),
bicarbonate (HC03~), PaC02 and lactate. Peak creatinine and
peak INR were documented. SIRS was defined as two or more
of temperature <36°C or >38°C, heart rate >90 beats/min
(bpm), white cell count <4xl0'/l or >12xl09/i and PaC02
<4.3 kPa.28 Regular alcohol intake prior to admission was
recorded; alcohol excess was defined for women as >112 g/
week and for men as >168 g/week as per the UK guidelines.29
The presence of the following variables at any point during
admission was documented: ventilation, treatment for
increased intracranial pressure (ICP), hypotension (systolic
blood pressure <90 mm Hg), need for inotropes (noradrena-
line/adrenaline), hypoglycaemia, prognosis assessed using the
KCH criteria, and infection (positive cultures and/or ascitic fluid
polymorphonuclear count >250/mm3 and/or radiological evi¬
dence of infection).3 All patients had cultures (sputum/stool/
ascites/intravascular catheter where appropriate) and a chest x
ray performed routinely on admission, and repeat cultures if
clinically indicated. Spontaneous survival and death were
defined as survival without liver transplantation and death
without liver transplantation, respectively: patients who
received a liver transplant were excluded from all survival
analyses.
Statistical analyses
Normally distributed continuous variables and non-parametric
continuous variables were compared using the Student t test
and Mann-Whitney test, respectively, x2 analysis was used for
comparison of categorical data. Stepwise backwards logistic
regression models, verified with forwards models, were used to
determine the factors independently associated with death and
AKI. Patients who received a liver transplant were excluded
from all survival analyses. Only those variables with p<0.10
were included in the multivariate analyses. p<0.05 was
considered significant. Data was analysed using the SPSS 15
package.
All values are expressed as mean (SD) and median and
interquartile range (IQR) as appropriate.
RESULTS
Prevalence of AKI
At the time of admission to hospital, the median serum
creatinine was 149 (IQR 96-256) pmol/1, and 133 patients
(43%) fulfilled the criteria for AKI. Thereafter, most patients
demonstrated a decline in renal function: 196 patients (64%)
had a >10% increase in serum creatinine, 106 patients (34%)
had no change in serum creatinine and 6 patients (2%) had a
>10% improvement in serum creatinine. The median peak
serum creatinine was 288 (IQR 135-392) pmol/1. Two hundred
and eight patients (67%) fulfilled the criteria for AKI at some
point during their illness, of whom 70% underwent renal
replacement therapy.
Prevalence of SIRS
Seventy percent of patients had SIRS. SIRS was more prevalent
in patients with paracetamol-induced ALF compared with
patients with non-paracetamol-induced ALF (77% vs 54%,
p<0.001). The frequency of SIRS was not affected by the
presence of infection (infected, 70%; non-infected, 70%;
p = 0.880). SIRS was not more common in patients who
achieved KCH poor prognostic criteria (achieved, 72%; not
achieved, 67%; p = 0.344), although a greater proportion of
patients who were hypoglycaemic (hypoglycaemic, 78%; non-
hypoglycaemic, 65%; p = 0.040) or required treatment for
increased ICP (treatment, 79%; no treatment, 66%; p = 0.032)
demonstrated SIRS.
AKI, SIRS and mortality
Patients with AKI had a prolonged hospital admission (AKI, 11
(7-20) days; non-AKI, 6 (4-10) days, median (IQR); p<0.001)
and reduced spontaneous survival (AKI, 36%; non-AKI, 84%;
p<0.001, fig 1). There was no relationship between AKI and
liver transplantation (AKI, 25%; non-AKI, 33%; p = 0.118).
However, the transplanted patients who had AKI preopera-
tively had a longer postoperative hospital stay (AKI, 26 (20-33)
days; non-AKI, 15 (13-20) days, median (IQR); p<0.001) and a
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trend towards reduced survival to hospital discharge (AKI, 67%;
non-AKI, 85%; p = 0.064).
The presence of SIRS was also associated with reduced
spontaneous survival (SIRS, 42%; non-SIRS, 60%, p = 0.035).
Nevertheless, a similar proportion of patients with and without
SIRS received a liver transplant (26% vs 32%, p = 0.386) and
there was no association between SIRS and survival following
transplantation (SIRS, 70%; non-SIRS, 71%, p = 0.957).
Other variables associated with spontaneous survival are
outlined in table 1. On multivariate analysis, AKI, and not SIRS,
was independently associated with mortality.
Relationship between AKI and the aetiology of ALF
Patients who developed AKI were more likely to have ALF as a
result of paracetamol ingestion than those who did not have
AKI (80% vs 51%, p<0.001). The median peak serum creatinine
for patients with paracetamol-induced ALF was 300 (IQR 183—
413) jimol/l and for patients with non-paracetamol-induced ALF
it was 149 (IQR 99-322) pmol/l (p<0.001). Seventy-six percent
of patients with paracetamol-induced ALF and 46% of patients
with non-paracetamol-induced ALF fulfilled the criteria for AKI
(p<0.001).
Relationship between AKI and the severity of ALF
Clinical and biochemical characteristics of the AKI and non-AKI
patients on admission to hospital are outlined in table 2.
Patients with AKI had a higher ALT level (p<0.001), INR
(p = 0.001) and lactate (p = 0.007), and were more likely to be
acidotic (31% vs 0%, p<0.001).
By definition all patients became encephalopathic. However,
the AKI group were more likely than the non-AKI group to be
ventilated (77% vs 56%, p<0.001) and a greater proportion
required treatment for increased ICP (AKI, 34%; non-AKI, 14%;
p<0.001). In addition, patients with AKI were more likely to
Time (weeks)
Number of patients at risk
No acute kidney injury
67 28 8 4 0 0 0 0
Acute kidney injury
156 84 32 15 2 2 2 0
Figure 1 Spontaneous survival in patients with acute liver failure
subdivided based on the presence or absence of acute kidney injury.
Patients who received a liver transplant were excluded from the survival
analysis.
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demonstrate hypoglycaemia (AKI, 50%; non-AKI, 18%;
p<0.001) and to fulfil KCH poor prognostic criteria (AKI,
64%; non-AKI, 37%; p<0.001).
Relationship between AKI and SIRS
Patients who developed AKI had evidence of a greater systemic
inflammatory response. At the time of hospital admission they
were more likely to have a temperature <36°C (AKI, 34%; non-
AKI, 12%; p = 0.010), had a faster heart rate (p<0.001), a higher
white cell count (p = 0.001) and a lower PaC02 (p = 0.033)
(table 2). Furthermore, a greater proportion of those with AKI
developed hypotension (AKI, 63%; non-AKI, 13%; p<0.001) and
required inotropic support (AKI, 56%; non-AKI, 9%; p<0.001).
Seventy-eight percent of the AKI patients had SIRS compared
with 53% of the non-AKI patients (p<0.001). An increasing
number of components of SIRS was associated with an
increased probability of renal dysfunction: 47, 60, 69, 79 and
81% of the patients with 0, 1, 2, 3 and 4 components of SIRS at
admission, respectively, developed AKI (p = 0.047). The AKI
group were more likely to demonstrate infection (AKI, 56%.
non-AKI, 38%; p = 0.003). Nevertheless, in both those with
infection (AKI, 74%; non-AKI, 57%; p = 0.062) and those
without infection (AKI, 82%; non-AKI, 50%; p<0.001) SIRS
was more common in the AKI patients.
Independent risk factors for the development of AKI in ALF
A multivariate analysis was performed to identify the factors
that are independently associated with renal dysfunction
(table 3). This revealed that the severity of ALF, the systemic
inflammatory response to ALF and superimposed factors may
all be relevant. The variables independently associated with AKI
were age (p = 0.024), fulfilled KCH poor prognostic criteria
(p<0.001), hypotension (p<0.001), SIRS (p = 0.017), super¬
imposed infection (p = 0.077) and paracetamol as the cause of
ALF (p<0.001).
In view of the strong association of paracetamol with AKI,
the entire cohort was then subdivided into two groups:
paracetamol-induced ALF and non-paracetamol-induced ALF
based on the presence or absence of paracetamol-induced liver
injury, respectively. The associations between the severity of
ALF and AKI, and SIRS and AKI, were reassessed.
AKI in paracetamol-induced ALF
In the paracetamol-induced ALF subgroup, patients with AKI
had evidence of more severe liver injury when compared with
patients with no AKI (table 4): they were more likely to be
hypoglycaemic (p<0.001), to require treatment for increased
ICP (p = 0.003) and to fulfil KCH poor prognostic criteria
(p<0.001). In contrast, the AKI patients were not more likely to
demonstrate SIRS (p = 0.373) and were not more likely to have
infection (p = 0.287). However, they did have a lower admission
temperature (p<0.001), higher white cell count (p = 0.043),
trend towards a lower PaC02 (p = 0.070), and were more likely
to have 3=3 systemic inflammatory response components (AKI,
43%; non-AKI, 27%; p = 0.055). On multivariate analysis the
factors associated with AKI in patients with paracetamol-
induced ALF were age (OR 1.03; 95% CI 1.00 to 1.06, p = 0.059),
treatment for increased ICP (OR 2.74; 95% CI 1.05 to 7.15,
p = 0.039) and hypotension (OR 11.38; 95% CI 4.19 to 30.91,
p<0.001).
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Table 1 Factors predictive of mortality on univariate and multivariate
analysis in patients with ALF*
Univariate OR Multivariate OR
Variable (95% CI) p Value (95% CI) p Value
Age (years) 1.04(1.02 to 1.06) <0.001 1.06 (1.03 to 1.09) <0.001
Hypoglycaemia 6.20 (3.40 to
11.27)
<0.001 4.97 (2.27 to 10.91) <0.001
Treatment for 5.17 (2.54 to <0.001 6.72 (2.56 to 17.67) <0.001
increased ICP 10.55)
SIRS 2.00 (1.04 to 3.85) 0.037
AKI 9.18 (4.45 to
18.94)
<0.001 5.48 (2.20 to 13.64) <0.001
Reference group (relative risk 1.00): no hypoglycaemia, no treatment for increased
ICP, no SIRS, no acute kidney injury, male gender, non-paracetamol-induced ALF, no
infection.
•Variables not associated with mortality: female gender (p = 0.502), paracetamol-
induced ALF (p = 0.129), infection (p = 0.547).
AKI, acute kidney injury; ALF, acute liver failure; ICP, intracranial pressure; SIRS,
systemic inflammatory response syndrome.
AKI in non-paracetamol-induced ALF
In the non-paracetamol-induced ALF subgroup, patients with
AKI did not have evidence of more severe liver injury relative to
patients with no AKI (table 4). Despite a trend towards an
association between AKI and hypoglycaemia (p = 0.062),
patients with renal dysfunction were not more likely to require
treatment for increased ICP (p = 0.285) or to achieve KCH poor
prognostic criteria (p = 0.491). Nevertheless, there was a strong
relationship between AKI and SIRS (p<0.001, fig 2). Patients
with AKI were more likely to have infection (p = 0.002), and in
both infected (AKI, 78%; non-AKI, 40%; p = 0.017) and non-
infected patients (AKI, 73%; non-AKI, 33%; p = 0.037) the
prevalence of SIRS was greater in those with AKI. On
multivariate analysis the factors associated with AKI in patients
with non-paracetamol-induced ALF were hypotension (OR
8.63; 95% CI 2.63 to 28.3, p<0.001) and SIRS (OR 6.98; 95%
CI 2.13 to 22.83, p = 0.001).
DISCUSSION
We have shown for the first time that in ALF renal dysfunction
is associated with SIRS. On univariate analysis, patients with
AKI were more likely to be hypothermic, had a faster heart rate,
a higher white cell count and a lower PaC02. Multivariate
analysis confirmed that SIRS was a risk factor for the
development of AKI. Importantly, this association was inde¬
pendent of the presence of infection and of severity of liver
injury as assessed by the KCH prognostic criteria. A further
novel finding of our study is the strikingly increased risk of AKI
demonstrated by patients with paracetamol-induced ALF. This
relationship supports in vitro animal data and clinical suspicion
that paracetamol has a direct nephrotoxic effect. Drug-induced
renal injury could mask any relationship between SIRS and
renal dysfunction. Therefore, a key finding of our study is the
strong association between SIRS and AKI in the subgroup of
patients with non-paracetamol-induced ALF.
To our knowledge, this is the first study to examine the
prevalence of SIRS in ALF using all four components of the
systemic inflammatory response.28 Previous groups have
excluded the respiratory component because of the influence
of mechanical ventilation.18 19 30 Using similar methodology to
the earlier studies the prevalence of SIRS in our cohort was
comparable (50%; Rolando et al, 57%; Vaquero et al, 34%;
Schmidt et al, 55%). However, when all four components were
applied, the prevalence of SIRS rose to 70%. The diagnosis of
SIRS was based on parameters at the time of admission to our
unit. Therefore, additional patients may have developed SIRS at
a later stage.
The observation that SIRS may be present in patients with
ALF even in the absence of infection confirms previous
Table 2 Clinical and biochemical characteristics on admission of patients with ALF who did/did not develop
AKI
Variable AKI (208) Non-AKI (100) p Value
Age (years) 41.0 (14.0) 36.9 (15.7) 0.020
Male:female 1:1.2 1:1.4 0.439
Alcohol excess (%) 88 (52) 30 (38) 0.043
Temperature (°C) 36.4 (1.1) 36.8 (0.8) 0.001
Heart rate (bpm) 107 (92-120) 96 (80-110) <0.001
WCC (x10s/l) 12.8 (9.4-18.0) 11.0 (6.9-13.7) 0.001
Neutrophil count (x10'/l) 11.2 (7.6-16.5) 8.8 (5.9-12.2) <0.001
Lymphocyte count (xlO'/l) 0.7 (0.5-1.2) 1.0 (0.7-1.5) 0.002
Platelet count (x10"/l) 115 (55-162) 158 (99-237) <0.001
INR 4.9 (3.0-7.1) 3.7 (2.5-5.6) 0.001
Sodium (mmol/l) 134 (129-138) 136 (133-138) 0.007
Potassium (mmol/l) 4.1 (3.6-5.0) 3.6 (3.3-4.2) <0.001
Urea (mmol/l) 7.7 (5.0-12.5) 4.1 (2.7-7.4) <0.001
Creatinine (pmol/l) 221 (138-298) 92 (74-113) <0.001
Bilirubin (pmol/l) 96 (68-139) 140 (88-433) <0.001
ALT (U/l) 5856 (2105-10 000) 2655 (957-6775) <0.001
Albumin (g/l) 32.9 (8.2) 32.9 (7.2) 0.946
H< (nmol/l) 41 (35-50) 33 (31-37) <0.001
PaC02 (kPa) 4.0 (3.2-4.6) 4.2 (3.8-4.8) 0.033
HCO3' (mmol/l) 18.1 (13.7-22.8) 24.0 (20.9-26.9) <0.001
Lactate (mmol/l) 4.2 (2.6-8.4) 2.7 (2.0-4.5) 0.007
Any encephalopathy (%) 125 (61) 68 (68) 0.253
SIRS (%) 136 (78) 43 (53) <0.001
AKI, acute kidney injury; ALF, acute liver failure; ALT, alanine aminotransferase; INR, international normalised ratio; SIRS, systemic
inflammatory response syndrome; WCC, white cell count.
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Table 3 Factors predictive of AKI on univariate and multivariate analysis in all patients with ALF
Variable Univariate OR (95% CI) p Value Multivariate OR (95% CI) p Value
Age (years) 1.02 (1.00 to 1.04) 0.021 1.03 (1.00 to 1.06) 0.024
Paracetamol-induced ALF 3.80 (2.26 to 6.38) <0.001 10.72 (4.24 to 27.09) <0.001
KCH poor prognosis 3.08 (1.88 to 5.06) <0.001 6.33 (2.65 to 15.13) <0.001
Hypoglycaemia 4.44 (2.49 to 7.94) <0.001
Treatment for increased ICP 3.03 (1.60 to 5.73) 0.001
Hypotension 11.23 (5.87 to 21.48) <0.001 7.01 (3.06 to 16.07) <0.001
SIRS 3.16(1.80 to 5.57) <0.001 2.42 (1.17 to 5.00) 0.017
Infection 2.07 (1.27 to 3.39) 0.004 1.93 (0.93 to 4.02) 0.077
Reference group (relative risk 1.00): non-paracetamol-induced ALF, did not achieve KCH prognostic criteria. No hypoglycaemia, no
treatment for increased ICP, no hypotension, no SIRS, no infection.
AKI, acute kidney injury; ALF, acute liver failure; ICP, intracranial pressure; KCH, Kings College Hospital; SIRS, systemic
inflammatory response syndrome.
findings.1819 In fact, the prevalence of SIRS was similar in
infected and non-infected groups. We acknowledge that occult
infection may have influenced our results. However, our unit
actively seeks infection with cultures performed routinely on
admission, and repeated thereafter if clinically indicated. SIRS is
the clinical sequelae of a massive inflammatory cascade that
results from systemic cytokine release.31 SIRS occurs not only in
infected patients but also in a variety of other conditions
including trauma and acute pancreatitis.31 In ALF, non-infected
patients similarly demonstrate high circulating levels of
cytokines.32"35 The source of the systemic cytokines in this
setting remains unclear, although release from the necrotic liver,
or secondary to endotoxaemia, or impaired hepatic cytokine
metabolism are possible.3136 37
The findings of our study suggest that the systemic
inflammatory response plays a role in the pathogenesis of renal
dysfunction in ALF. Consequently, the renal dysfunction of
sepsis may be a more accurate parallel than the hepatorenal
syndrome of cirrhosis. In sepsis, renal dysfunction probably
occurs as a result of haemodynamic and non-haemodynamic
factors.17 There is reduced glomerular filtration pressure, which
reflects altered intrarenal and extrarenal vascular activity.17 20
Furthermore, the systemic inflammatory response may con¬
tribute directly to renal tubular dysfunction by stimulating
Table 4 Univariate analysis of variables as predictors of AKI in patients with paracetamol-induced ALF and
non-paracetamol-induced ALF
Variable Paracetamol-induced ALF Non-paracetamol-induced ALF
AKI (166) Non-AKI (51) AKI (42) Non-AKI (49)
Peak creatinine (pmo(4) 341 (294-454) 109 (86-140) 329 (258-474) 99 (86-113)
Renal replacement therapy (%) 124 (75) 0 22 (52) 0
Age (years) 39.5 (13.1) 33.6 (14.2)** 47.4 (15.5) 40.3 (16.6)*
Male:female 1.1.0 1:1.2 1:2.0 1:1.7
Alcohol excess (%) 80 (57) 22 (54)
Jaundice-encephalopathy time (days) 11 (2-25) 12 (2-23)
Temperature OA (°C) 36.4 (1.1) 37.0 (0.9)*** 36.3 (1.3) 36.6 (0.6)
Heart rate OA (bpm) 109 (92-120) 102(86-120) 100 (90-120) 90 (80-100)**
WCC OA (x10!/l) 13.0 (9.4-18.0) 11.5 (6.9-14.3)* 12.0 (9.4-18.0) 10.7 (7.0-12.8)*
Neutrophil count OA (x109/l) 11.5 (8.2-16.5) 10.5 (5.9-12.7) 9.6 (7.0-14.9) 7.7 (5.5-10.4)*
Platelet count OA (x10'/l) 112 (47-157) 154 (92-220)** 136 (77-182) 164 (113-284)*
INR OA 5.3 (3.6-7.7) 4.6 (3.1-6.6)* 2.4 (1.9-4.3) 2.7 (2.0-4.2)
Peak INR 7.9 (5.0-10.7) 6.4 (4.3-9.3) 4.3 (2.2-5.1) 3.2 (2.3-5.1)
Bilirubin OA (pmol/l) 89 (62-116) 100 (74-124) 325 (110-531) 438 (241-524)
ALT OA (U/l) 6949 (3884-10 925) 6547 (4373-8790) 613 (171-2712) 1050 (365-2228)
Albumin OA (g/l) 34.3 (8.1) 36.5 (6.1) 28.1 (6.7) 29.2 (6.4)
H+ OA (nmol/l) 41 (35-50) 33 (30-38)*** 41 (34-45) 34 (31-36)**
PaC02 (kPa) 4.0 (3.2-4.6) 4.2 (3.7-4.8) 4.0 (3.4-5.1) 4.4 (3.8-4.7)
HC03" OA (mmol/1) 18.0 (13.0-22.4) 23.0 (20.0-26.9)*** 20.3 (15.1-24.7) 24.6 (21.8-27.0)*
Lactate OA (mmol/l) 4.7 (2.8-9.0) 3.0 (2.1-5.3) 3.7 (2.3-7.0) 2.5 (1.7-4.0)
Hypotension (%) 102 (63) 5 (10)*** 27(64) 8 (17)***
Inotropes (%) 98 (60) 4 (8)*** 18 (43) 5 (10)***
Hypoglycaemia (%) 89 (55) 11 (22)*** 13 (31) 7 (15)
Treatment for increased ICP (%) 59 (36) 7 (14)** 10 (24) 7 (15)
Infection (%) 89 (55) 23 (46) 26 (63) 15 (31)**
SIRS (%) 110 (79) 28 (72) 26 (76) 15 (36)***
KCH poor prognosis (%) 105 (63) 0 (0)*** 29 (69) 37 (76)
Spontaneous survival (%) 48 (37) 47 (92)*** 8 (30) 10 (63)*
*p<0.05, **p<0.01, ***p<0.001 vs no acute kidney injury group
AKI, acute kidney injury; ALF, acute liver failure; ALT, alanine aminotransferase; ICP, intracranial pressure; INR, international
normalised ratio; KCH, Kings College Hospital; OA, on admission to hospital; SIRS, systemic inflammatory response syndrome;
WCC, white cell count.
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Figure 2 Boxplot of peak change in serum creatinine (peak serum
creatinin^aseline serum creatinine) in patients with acute liver failure
(ALF) subdivided based on aetiology, and presence or absence of the
systemic inflammatory response syndrome (SIRS). A peak change in
serum creatinine &2, represented by the horizontal line, is the definition
of acute kidney injury.
apoptotic death of tubular cells.17 38 Most research has focused
on tumour necrosis factor a (TNFa). This cytokine appears to
play a major role in the pathogenesis of the circulatory
dysfunction and renal injury of sepsis.17 20 39 In ALF, TNFa and
interleukin 6 (IL6) levels have been shown to correlate with the
development of renal failure and circulatory failure, respec¬
tively.'10 Therefore, we propose that in ALF, as in sepsis,
cytokines responsible for the systemic inflammatory response
are central to the development of renal dysfunction.
The systemic inflammatory response has also been implicated
in the pathogenesis of the circulatory and renal dysfunction of
cirrhosis.4142 These patients demonstrate endotoxaemia in the
absence of infection and have increased systemic cytokine levels,
which correlate with the severity of disease.43"18 Furthermore,
prophylactic antibiotics reduce the incidence of hepatorenal
syndrome and improve survival in patients with decompensated
cirrhosis, independent of the prevention of infection.49
Nevertheless, portal hypertension remains the primary event.4 50
Moreover, the frequency of SIRS in patients with cirrhosis, even
when renal dysfunction is present (41%), is much less than we
have demonstrated in ALF (AKI, 78%; non-AKI, 53%).41 Patients
with subfulminant ALF are more likely to have clinically
significant portal hypertension than those with fulminant
ALF, and may develop ascites.9 Therefore, in subfulminant
ALF, renal dysfunction may share similarities with hepatorenal
syndrome of cirrhosis. However, in fulminant hepatic failure,
the systemic inflammatory response may be the key mediator of
renal dysfunction.
We were unable to demonstrate a relationship between the
severity of ALF, as assessed by the KCH prognostic criteria, and
SIRS. It is well recognised that there are significant inter-
individual differences in the systemic inflammatory response to
infection and other forms of injury, which may be genetically
predetermined.3151 Therefore, it is likely that some individuals
will be more at risk of the circulatory and renal complications of
the systemic inflammatory response to ALF than others.
Paracetamol as the cause of ALF was an independent
predictor of AKI, consistent with the clinical suspicion that
paracetamol has a direct nephrotoxic effect. The mode of
paracetamol-related nephrotoxicity remains undefined,
although case reports of isolated renal failure following
paracetamol overdose indicate that it is independent of hepatic
injury.23 25 It is postulated that a locally produced toxic
metabolite of paracetamol induces proximal tubular cell
necrosis.23 24 52 Functional renal effects may also contribute as
alterations in renal plasma flow and glomerular filtration rate
have been demonstrated in the absence of structural and hepatic
dysfunction.24
Our study has some potential limitations. We chose to use
Trey and Davidson's definition of ALF and include all patients
with encephalopathy in the study. Grade I encephalopathy is
difficult to diagnose, and previous similar studies have included
patients with severe encephalopathy only.12 7 However, our
cohort was comparable with the described populations with
regards to severity of liver injury and outcome, and the
diagnosis of encephalopathy was made by a small number of
doctors, indicating relative consistency of opinion. Secondly, we
did not have details of co-morbidities and, in particular, pre¬
existing renal disease or nephrotoxic medications that may have
influenced our results. The patients studied were of a young age
and it is therefore assumed that pre-existing renal function was
normal. Our unit avoids nephrotoxic drugs when managing
patients with ALF, although this does not preclude exposure
prior to transfer.
The identification of modifiable risk factors for the develop¬
ment of AKI in ALF has important implications for patient
management. As in sepsis, early and aggressive optimisation of
haemodynamics with fluid therapy, central venous pressure
monitoring and inotrope administration may significantly
reduce the occurrence of renal dysfunction.20 53 54 Furthermore,
manipulation of the systemic inflammatory response itself is
likely to be advantageous. Prompt diagnosis and treatment of
superimposed infection is essential.53 54 In addition, removal of
cytokines and other inflammatory mediators by haemofiltration
or albumin dialysis (MARS) may be beneficial.55"57 Finally,
pentoxifylline, by downregulation of pro-inflammatory cyto¬
kines, is a possible future therapeutic option.58 59
In conclusion, in this large single-centre retrospective study,
we have examined the relationship between SIRS and AKI in
ALF. We have shown that the SIRS is strongly associated with
renal dysfunction and we hypothesise that the inflammatory
cascade plays a key role in its pathogenesis. Given the reduced
spontaneous survival of patients with AKI, we suggest that the
early administration of therapies that target the systemic
inflammatory response and limit the development of AKI may
have a favourable effect on patient morbidity and mortality.
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Summary
Serum creatinine is an important prognostic indicator in patients on the liver
transplant waiting-list, being a component of the Model for End Stage Liver Dis¬
ease (MELD) score. However, creatinine is influenced by age, gender and race,
and in this role may disadvantage some individuals. The Modification of Diet in
Renal Disease (MDRD) estimated glomerular filtration rate (eGFR) takes into
account these variables and may be a superior measure of renal function. Our
aim was to examine whether the MDRD 4-variable, 5-variable and 6-variable
eGFRs are superior to serum creatinine in predicting 3-month waiting-list
mortality in patients with end-stage liver disease. This was a retrospective single-
centre study of 427 adults listed for first liver transplantation. The median listing
MDRD 4-variable, 5-variable and 6-variable eGFR was 69, 71 and 73 ml/min/
1.73 m2, respectively. The median listing serum creatinine was 89 |iM. MDRD
4-variable (P = 0.002), 5-variable (P < 0.001) and 6-variable eGFR (P < 0.001),
and serum creatinine (P < 0.001), were all predictors of mortality on the trans¬
plant waiting-list. Of the three MDRD equations, the 6-variable eGFR was the
better prognostic indicator. The substitution of 6-variable eGFR for serum creati¬
nine did not improve the prognostic accuracy of the MELD (P = 0.825) and UK
score for Patients with End-Stage Liver Disease (P = 0.781) scores. In conclusion
the MDRD eGFR is comparable, but not superior to serum creatinine, in predict¬
ing death within 3 months of listing for liver transplantation.
Cirrhosis is associated with a progressive functional renal
impairment characterised by increased tubular sodium
reabsorption, impaired free water clearance and prerenal
azotemia [1], This spectrum of renal dysfunction evolves
in parallel with advancing disease and consequently the
clinical manifestations of renal dysfunction, ascites, hyp-
onatraemia and hepatorenal syndrome, are important
prognostic markers [2-5]. Serum creatinine as a continu¬
ous variable is an independent predictor of mortality fol¬
lowing the transjugular intrahepatic portosystemic shunt
procedure and in those on the liver transplant waiting list
[6,7]. It is a component of the Model For End-Stage Liver
Disease (MELD) score, which is used to prioritise graft
allocation.
However, serum creatinine is not solely influenced by
glomerular filtration and is not an accurate estimator of
renal function [8], Creatinine production is proportional
to muscle mass, and is greater in men than in women, in
younger than older individuals and in black people than
in white people, despite similar glomerular filtration rate
[9], In addition, in cirrhosis reduced creatine production
by the liver, muscle wasting and increased renal tubular
secretion of creatinine may result in a falsely low serum
creatinine level [10,11].
© 2011 The Authors
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The effect of gender, age and race on serum creatinine
is of particular concern in the MELD era of organ alloca¬
tion. United Network for Organ Sharing (UNOS) data
has demonstrated that women listed for liver transplanta¬
tion are less likely to survive to transplantation than men,
supporting a systematic bias of the scoring system [12-
14], Similarly, an inherent discrimination against older
patients could explain the independent association of
increasing age with waiting-list mortality [15]. It follows
that a scoring system with an alternative measure of renal
function may be preferable to MELD.
The gold standard measure of glomerular filtration
rate, inulin clearance, has recently been shown to be
superior to serum creatinine in predicting liver transplant
waiting-list mortality [16]. Unfortunately, inulin clearance
is time consuming, impractical and costly and is not a
useful test if repeated measures are required [10,11], Cal¬
culated glomerular filtration rate is a possible alternative
and has been evaluated as an absolute measure of renal
function, although not as a prognostic marker, in this set¬
ting [17],
The most accurate calculated glomerular filtration rate
for cirrhotic patients is provided by the Modification of
Diet in Renal Disease study (MDRD) equations, which
are creatinine-based estimates modified for age, gender
and race [17-19], The MDRD 4-variable calculated glo¬
merular filtration rate is readily available, at minimal cost,
with routine reporting advocated in several countries, and
is an attractive measure of renal function [20,21]. The
MDRD 5-variable and 6-variable calculated glomerular
filtration rates, in addition, adjust for blood urea nitro¬
gen, and blood urea nitrogen and serum albumin, respec¬
tively, and could be superior prognostic indicators.
The aim of our study was to examine whether the
MDRD calculated glomerular filtration rate is superior to
serum creatinine in predicting prognosis on the liver
transplant waiting list. In a subgroup of patients mea¬
sured creatinine clearance (CrCl) was also available and
was examined as a prognostic indicator.
Methods
This was a single-centre retrospective study of consecutive
adults listed for first liver transplantation between
November 1992 and June 2007. Patients listed for acute
liver failure, hepatocellular carcinoma, or joint liver/kid¬
ney transplantation, or who had documented intrinsic
renal disease were not assessed. Those removed from or
still active on the waiting list were also not included.
The following variables at time of liver transplant
assessment were recorded: gender, age, race, aetiology of
liver disease, presence of ascites or hepatic encephalopa¬
thy and laboratory data (serum sodium, creatinine, biliru¬
bin, albumin and international normalised ratio).
Estimated glomerular filtration rate was calculated from
the relevant parameters using the MDRD 4-variable
[eGFR (MDRD4) = 186 x creatinine (mg/dl)-1'154 x age
(years)-0'203 X (0.742 if female) x (1.210 if black)],
MDRD 5-variable [eGFR (MDRD5) = 270 x creatinine
(mg/dl)-1'007 x age (years)-0'180 x blood urea nitrogen
(mg/dl)-0'169 x (0.755 if female) x (1.178 if black)] and
MDRD 6-variable [eGFR (MDRD6) = 170 x creatinine
(mg/dl)-0'999 x age (years)-0'176 x blood urea nitrogen
(mg/dl)-0'170 X albumin (g/dl)+0'318 X (0.762 if female) X
(1.180 if black)] equations [18,19]. The MELD score was
determined as previously described [22]. The UK Score
for Patients with End-Stage Liver Disease (UKELD), a
recently devised scoring system that incorporates serum
sodium in addition to the MELD variables, was also cal¬
culated [23].
In a subgroup of patients transplanted between May
2000 and June 2007 CrCl was available. This was deter¬
mined from a 24-h urinary collection performed routinely
during the in-patient assessment period. Failure to obtain
a CrCl was, in most cases, secondary to poor patient
compliance.
Statistical analyses
Normally distributed continuous variables and nonpara-
metric continuous variables were compared using the Stu¬
dent's f-test and Mann-Whitney test, respectively. Chi-
square analysis was used for the comparison of categorical
variables. Survival modelling was performed using Cox
proportional hazards regression. Data was censored at the
time of liver transplantation and to lessen the influence
of extreme values all continuous laboratory variables were
transformed into their natural logarithms. To allow the
comparison of MELD or UKELD with a similar model
with logeGFR or logeCrCl substituted for logecreatinine
the regression coefficients of MELD or UKELD were ini¬
tially adjusted for our patient population. Regression
coefficients were then recalculated in the presence of loge¬
GFR instead of logecreatinine. Receiver-operating charac¬
teristic (ROC) curves were generated to assess the
accuracy of models in predicting 3-month waiting-list
mortality. Concordance statistics were compared using
the method described by Hanley and McNeil [24]. All
patients censored prior to the specified time point were
excluded from these analyses. A value of P < 0.05 was
considered statistically significant at all times. Data were
analysed using the spss 15 package (SPSS Inc., Chicago,
IL, USA).
Values are expressed as mean and standard deviation
(SD), and median and inter-quartile range (IQR) as
appropriate.
© 2011 The Authors
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Results
Patient characteristics
The mean age of the patients (n = 427) at time of listing
for liver transplantation was 55.3 (SD 11.6) years and the
male to female ratio was 1:1. The main indications for
transplantation were primary biliary cirrhosis (119
patients, 27.9%), alcoholic liver disease (103 patients,
24.1%), sclerosing cholangitis (62 patients, 14.5%), hepa¬
titis C cirrhosis (37 patients, 8.9%) cryptogenic cirrhosis
(36 patients, 8.4%) and autoimmune hepatitis (33
patients, 7.7%). The median listing MELD score was 16
(IQR 13-20) and the median listing UKELD score was 56
(IQR 54-60).
Sixty patients (14.1%) died prior to liver transplanta¬
tion. The median time from listing to death was 50 (IQR
26-101) days. For patients who were transplanted the
median waiting-time was 68 (IQR 27-142) days. Two
hundred and twelve patients (49.6%) were transplanted
and 44 patients (10.3%) died within 3 months of listing.
The median listing serum creatinine was 89 (IQR
77-107) |im, the median listing serum sodium was 136
(IQR 132-139) mm, and 60.6% of patients had asci¬
tes. The median eGFR (MDRD4), eGFR (MDRD5) and
eGFR (MDRD6) was 69 (IQR 57-83) ml/min/1.73 m2,
71 (IQR 56-86) ml/min/1.73 m2, and 73 (IQR 57-89)
ml/min/1.73 m2, respectively.
Comparison of MDRD equations as predictors of waiting
list mortality
Logecreatinine (OR 14.12; 95% CI 3.76-53.13,
P < 0.001), logeGFR (MDRD4) (OR 0.18; 95% CI 0.06-
0.53, P = 0.002), logeGFR (MDRD5) (OR 0.16; 95% CI
0.06-0.44, P < 0.001), and logeGFR (MDRD6) (OR 0.14;
95% CI 0.05-0.39, P < 0.001) demonstrated an associa¬
tion with 3-month waiting-list mortality.
Receiver-operating characteristic curves for logecreati¬
nine, logeGFR (MDRD4), logeGFR (MDRD5) and loge¬
GFR (MDRD6) as predictors of 3-month waiting list
mortality are shown in Fig. 1. When all eGFR equations
were compared logeGFR (MDRD6) had the greatest con¬
cordance statistic [logeGFR (MDRD4) 0.648; 0.548-0.749:
logeGFR (MDRD5) 0.683; 0.587-0.780: logeGFR
(MDRD6) 0.695; 0.601-0.789, logecreatinine 0.696;
0.598-0.793, c-statistic and 95% confidence interval],
LogeGFR (MDRD6) statistically outperformed logeGFR
(MDRD4) (P = 0.054), and was comparable to logeGFR
(MDRD5) (P = 0.614) and logecreatinine (P = 0.981).
Following on from this, all further analyses comparing
eGFR with serum creatinine were performed using the
eGFR MDRD 6-variable equation.
0.0 0.2 0.4 0.6 0.8 1.0
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Figure 1 Receiver-operating characteristic curves of log serum creati¬
nine (logecreatinine), log eGFR calculated using the Modification of
Diet in Renal Disease (MDRD) 4-variable equation [logeGFR (MDRD4)],
log eGFR calculated using the MDRD 5-variable equation [logeGFR
(MDRD5)] and log eGFR calculated using the MDRD 6-variable equa¬
tion [logeGFR (MDRD6)] for predicting 3-month liver transplant wait¬
ing list mortality.
Does substitution of eGFR (MDRD6) for serum
creatinine improve the prognostic accuracy of MELD
and UKELD?
ROC analysis was used to determine whether the substi¬
tution of logeGFR (MDRD6) for logecreatinine improved
the accuracy of the existing prognostic models, MELD
and UKELD (Table 1). The regression coefficients for
Table 1. AUC for receiver-operating characteristic curves for predic¬
tion of 3-month liver transplant waiting-list mortality in all patients.
Model c-statistic 95% CI
MELD (adj) 0.841 0.773-0.909
MELD (eGFR) 0.846 0.777-0.915
UKELD (adj) 0.859 0.790-0.928
UKELD (eGFR) 0.864 0.795-0.933
eGFR, estimated glomerular filtration rate; MELD, Model for End-
Stage Liver Disease; MELD (adj), MELD score with regression coeffi¬
cients adjusted for our model; UKELD, UK score for Patients with End-
Stage Liver Disease; UKELD (adj), UKELD score with regression coeffi¬
cients adjusted for our model; MELD (eGFR), MELD score with loge¬
GFR substituted for logecreatinine; UKELD (eGFR), UKELD score with
logeGFR substituted for logecreatinine; c-statistic, concordance statis¬
tic.
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each model were initially adjusted for our study popula¬
tion [MELD (adj)/UKELD (adj)], and thereafter recalcu¬
lated in the presence of logeGFR (MDRD6) instead of
logecreatinine [MELD (eGFR)/UKELD (eGFR)].
The LogeGFR (MDRD6) substituted for logecreatinine
did not change the concordance statistic for MELD as a
predictor of 3-month waiting-list mortality [MELD (adj)
versus MELD (eGFR), P = 0.825). Furthermore, logeGFR
(MDRD6) substituted for logecreatinine did not alter the
concordance statistic for UKELD as a predictor of death
by 3 months [UKELD (adj) versus UKELD (eGFR),
P = 0.781],
In view of the concern that the MELD and UKELD
scoring systems are systemically biased and may discrimi¬
nate against female and older patients the concordance
statistics of individual patient groups were also deter¬
mined (Table 2). There was no statistically significant dif¬
ference in the concordance statistics of the MELD score
or UKELD score between genders (MELD, P = 0.718;
UKELD, P = 0.645) and age groups (MELD, P = 0.099;
UKELD, P = 0.216). LogeGFR (MDRD6) substituted for
logecreatinine did not change the concordance statistic
for MELD or UKELD as predictors of 3-month waiting-
list mortality in female, male, older or younger patients
(P values not shown).
Does substitution of CrCl for serum creatinine improve
the prognostic accuracy of MELD and UKELD?
Measured creatinine clearance was available in 139 of the
256 patients (54.3%) listed for liver transplantation
between May 2000 and June 2007. The CrCl patients were
comparable to patients who did not have a recorded CrCl
(Table 3). In this cohort of 139, 31 patients (22.3%) died
prior to transplantation. The median time from listing to
death was 49 (IQR 19-88) days. The median waiting-time
to transplantation was 85 (IQR 35-179) days. Fifty-five
patients (39.6%) were transplanted and 25 patients
(18.0%) died within 3 months of listing.
The median listing serum creatinine, serum sodium,
eGFR (MDRD6) and CrCl was 91 (IQR 79-110) pM, 136
(IQR 131-139) mM, 75 (60-87) ml/min/1.73 m2, and 72
(51-95) ml/min, respectively. CrCl demonstrated a greater
correlation with eGFR (MDRD6) (0.615, P < 0.001) than
with serum creatinine (-0.452, P < 0.001).
Logecreatinine (OR 7.77, 95% CI 1.33-45.51,
P = 0.023) and logeCrCl (OR 0.22, 95% CI 0.07-0.67,
Table 3. Comparison of listing variables in patients listed for liver
transplantation between May 2000 and June 2007 who did and did
not have measured creatinine clearance available.
Variable No CrCl (n = 117) CrCl (n = 139) P-value
Age (years) 54.0 (12.3) 55.3 (11.4) 0.374
Male gender 62 (53.0) 85 (61.2) 0.188
Noncholestatic 71 (60.7) 83 (59.7) 0.874
disease
INR 1.4(1.2-1.6) 1.3 (1.1-1.6) 0.553
Bilirubin (pM) 76 (42-139) 84 (46-156) 0.526
Albumin (g/l) 28.9 (5.4) 29.0 (5.4) 0.876
Encephalopathy 36 (43.9) 35 (42.7) 0.875
Ascites 60 (60.6) 70 (60.3) 0.969
Sodium (mM) 135 (132-138) 136 (131-139) 0.591
Creatinine (pM) 91 (78-106) 91 (79-106) 0.795
eGFR (MDRD6) 73 (58-90) 76 (60-87) 0.997
MELD 17 (14-20) 16 (14-21) 0.771
UKELD 57 (54-61) 57 (54-61) 0.936
Values expressed as mean (standard deviation), median (inter-quartile
range) and number (percentage) where appropriate.
Units for eGFR (MDRD6) = ml/min/1.73 m2.
CrCl, measured creatinine clearance; INR, international normalised
ratio; MDRD, Modification of Diet in Renal Disease; MELD, Model for
End-Stage Liver Disease; eGFR (MDRD6), estimated glomerular
filtration rate derived from 6-variable MDRD equation.
Table 2. AUC for receiver-operating characteristic curves for prediction of 3-month liver transplant waiting-list mortality in different patient
groups.
Model
Females Males Older Younger
c-statistic 95% CI c-statistic 95% CI c-statistic 95% CI c-statistic 95% CI
MELD 0.807 0.677-0.938 0.775 0.660-0.890 0.734 0.612-0.857 0.872 0.764-0.981
MELD (adj) 0.847 0.740-0.955 0.820 0.723-0.917 0.810 0.703-0.916 0.882 0.797-0.967
MELD (eGFR) 0.848 0.733-0.962 0.843 0.752-0.933 0.791 0.677-0.906 0.880 0.788-0.971
UKELD 0.794 0.664-0.924 0.833 0.729-0.936 0.771 0.659-0.884 0.876 0.755-0.988
UKELD (adj) 0.826 0.712-0.940 0.874 0.784-0.963 0.833 0.731-0.936 0.891 0.794-0.989
UKELD (eGFR) 0.828 0.715-0.941 0.879 0.790-0.967 0.825 0.719-0.931 0.891 0.788-0.993
Older defined as age >60 years, younger defined as age <60 years.
eGFR, estimated glomerular filtration rate; MELD, standard Model for End-Stage Liver Disease score; UKELD, standard UK score for Patients with
End-Stage Liver Disease score; MELD (adj), MELD score with regression coefficients adjusted for our model; UKELD (adj), UKELD score with regres¬
sion coefficients adjusted for our model; MELD (eGFR), MELD score with logeGFR substituted for logecreatinine; UKELD (eGFR), UKELD score with
logeGFR substituted for logecreatinine; c-statistic, concordance statistic.
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Figure 2 Receiver-operating characteristic curves of log serum creati¬
nine (logecreatinine) and log creatinine clearance (logeCrCI) for pre¬
dicting 3-month liver transplant waiting list mortality.
P = 0.008) were associated with 3-month waiting-list
mortality. The ROC curves for logecreatinine and loge¬
CrCI are shown in Fig. 2. Logecreatinine and logeCrCI
had similar concordance statistics for the prediction of
death by 3 months (logecreatinine 0.660; 0.532-0.788:
logeCrCI 0.718; 0.604-0.831, c-statistic and 95% confi¬
dence interval, P = 0.353).
As before, ROC analysis was used to determine whether
the substitution of logeCrCI for logecreatinine improved
the accuracy of the existing prognostic models, MELD
and UKELD (Table 4). LogeCrCI substituted for logecre¬
atinine did not change the concordance statistic for
MELD [MELD (adj) versus MELD (CrCl), P = 0.249] or
Table 4. AUC for receiver-operating characteristic curves for predic¬
tion of 3-month liver transplant waiting-list mortality.
Model c-statistic 95% CI
MELD (adj) 0.809 0.708-0.910
MELD (CrCl) 0.845 0.765-0.926
UKELD (adj) 0.849 0.756-0.942
UKELD (CrCl) 0.881 0.808-0.954
CrCl, measured creatinine clearance; MELD, Model for End-Stage Liver
Disease; MELD (adj), MELD score with regression coefficients adjusted
for our model; UKELD, UK score for Patients with End-Stage Liver Dis¬
ease; UKELD (adj), UKELD score with regression coefficients adjusted
for our model; MELD (CrCl), MELD score with logeCrCI substituted for
logecreatinine; UKELD (CrCl), UKELD score with logeCrCI substituted
for logecreatinine; c-statistic, concordance statistic.
UKELD [UKELD (ad)) versus UKELD (CrCl), P = 0.198]
as a predictor of 3-month waiting-list mortality.
Discussion
Our study has examined for the first time eGFR, calcu¬
lated using the MDRD equations, in the prediction of
mortality on the liver transplant waiting list. We have
demonstrated that decreasing eGFR, as a continuous vari¬
able, was associated with an increased risk of death within
3 months of listing. This reiterates the well recognised
spectrum of renal dysfunction that occurs in the setting
of cirrhosis and reflects the underlying circulatory
derangement of advanced disease. Of the three MDRD
equations, the eGFR derived from the 6-variable equation
was the better prognostic indicator. On univariate analy¬
sis, eGFR (MDRD6) was comparable, but not superior, to
listing serum creatinine for prediction of 3-month wait¬
ing-list mortality. When substituted for serum creatinine
eGFR (MDRD6) did not improve the prognostic accuracy
of the existing MELD and UKELD models.
Although a negative study, the finding that eGFR
(MDRD6) is not superior to serum creatinine in the pre¬
diction of waiting-list mortality is an important observa¬
tion. Several studies have previously highlighted the
prognostic inadequacies of serum creatinine in patients
with end-stage liver disease [12,13], Concerns have been
raised that scoring systems for graft allocation that incor¬
porate serum creatinine may disadvantage some individu¬
als. In searching for alternative measures of renal function
the next step is to use creatinine-based estimates of glo¬
merular filtration rate that adjust for patient factors poten¬
tially conferring systemic bias. The MDRD eGFR is well
validated in the nonliver setting, is calculated from readily
available variables including age, gender and race, and has
been shown to be the most accurate eGFR in cirrhotic
patients [9,17-19]. Our negative results support the need
for further research to identify more precise noncreati-
nine-based measures of renal function in these patients.
An explanation for the failure of eGFR (MDRD6) to
improve the MELD and UKELD scoring systems is that
the equation does not take into account disease-related
factors such as nutritional status. Consequently, eGFR
(MDRD6) is not an accurate measure of absolute renal
function with one-third of patients demonstrating an
MDRD estimate outwith 30% of the measured glomerular
filtration rate [17]. The Cockcroft-Gault eGFR adjusts for
body weight and, although a less precise estimator of glo¬
merular filtration rate in this population, its ability to
predict survival remains unknown [17,25]. Notably, the
difficulty in obtaining an accurate dry weight in patients
with significant ascites and peripheral oedema makes the
Cockcroft-Gault eGFR a less attractive option [10,11].
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Other possible weaknesses of eGFR for predicting mor¬
tality on the liver transplant waiting list are as follows:
similar to ascites and serum sodium concentration, eGFR
may be influenced by diuretic use and could theoretically
be subject to manipulation [2], Furthermore, a reduced
eGFR may reflect intrinsic renal disease, which may not
confer the same prognostic significance. All patients with
evidence of renal impairment should have renal pathology
excluded with urinalysis and renal imaging [4]. Creatinine
assays are not currently standardised and there is signifi¬
cant variability in serum creatinine levels using different
methods [26]. Therefore, the prognostic significance of
eGFR may not be echoed in all centres.
The association of CrCl with mortality in patients listed
for liver transplantation was a further novel finding of
this study. Decreasing CrCl, as a continuous variable, was
associated with an increased risk of death within
3 months of listing. Mirroring the findings of eGFR
(MDRD6) CrCl was a comparable, but not superior prog¬
nostic indicator to serum creatinine. When substituted
for serum creatinine CrCl increased the accuracy of
MELD and UKELD by 3.6% and 3.2%, respectively,
although statistical significance was not achieved. The
negative result may reflect a relatively small patient sub¬
group, but probably reflects the inaccuracy of CrCl as a
measure of absolute renal function [27].
Despite the large population assessed in this single-cen¬
tre study, we recognise some potential limitations. Firstly,
because of the retrospective nature we cannot ensure that
all patients with intrinsic renal disease were excluded
from the analysis. In our unit, patients assessed for liver
transplantation routinely undergo urine testing and renal
ultrasonography, and those with significant renal impair¬
ment are considered for renal biopsy. As a result, most
patients with intrinsic renal disease should have been
identified. Secondly, biochemical values were based on a
single measurement and may not have been a true repre¬
sentation of the steady state in all. However, during the
5-day liver transplant assessment our patients are rela¬
tively stable and less likely to be subject to diuretic-
induced or sepsis-related acute renal impairment. Thirdly,
the patients included in the study were listed over a 15-
year period during which advances have been made in
the management of chronic liver disease, such as the
widespread use of terlipressin and albumin for hepatore¬
nal syndrome. Therefore, there may be a small time effect
that could not be factored into the statistical analysis.
Finally, the indications for transplantation in this cohort
differ somewhat from the typical transplant centre with a
greater proportion of patients listed for primary biliary
cirrhosis and less for viral hepatitis. The MELD score has
been shown to have comparable 3-month mortality risk
prediction in a diverse range of liver diseases, both chole-
eGFR for predicting waiting list mortality
static and noncholestatic [7]. Consequently, we do not
believe that the somewhat atypical spread of aetiologies
should have influenced our findings.
Clinically applicable, precise measures of renal function
are not currently available in cirrhotic patients. Serum
creatinine remains the most widely used parameter and
despite its limitations has some clinical relevance. A
change in serum creatinine may indicate haemodynamic
decompensation or intrinsic renal disease, and serum cre¬
atinine is an important prognostic indicator [6,7], In this
study we have demonstrated that listing eGFR (MDRD6)
was comparable, but not superior, to listing serum creati¬
nine for prediction of 3-month waiting-list mortality, and
when substituted for serum creatinine eGFR (MDRD6)
did not improve the prognostic accuracy of the existing
MELD and UKELD models. Our findings support the
need for further research to identify more precise noncre-
atinine-based measures of renal function.
Authorship
JAL: research design, data collection, data analysis and
paper writing. SMMK: data collection. JWF and PCH:




The authors would like to thank Kirsty Martin, Database
Coordinator, for her help with this study.
References
1. Arroyo V, Gines P, Gerbes AL, et al. Definition and diag¬
nostic criteria of refractory ascites and hepatorenal syn¬
drome in cirrhosis. International Ascites Club. Hepatology
1996; 23: 164.
2. Heuman DM, Abou-Assi SG, Habib A, et al. Persistent
ascites and low serum sodium identify patients with cir¬
rhosis and low MELD scores who are at high risk for early
death. Hepatology 2004; 40: 802.
3. Biggins SW, Rodriguez HJ, Bacchetti P, Bass NM, Roberts
JP, Terrault NA. Serum sodium predicts mortality in
patients listed for liver transplantation. Hepatology 2005;
41: 32.
4. Salerno F, Gerbes A, Gines P, Wong F, Arroyo V. Diagno¬
sis, prevention and treatment of hepatorenal syndrome in
cirrhosis. Gut 2007; 56: 1310.
5. Kim WR, Biggins SW, Kremers WK, et al. Hyponatraemia
and mortality among patients on the liver-transplant wait¬
ing list. N Engl J Med 2008; 359: 1018.
© 2011 The Authors
Transplant International © 2011 European Society for Organ Transplantation 24 (2011) 482-488 487
eGFR for predicting waiting list mortality
6. Malinchoc M, Kamath PS, Gordon FD, Peine CI, Rank J,
ter Borg PC. A model to predict poor survival in patients
undergoing transjugular intrahepatic portosystemic shunts.
Hepatology 2000; 31: 864.
7. Kamath PS, Wiesner RH, Malinchoc M, et al. A model to
predict survival in patients with end-stage liver disease.
Hepatology 2001; 33: 464.
8. Levey AS, Perrone RD, Madias NE. Serum creatinine and
renal function. Annu Rev Med 1988; 39: 465.
9. National Kidney Foundation. K/DOQI Clinical Practice
Guidelines for Chronic Kidney Disease: Part 5. Evaluation
of laboratory measurements for clinical assessment of kid¬
ney disease. Guideline 4: Estimation of GFR. Am J Kidney
Dise 2002; 39: s76.
10. Sherman DS, Fish DN, Teitelbaum I. Assessing renal func¬
tion in cirrhotic patients: problems and pitfalls. Am J Kid¬
ney Dis 2003; 41: 269.
11. Cholongitas E, Shusang V, Marelli L, et al. Review article:
renal function assessment in cirrhosis - difficulties and
alternative measurements. Aliment Pharmacol Ther 2007;
26: 969.
12. Cholongitas E, Marelli L, Kerry A, et al. Female liver trans¬
plant recipients with the same GFR as male recipients have
lower MELD scores - a systemic bias. Am J Transplant
2007; 7: 685.
13. Huo SC, Huo Tl, Lin HC, et al. Is the corrected-creatinine
model for end-stage liver disease a feasible strategy to
adjust gender difference in organ allocation for liver trans¬
plantation? Transplantation 2007; 84: 1406.
14. Kanwal F, Dulai GS, Gralnek IM, Han SB, Speigel BM.
The impact of gender on access to liver transplantation in
the MELD era. Gastroenterology 2006; 4(Suppl. 2): S931.
15. Luca A, Angermayr B, Bertolini G, et al. An integrated
MELD model including serum sodium and age improves
the prediction of early mortality in patients with cirrhosis.
Liver Transpl 2007; 13: 1174.
16. Lim YS, Benson JT, Kremers W, Kamath PS, Therneau
TM, Kim WR. Glomerular filtration rate as an improved
prognostic indicator in patients with end stage liver disease
[abstract], Hepatology 2007; 46: 250A.
17. Gonwa TA, Jennings L, Mai ML, Stark PC, Levey AS,
Klintmalm GB. Estimation of glomerular filtration rates
Leithead et al.
before and after orthoptic liver transplantation: evaluation
of current equations. Liver Transpl 2004; 10: 301.
18. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth
D. A more accurate method to estimate glomerular filtra¬
tion rate from serum creatinine: a new prediction equa¬
tion. Modification of Diet in Renal Disease Study Group.
Ann Intern Med 1999; 130: 461.
19. Levey AS, Greene T, Kusek JW, Beck GJ. A simplified
equation to predict glomerular filtration rate from serum
creatinine [abstract]. / Am Soc Nephrol 2000; 11: A0828.
20. Estimating Glomerular Filtration Rate (eGFR): Information
for Laboratories. The National Service Framework for
Renal Services. Department of Health, NHS, 2006.
www.dh.gov.uk/publications
21. The Australasian Creatinine Consensus Working Group.
Chronic kidney disease and automatic reporting of esti¬
mated glomerular filtration rate: position statement. Med J
Aust 2005; 183: 138.
22. United Network for Organ Sharing (UNOS). MELD/PELD
calculator documentation, http://www.unos.org/docs/
MELD_PELD_Calculator_Documentation.pdf
23. Barber KM, Pioli SE, Blackwell JE, Collett D, Neuberger
JM, Gimson AE. Development of a UK score for patients
with end-stage liver disease [abstract]. Hepatology 2007;
46(S1): 51 OA.
24. Hanley JA, McNeil BJ. A method of comparing the areas
under the receiver operating characteristic curves derived
from the same cases. Radiology 1983; 148: 839.
25. Cockcroft DW, Gault MH. Prediction of creatinine clear¬
ance from serum creatinine. Nephron 1976; 16: 31.
26. Cholongitas E, Marelli L, Kerry A, et al. Different methods
of creatinine measurement significantly affect MELD
scores. Liver Transpl 2007; 13: 523.
27. Proulx NL, Akbari A, Garg AX, Rostom A, Jaffet J, Clark
HD. Measured creatinine clearance from timed urine col¬
lections substantially overestimates glomerular filtration
rate in patients with liver cirrhosis: a systemic review and
individual patient meta-analysis. Nephrol Dial Transplant
2005; 20: 1617.
488
© 2011 The Authors
Transplant International © 2011 European Society for Organ Transplantation 24 (2011) 482^188
American Journal of Transplantation 2011; 11: 1905-1915
Wiley Periodicals Inc.
© 2011 The Authors
Journal compilation © 2011 The American Society of
Transplantation and the American Society of Transplant Surgeons
doi: 10.1111/j.1600-6143.2011,03649.x
Chronic Kidney Disease After Liver Transplantation
for Acute Liver Failure Is Not Associated With
Perioperative Renal Dysfunction
J. A. Leithead,8'* J. W. Ferguson,6 C. M. Bates,8
J. S. Davidson,8 K. J. Simpson8 and R C. Hayes8
a Scottish Liver Transplant Unit, Royal Infirmary of
Edinburgh, Edinburgh, UK
b Liver Unit, Queen Elizabeth Hospital, Birmingham, UK
*Corresponding author: Joanna Agnes Leithead,
jleithea@staffmail. ed. ac. uk
Renal dysfunction of acute liver failure (ALF) may
have distinct pathophysiological mechanisms to
hepatorenal syndrome of cirrhosis. Yet, the impact of
perioperative renal function on posttransplant renal
outcomes in ALF patients specifically has not been
established. The aims of this study were (1) to describe
the incidence and risk factors for chronic renal dys¬
function following liver transplantation for ALF and (2)
to compare renal outcomes with age-sex-matched pa¬
tients transplanted for chronic liver disease. This was
a single-center study of 101 patients transplanted for
ALF. Fifty-three-and-a-half percent had pretransplant
acute kidney injury and 64.9% required perioperative
renal replacement therapy. After transplantation the
5-year cumulative incidence of chronic kidney disease
(eGFR <60 mL/min/1.73 m2) was 41.5%. There was
no association between perioperative acute kidney
injury (p = 0.288) or renal replacement therapy (p =
0.134) and chronic kidney disease. Instead, the inde¬
pendent predictors of chronic kidney disease were
older age (p = 0.019), female gender (p = 0.049),
hypertension (p = 0.031), cyclosporine (p = 0.027) and
nonacetaminophen-induced ALF (p = 0.039). Despite
marked differences in the perioperative clinical condi¬
tion and survival of patients transplanted for ALF and
chronic liver disease, renal outcomes were the same.
In conclusion, in patients transplanted for ALF the
severity of perioperative renal injury does not predict
posttransplant chronic renal dysfunction.
Key words: Acute kidney injury, acute liver failure,
chronic kidney disease, transplant
Abbreviations: ALF, acute liver failure; SIRS, systemic
inflammatory response syndrome; INR, international
normalised ratio; eGFR, estimated glomerular filtration
rate; MDRD, Modification of Diet in Renal Disease; SD,
standard deviation; IQR, interquartile range; HR, haz¬
ard ratio; CI, confidence interval; MELD, Model for End-
Stage Liver Disease; CNI, calcineurin inhibitor; RRT, re¬
nal replacement therapy; CLD, chronic liver disease.
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Renal dysfunction is a common complication of acute liver
failure (ALF) with two-thirds of patients manifesting acute
kidney injury, and almost half requiring renal replacement
therapy (1). Many have postulated that the pathogenesis
is similar to the hepatorenal syndrome of cirrhosis (2,3).
However, a growing body of evidence supports a systemic
inflammatory response to ALF, and the systemic inflamma¬
tory response syndrome (SIRS) is an independent predic¬
tor of acute kidney injury in ALF patients (1,4,5). It follows
that the renal dysfunction of sepsis may be a more accu¬
rate parallel than the hepatorenal syndrome (1). Additional
factors that may contribute to renal dysfunction in ALF
but are less likely in stable cirrhotic patients include hy¬
povolemia, nephrotoxic drugs particularly acetaminophen,
infection and disseminated intravascular coagulation (6-8).
Despite the contrasting perioperative clinical condition of
patients transplanted for ALF and chronic liver disease
(CLD), post-liver transplant renal outcomes have not been
examined specifically in this group. Pretransplant glomeru¬
lar filtration rate, pretransplant renal failure requiring renal
replacement therapy and acute renal injury are consistent
predictors of chronic renal dysfunction after elective liver
transplantation (9,10). Given the greater baseline circula¬
tory and neuro-humoral derangement of ALF it seems pos¬
sible that the acute hemodynamic effects of the calcineurin
inhibitors administered immediately following transplan¬
tation are exaggerated (11-14). On the other hand, the
differing pathophysiological mechanisms could offer rela¬
tive reno-protection and a reduced risk of chronic kidney
disease.
The clarification of the impact of liver transplantation for
ALF on posttransplant renal function has important impli¬
cations for patient management. Chronic renal dysfunction
is a major cause of patient morbidity and mortality and the
minimization of renal injury has emerged as a priority for
transplant physicians (9,15-17). Simultaneous liver-kidney
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transplantation is not an option in patients transplanted for
ALF because of the medical urgency, but the identification
of prognostic variables could help to determine those who
may benefit from tailored renal sparing immunosuppres¬
sive regimens (18).
The aims of this study were first to describe the incidence
and risk factors for chronic renal dysfunction following liver
transplantation for ALF and second to compare renal out¬
come with an age-sex-matched group of patients trans¬
planted for CLD.
Methods
This was a retrospective single-center study of consecutive patients who
underwent super-urgent liver transplantation for ALF (UK Transplant Super
Urgent Scheme Category 1-7) between December 1992 and July 2007
(19). Eight patients had inadequate documentation available and were ex¬
cluded from the analysis. A further 1 patient was lost to follow-up. There¬
fore, the study cohort comprised 101 patients. The causes of ALF were
acetaminophen (46 patients, 45.5%), seronegative hepatitis (27 patients,
26.7%), idiosyncratic drug reaction (11 patients, 10.9%), autoimmune hep¬
atitis (7 patients, 6.9%), hepatitis B (4 patients, 4.0%), Budd-Chiari (3 pa¬
tients, 3.0%), Wilsons disease (2 patients, 2.0%) and hepatitis A (1 patient,
1.0%).
ALF was defined as severe liver injury with hepatic encephalopathy in which
the onset of encephalopathy was within 8 weeks for the first symptoms of
illness, and in the absence of preexisting liver disease (20).
Data were collected on the following preoperative variables at the time
of listing: age, gender, race, liver disease etiology, additional comorbidity,
smoking status, international normalized ratio (INR), serum bilirubin, albu¬
min, serum creatinine, serum sodium (hyponatremia: sodium <135mmol/L)
and presence of ascites (on ultrasound). SIRS was defined as >2 of tem¬
perature <36°C or >38°C, heart rate >90 beats per minute, white cell
count <4 x 109/L or >12 x 109/L and PaCC>2 < 4.3kPa at the time
of admission (21). Documented perioperative variables were peak pre¬
operative serum creatinine, preoperative renal replacement therapy, post¬
operative renal replacement therapy, inotropes (noradrenaline/adrenaline),
bacterial sepsis and fungal sepsis. Immunosuppression was noted
and calcineurin inhibitor trough levels at 1 week, 1 month and
12 months (a comparable 12-month value for the linear regression analysis
was obtained for all patients regardless of calcineurin inhibitor by express¬
ing the trough as relative to the median value). Renal function was recorded
at 1 month, 6 months, 12 months and 2, 3, 4 and 5 years following trans¬
plantation. Patients still receiving renal replacement therapy at 1 month
were given an arbitrary serum creatinine of 350 pmol/L and an estimated
glomerular filtration rate (eGFR) of 15 mL/min/1.73 m2.
A patient was considered to have significant renal dysfunction preopera-
tively if they fulfilled the RIFLE criteria for acute kidney injury: peak serum
creatinine >2 times the baseline level (22). The baseline serum creatinine
was unavailable for most patients and was estimated as previously de¬
scribed (1,22). Following transplantation the main measure of renal func¬
tion was eGFR, determined using the Modification of Diet in Renal Disease
(MDRD) Study4-variableequation (eGFR = 186 x creatinine (mg/dL)-1154 x
age (years)"0,203 x 1.2 1 0 (if black) x 0.742 (if female) (23). Chronic kidney
disease was defined as eGFR < 60 mL/min/1.73 m2 on at least 2 occa¬
sions from 6 months posttransplant onwards: stage 3, stage 4 and stage 5
chronic kidney disease were defined as eGFR 30-59 mL/min/1.73 m2, 15-
29 mL/min/1.73 m2 and <15 mL/min/1.73 m2 or on dialysis, respectively
(24).
To examine whether the renal dysfunction of ALF has a different renal prog¬
nosis after transplantation to the renal dysfunction of CLD a control group
of patients transplanted for CLD was identified. These patients were age-
matched (to within 5 years) and sex-matched to the original cohort. The
relatively young age of the patients transplanted for ALF meant that only
71 patients could be appropriately matched. The causes of CLD were pri¬
mary biliary cirrhosis (18 patients, 25.4%), alcohol (10 patients, 14.1%),
chronic active hepatitis (9 patients, 12.7%), sclerosing cholangitis (9 pa¬
tients, 12.7%), cryptogenic cirrhosis (9 patients, 12.7%), hepatitis C (5
patients, 7.0%) and other (11 patients, 15.5%). Three patients (4,2%) were
transplanted for hepatocellular carcinoma. None of the control patients had
intrinsic renal disease prior to transplantation and no patient underwent
combined liver-kidney transplantation.
Immunosuppression was similar for patients transplanted for ALF and for
CLD, and consisted of a calcineurin inhibitor, azathioprine and prednisolone
in most cases. Midway through the specified time period the unit policy for
calcineurin inhibitor changed from cyclosporine to tacrolimus. Prednisolone
was usually discontinued by 3 to 6 months posttransplant unless otherwise
indicated. Deviation from the protocol occurred only in the setting of ad¬
verse event or graft rejection. Acute rejection was usually managed with 1 g
of methyl-prednisolone intravenously for 3 days followed by reintroduction
of oral steroids with or without increased dose of, or switch to, alternative
calcineurin inhibitor. Chronic rejection was managed with the latter and in a
small number of patients azathioprine was changed to mycophenolate. In-
terleukin (IL)-2 receptor antagonist induction therapy was not administered
to any of the patients.
Statistical analyses
Cumulative incidence of chronic kidney disease was estimated using the
Kaplan-Meier method. Survival was estimated using Kaplan-Meier plots
with log-rank test for differences, and age-adjusted survival was determined
using Cox proportional hazards analyses. Normally distributed continuous
variables and nonparametric continuous variables were compared using the
Student's t-test and Mann-Whitney test, respectively. Chi-squared analysis
or Fisher's exact test were used for comparison of categorical data. A mul¬
tivariate linear regression analysis was performed to explore the relation¬
ship between perioperative renal dysfunction and long-term renal function
following transplantation. Clinically relevant factors were included simulta¬
neously with 12-month eGFR as the dependent variable. Cox proportional
hazards analysis was then used to identify variables predictive of chronic kid¬
ney disease by 5-years posttransplant. Three multivariate models were con¬
structed with all clinically relevant factors entered simultaneously. Variables
entered into Model 1 were age, gender, pretransplant diagnosed hyper¬
tension, category of ALF (acetaminophen-induced vs. nonacetaminophen-
induced), SIRS, calcineurin inhibitor at time of hospital discharge and pre¬
transplant acute kidney injury. In Models 2 and 3 acute kidney injury was
replaced by the other measures of perioperative renal dysfunction, peak pre¬
operative change in serum creatinine and immediate posttransplant renal
replacement therapy, respectively. All three measures of perioperative renal
dysfunction were not included in the same model because of collinearity.
None of the multivariate models was adjusted for the presence of pre¬
transplant diabetes mellitus secondary to small patient numbers, p < 0.05
was considered statistically significant unless otherwise stated. Data were
analyzed using the SPSS 15 package (SPSS Inc., Chicago, IL, USA).
All values are expressed as mean and standard deviation (SD), and median
and interquartile range (IQR) as appropriate.
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Table 1: Clinical characteristics of acute liver failure patients at
time of listing for liver transplantation (n = 101)
Clinical characteristics
Baseline demographics
Age (years) 36.3 (14.1)
Male : Female 1:1.5
Caucasian 99 (98)
Comorbidity
Diagnosed hypertension 6 (5.9)
Type I diabetes mellitus 2 (2.0)




Seronegative hepatitis 27 (26.7)
Idiosyncratic drug reaction 11 (10.9)
Autoimmune hepatitis 7 (6.9)
Hepatitis B 4 (4.0)
Budd-Chiari 3 (3.0)
Wilsons disease 2 (2.0)
Hepatitis A 2 (1.0)
Clinical characteristics at listing
Bilirubin (pmol/L) 193 (80-463)
INR 8.3 (3.2-11.7)
Albumin (g/L) 30.8(10.2)
Creatinine (pmol/L) 160 (94-298)
Sodium (mmol/L) 135 (5)
MELD score 43 (35-52)
Ascites 24 (23.8)
SIRS 59 (70.2)
Grade lll/IV encephalopathy 57 (59.4)
Inotropes 36 (37.9)
Values expressed as mean (standard deviation), median (inter¬
quartile range) and number (percent) where appropriate.
ALF = acute liver failure: INR = international normalised ratio:




The median jaundice to encephalopathy time for patients
with nonacetaminophen-induced ALF was 14 (IQR 11-31)
days. In patients with acetaminophen-induced ALF the me¬
dian time from overdose to listing for liver transplantation
was 69 (IQR 54-72) h. Patient characteristics at the time of
listing are outlined in Table 1. The median time from listing
to transplantation was 1 (IQR 1-2) day. The estimated 1-
month, 12-month and 5-year posttransplant patient survival
was 83%, 75% and 68%, respectively.
Perioperative renal function
Actual baseline renal function was available in 21 patients:
the median baseline serum creatinine was 75 (IQR 60-
93) pmol/L and the mean baseline eGFR was 106 (SD 45)
mL/min/1.73 m2.
During the immediate preoperative period the median peak
serum creatinine of the entire cohort was 203 (IQR 102—
362) pmol/L. Fifty-four patients (53.5%) fulfilled the criteria
for acute kidney injury, of whom 72.2% underwent renal
replacement therapy. A further five patients were com¬
menced on hemofiltration in the absence of a creatinine
rise. Following transplantation 64.9% (n = 63) received re¬
nal replacement therapy. By 1-month posttransplant the
median serum creatinine was 97 (IQR 83-136) pmol/L and
the mean eGFR was 67 (SD 40) mL/min/1.73 m2. Four of
the surviving patients (4.8%) were still on renal replace¬
ment therapy at this time point.
When patients with and without acetaminophen-induced
ALF were compared the former were more likely to demon¬
strate perioperative renal dysfunction. Acetaminophen-
induced ALF patients had a greater median peak pre¬
operative serum creatinine (acetaminophen-induced-ALF,
332 (217-415) pmol/L, n = 47; nonacetaminophen-induced
ALF 108 (86-187) pmol/L, median (IQR), n = 54; p < 0.001),
a greater frequency of acute kidney injury (acetaminophen-
induced ALF, 83%; nonacetaminophen-induced ALF,
28%; p < 0.001) and a greater frequency of pre-
(acetaminophen-induced ALF 74%; nonacetaminophen-
induced ALF, 15%; p < 0.001) and postoperative renal
replacement therapy (acetaminophen-induced ALF 95%;
nonacetaminophen-induced ALF, 38%; p < 0.001). At 1-
month posttransplant mean eGFR was similar for the two
groups (acetaminophen-induced ALF, 57 (30) mL/min/1.73
m2, n = 36; nonacetaminophen-induced ALF, 74 (44)
mL/min/1.73 m2; mean (SD), n = 48; p = 0.053).
Postoperative renal function
In most patients renal function demonstrated maximal re¬
covery by 6- to 12-months following transplantation. The
mean 12-month eGFR was 70 (SD 21) mL/min/1.73 m2,
and 21.1% (n = 16) of patients had stage 3-5 chronic
kidney disease by this time point. In those patients with
follow-up up to 5 years after transplantation the mean eGFR
remained stable at 70 (SD 20) mL/min/1.73 m2, and the
prevalence of stage 3-5 chronic kidney disease was 29.5%
(n = 13). Twelve-month eGFR demonstrated a close corre¬
lation with 5-year eGFR (r = 0.809, p < 0.001). The cumu¬
lative incidence of stage 3-5, and stage 4-5 chronic kidney
disease by 5 years was 41.5% and 2.6%, respectively.
Relationship between perioperative renal dysfunction
and posttransplant mortality
ALF patients who fulfilled the criteria for acute kidney injury
prior to transplantation had greater mortality post trans¬
plant (log-rank p = 0.061: age-adjusted FIR 2.09; 95% CI
1.01-4.34, p = 0.048; Figure 1). Similarly, patients who
required postoperative renal replacement therapy demon¬
strated an increased risk of death (age-adjusted HR 6.22;
95% CI 2.01-19.26, p = 0.002).
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Figure 1: Kaplan-Meier plot of the
probability of survival following liver
transplantation for acute liver failure
subdivided based on the presence or
absence of preoperative acute kid¬
ney injury.
Relationship between perioperative renal dysfunction
and posttransplant renal function
To explore the relationship between perioperative renal
dysfunction and long-term renal function following trans¬
plantation for ALF a multiple linear regression analysis was
performed, therefore, allowing adjustment for other rel¬
evant clinical factors such as age, gender and immuno¬
suppressive therapy. Given the close correlation between
12-month eGFR and 5-year eGFR, 12-month eGFR was
used as the dependent variable (Table 2). The analysis re¬
vealed no significant association between pretransplant
acute kidney injury and 12-month posttransplant eGFR
(p = 0.098). Instead, increasing age (p = 0.012), female
gender (p = 0.005), preoperative SIRS (p = 0.041) and
cyclosporine as primary immunosuppression (p = 0.021)
were associated with worse renal function. Patients with
acetaminophen-induced ALF had a higher 12-month eGFR
compared with patients with nonacetaminophen-induced
ALF (p = 0.027).
Predictors of chronic kidney disease following
transplantation
Recognizing the significant morbidity and mortality of
chronic kidney disease, as well as concerns regarding the
influence of early deaths after transplantation on the 12-
month data, Cox regression was then performed to identify
perioperative variables predictive of posttransplant chronic
kidney disease. Variables associated with the development
of chronic kidney disease following transplantation on uni¬
variate analysis are outlined in Table 3. A subsequent mul¬
tivariate regression analysis including all clinically relevant
variables simultaneously (Model 1 Table 3) identified older
age (overall p = 0.019), female gender (p = 0.049), pre¬
transplant diagnosed hypertension (p = 0.031) and cy¬
closporine immunosuppressive therapy (p = 0.027) to
be predictors of chronic kidney disease after transplan¬
tation. Patients transplanted for acetaminophen-induced
ALF were at lower risk of chronic kidney disease than
patients transplanted for nonacetaminophen-induced ALF
(p = 0.039).
Pretransplant AKI both on univariate analysis (p = 0.796),
and after adjusting for confounding factors (p = 0.288), was
not predictive of posttransplant chronic kidney disease.
Similarly, no relationship was demonstrated between peak
preoperative change in serum creatinine (univariate analy¬
sis, p = 0.838; multivariate analysis, p = 0.457, Model 2
Table 3), or renal replacement therapy during the immedi¬
ate posttransplant period (univariate analysis, p = 0.420;
multivariate analysis, p = 0.134, Model 3 Table 3) and
chronic renal dysfunction.
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Table 2: Multivariate linear regression analysis of variables as¬
sociated with eGFR 12-months following liver transplantation for
acute liver failure
Variable B (95% CI) P p-Value
Age (years) -0.516 -0.916,-0.116 -0.318 0.012
Female gender -14.500 -24.358, -4.643 -0.332 0.005
Past medical -20.354 -59.134, 18.426 -0.123 0.297
history:
hypertension
Acetaminophen- 16.176 1.889, 30.463 0.371 0.027
induced
ALF
Preoperative -12.780 -24.991,-0.570 -0.270 0.041
SIRS
Preoperative -10.204 -22.369, 1.960 -0.235 0.098
acute kidney
injury
CNI: -12.465 -22.947, -1.983 -0.263 0.021
cyclosporine
12-month CNI 0.583 -7.662, 8.832 0.016 0.887
trough
Reference group (relative risk 1.00): male gender, past med¬
ical history: no hypertension, nonacetaminophen-induced ALF,
no preoperative SIRS, no preoperative acute kidney injury, CNI:
tacrolimus (at time of 12-month eGFR). Bold indicates statistical
significance.
ALF = acute liver failure: B = unstandardized regression coeffi¬
cient: p = standardized regression coefficient; CNI = calcineurin
inhibitor; SIRS = systemic inflammatory response syndrome.
Comparison ofposttransplant renal function in
patients transplanted for ALF and age-sex matched
patients transplanted for CLD
To determine whether ALF per se is associated with re¬
nal function following transplantation age-sex-matched pa¬
tients transplanted for CLD were introduced into the sta¬
tistical analysis. Pre- and perioperative characteristics of
patients with ALF and with CLD are compared in Table 4.
The median waiting-list time was 1 (IQR 1-2) day for
ALF patients and 52 (IQR 20-136) days for CLD patients
(p < 0.001). Median listing serum creatinine was higher
(p < 0.001), mean listing eGFR lower (p < 0.001) and the
frequency of ascites less (p < 0.001) in the ALF group.
Furthermore, the ALF patients were more likely to receive
pre- (p < 0.001) and postoperative renal replacement ther¬
apy (p < 0.001). The estimated 1-month, 12-month and
5-year survival was 78%, 69% and 62%, respectively, for
ALF patients and 96%, 90% and 79% for patients with
CLD (Figure 2, log-rank p = 0.029).
By 1 month following transplantation the median serum
creatinine (ALF, 92 [83—127] pmol/L; CLD, 88 [79-101]
pmol/L, median [IQR]; p = 0.103) and the mean eGFR
(ALF, 69 [42] mL/min/1.73 m2; CLD, 74 [27] mLVmin/1.73
m2, mean [SD]; p = 0.451) were similar in ALF and CLD
patients. Figure 3 illustrates the mean pre- and posttrans¬
plantation eGFR in patients with ALF and CLD surviving
to 12 months. The accompanying table (Table 5) docu¬
ments relevant pre- and posttransplant clinical variables
of these surviving patients. Despite significantly lower list¬
ing eGFR in the ALF group renal function was similar at all
time points in the postoperative period. The cumulative in¬
cidence of stage 3-5 (ALF 48.7%; CLD, 49.6%; p = 0.930)
and stage 4-5 chronic kidney disease (ALF, 4.1%; CLD,
8.7%; p = 0.615) by 5 years was also no different between
ALF and CLD groups.
Discussion
In this large single-center study we have described for
the first time the risk factors for chronic renal dysfunction
following emergency liver transplantation for ALF. Impor¬
tantly, we have shown that perioperative kidney injury does
not appear to have negative consequences for long-term
renal function in this population. Contrary to observations
in CLD patients pretransplant acute kidney injury and re¬
nal replacement therapy were not associated with chronic
kidney disease. Only failure to recover renal function, as ev¬
idenced by eGFR at 1-month posttransplant, was a predic¬
tive factor. Despite marked differences in the perioperative
clinical condition of patients transplanted for ALF and CLD
long-term renal outcome following transplantation was the
same.
The rate of chronic kidney disease after transplantation for
ALF was similar to that reported by Aberg et al., the single
other publication of renal function in this setting (25). Al¬
though half of our patients fulfilled the criteria for acute kid¬
ney injury pretransplant, and more than 60% required renal
replacement therapy during the immediate postoperative
period, only 21 % had an eGFR less than 60mL/min/1.73 m2
12 months thereafter. This dramatic renal recovery echoes
clinical observations in spontaneous survivors of ALF. By
5-years posttransplant the cumulative incidence of chronic
kidney disease was 42%.
The identical posttransplant renal function of ALF and
CLD patients was unexpected when considering our
current understanding of the underlying mechanisms
(11-14,26). Based on the traditional hypothesis of hepa¬
torenal syndrome one might predict that severe perioper¬
ative renal vasoconstriction would exacerbate calcineurin-
inhibitor mediated kidney dysfunction (11-14,26).
Cyclosporine and tacrolimus cause an initially hemody¬
namic dose-dependent renal impairment that is feasibly
exaggerated in patients with greater baseline circulatory
and neuro-humoral derangement (11-14). Our results sup¬
port an alternative patho-physiological process underlying
the renal injury that occurs in ALF.
We have previously demonstrated that SIRS predicts
the development of acute kidney injury in patients
with nonacetaminophen-induced ALF a relationship that
appears to be independent of the severity of liver injury
(1). Consequently, we have postulated that the renal dys¬
function of sepsis may be a more accurate parallel than
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Table 4: Pre- and perioperative clinical characteristics of patients transplanted for acute liver failure and age-sex-matched patients
transplanted for chronic liver disease
Characteristic ALF patients (n = 71) CLD patients (n = 71) p-Value
Age (years) 42.2 (12.4) 42.5(12.1) 0.918
Male:Female 1:1.3 1:1.3 1.000
Time on waiting list (days) 1 (1-2) 52 (20-136) <0.001
Comorbidity
Diagnosed hypertension 6 (8.5) 2 (2.8) 0.137
Type I diabetes mellitus 0(0) (0) 1.000
Type II diabetes mellitus 1 (1.4) 5 (7.0) 0.104
Dyslipidemia 1 (1.4) 4 (5.6) 0.183
Hepatitis C 1 (1.4) 6 (8.5) 0.058
Active smoker 37 (56.9) 20 (29.4) 0.001
At listing
INR 5.8 (2.8-11.1) 1.2 (1.1-1.5) <0.001
Bilirubin (pmol/L) 227 (81-486) 67 (35-172) <0.001
Albumin (g/L) 30.8(11.4) 30.0 (5.6) 0.582
MELD score 41 (33-52) 16 (12-19) <0.001
Creatinine (pmol/L) 148 (94-298) 81 (71-97) <0.001
eGFR (mL/min/1.73 m2) 49 (42) 83 (30) <0.001
Hyponatremia 27 (38.0) 19 (26.8) 0.151
Ascites 18 (25.4) 41 (57.7) <0.001
Perioperative
Peak creatinine (|imol/L) 200 (99-384)
Pre RRT 30 (42.3) 0(0) <0.001
Post RRT 41 (61.2) 12 (16.9) <0.001
Fungal sepsis 5 (7.5) 3 (4.2) 0.327
Bacterial sepsis 35 (52.2) 25 (35.2) 0.044
Super-urgent retransplant 4 (5.6) 4 (5.6) 0.641
Early acute cellular rejection 17 (25.4) 28 (39.4) 0.078
CNI on discharge: cyclosporin 16(28.1) 27 (39.1) 0.192
Values expressed as mean (standard deviation), median (interquartile range) and number (percent) where appropriate.
ALF = acute liver failure; CLD = chronic liver disease; CNI = calcineurin inhibitor; eGFR = estimated glomerular filtration rate;
INR = international normalized ratio; MELD = Model for End-Stage Liver Disease; RRT = renal replacement therapy.
Table 5: Relevant pre-and posttransplant clinical characteristics of all patients transplanted for acute liver failure and patients transplanted
for chronic liver disease surviving to 12 months after transplant
ALF patients CLD patients P-
Characteristic (n = 49) (no = 62) Value
Age at listing (years) 41.8 (12.4) 42.5 (12.4) 0.772
Male:Female 1:1 1:1.3 0.569
Comorbidity at 12-month posttransplant
Diagnosed hypertension 14 (28.6) 17 (27.4) 0.893
Type II diabetes mellitus 7 (14.3) 7 (11.3) 0.637
Insulin-dependent diabetes mellitus 1 (2.0) 6 (9.7) 0.103
CNI on discharge: cyclosporine 16 (32.7) 25 (40.3) 0.406
1 week CNI trough:
Cyclosporine 181 (57) 145 (52) 0.157*
Tacrolimus 8.5 (3.3) 10.1 (3.1) 0.195*
1 month CNI trough:
Cyclosporine 151 (39) 162 (48) 0.492*
Tacrolimus 10.8 (4.6) 8.1 (3.2) 0.006*
12 month CNI trough:
Cyclosporine 133 (40) 160 (40) 0.073*
Tacrolimus 8.0 (3.3) 7.9 (2.8) 0.974*
Values expressed as mean (standard deviation) and number (percent) where appropriate.
*p-value <0.017 considered significant.
ALF = acute liver failure; CLD = chronic liver disease; CNI = calcineurin inhibitor.
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Figure 2: Kaplan-Meier plot of the
probability of survival following liver
transplantation for acute liver failure
and chronic liver disease.
the hepatorenal syndrome of cirrhosis (1). In fulminant
hepatic failure the systemic inflammatory response may
be the key mediator of renal impairment. Patients with
subfulminant ALF are more likely to have clinically signif¬
icant portal hypertension, and may develop ascites (27).
Therefore, this group may share some of the hemodynamic
and neuro-humoral features of hepatorenal syndrome (1).










«GFR tml/inin/J.7JniJ>«ompared at time points
1 month 6 months 12 months
Chronic Ifver disease (n:62) 35 5 74 5 69 2 66 2
Acute liverfailure (n 49) 51 1 69.8 69.0 66 7
P value <0 001 0.468 0 965 0 897
Figure 3: Mean estimated glomerular
filtration rate (eGFR) and 95% con¬
fidence intervals at the time of list¬
ing for liver transplantation and at
1, 6 and 12 months following trans¬
plantation in all patients surviving
to 12 months subdivided into acute
liver failure and chronic liver disease
groups, p-value <0.013 considered sig¬
nificant. The median time from listing
to transplantation for acute liver failure
patients was 1 (IQR 1-2) day and for
chronic liver disease patients was 52
(20-136) days.
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preserved or even increased renal perfusion, which is in
contrast to the intense renal vasoconstriction of hepatore¬
nal syndrome (26,28). We propose that relative renal hy¬
peremia may help to minimize the renal hemodynamic re¬
sponse to calcineurin inhibitors and explain the compara¬
ble long-term posttransplant renal function demonstrated
by ALF patients (14).
Alternatively, the failure of perioperative renal dysfunc¬
tion to impact on long-term posttransplant renal outcomes
may reflect the duration of renal impairment. In patients
transplanted for CLD renal dysfunction duration appears
to be a key determinant of chronic renal impairment.
Campbell et al. demonstrated that renal dysfunction du¬
ration of greater than 3.6 weeks pretransplant was an
appropriate cut-off to identify patients at risk of renal in¬
sufficiency 12-months thereafter (29). In our cohort the
renal injury, although more severe, was on the contrary
short-lived.
In the nontransplant population acute kidney injury is a risk
factor for chronic renal dysfunction. For example, in pa¬
tients who undergo major vascular surgery the occurrence
of perioperative acute kidney injury is associated with an
increased risk of chronic kidney disease (30). Furthermore,
patients requiring dialysis for acute kidney injury who are
dialysis-independent at the time of hospital discharge are
three times more likely to develop end-stage renal fail¬
ure (31). Animal studies have confirmed that acute kid¬
ney injury can cause permanent structural kidney damage
with progressive tubulo-interstitial fibrosis and long-term
implications for renal function (32). Our failure to show a
relationship between perioperative renal dysfunction and
posttransplant chronic kidney disease is not in accordance
with these observations. Acute kidney injury is an indepen¬
dent predictor of mortality in patients with ALF, and follow¬
ing transplantation for ALF (1). Yet, our findings suggest
that beyond hospital discharge acute renal impairment, if
short-lived, does not impact particularly on chronic renal
function.
Acetaminophen as the cause of ALF was associated with
a higher absolute eGFR at 12-months following transplan¬
tation and a reduced risk of chronic kidney disease. Ac¬
etaminophen is an independent predictor of acute kid¬
ney injury in patients with ALF and there are case re¬
ports of renal failure following acetaminophen overdose
in the absence of significant hepatic injury (1,33,34). Ani¬
mal models support a direct nephrotoxic effect although
the mechanism remains unclear (33). It has been hy¬
pothesized that a locally produced metabolite induces
proximal tubular cell necrosis while functional renal ef¬
fects may also contribute (33,35,36). Our findings support
the reversibility of acetaminophen-induced nephrotoxicity
(37,38).
The study has some potential limitations that should be
mentioned. First, baseline renal function was only avail¬
able in a small number of ALF patients and it is possible
that a proportion could have had undiagnosed intrinsic re¬
nal disease. The patients studied were of a relatively young
age and it is assumed that premorbid renal function was
normal. Second, nephrotoxic medications could have influ¬
enced the severity of perioperative renal dysfunction. Our
unit avoids nephrotoxic drugs, yet this does not preclude
exposure prior to transfer. Third, although our study con¬
sists of one of the largest single center cohorts of patients
transplanted for ALF it remains possible that the relatively
small numbers may have influenced our results.
With regards the CLD group, only 70% of the ALF pa¬
tients could be matched because of the young age range.
Furthermore, the pretransplant eGFR was only available
at the time of listing and not immediately prior to trans¬
plantation. Pretransplant kidney function may, therefore,
have been over represented in the CLD patients if there
was a significant deterioration on the list. Nevertheless,
no CLD patient required preoperative renal replacement
therapy or reassessment for combined liver-kidney trans¬
plantation and, given the relatively short median waiting-
list time of 52 days, it seems unlikely that this data would
have influenced the results. The lack of pretransplant re¬
nal impairment in the control arm may also raise some
concerns about its generalizability for a standard popula¬
tion of liver transplant recipients. This largely reflects the
younger age of the patients. Flowever, those with intrinsic
renal disease or who received a simultaneous liver-kidney
transplant were also deliberately excluded; we wished to
examine whether the physiological differences between
ALF and CLD would influence renal outcomes. Of course,
it is well recognized that eGFR is not an accurate measure
of renal function in patients listed for elective liver trans¬
plantation, tending to overestimate when the true GFR is
reduced (39). Sixty percent of the CLD patients had as¬
cites and one-third had hyponatraemia, indicating a high
prevalence of portal hypertensive-related renal impairment
(40). Finally, it is difficult to ensure retrospectively that
ALF and CLD patients received similar immunosuppres¬
sive regimes. However, during the period studied our unit
had a single protocol that was rarely deviated from with
calcineurin inhibitor administration within 24 h of trans¬
plantation. The similar posttransplant calcineurin inhibitor
trough levels support this claim.
The findings of our study have important implications for
patient management. Patients who undergo liver trans¬
plantation for ALF should not be considered a high-risk
group for developing chronic kidney disease even when
perioperative acute renal impairment is severe. Conse¬
quently, we do not support the routine use of interleukin-2
receptor antagonists and delayed introduction of the cal¬
cineurin inhibitor in this setting (18). Renal sparing immuno¬
suppression such as mycophenolate and reduced dose
tacrolimus could be considered in select patients, for ex¬
ample older females transplanted for nonacetaminophen-
induced ALF (41).
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In conclusion, in this large single-center study of patients
transplanted for ALF we have shown that the severity of
perioperative renal dysfunction was not predictive of post-
transplant chronic kidney disease. Despite greater periop¬
erative physiological derangement in ALF patients when
compared with an age-sex-matched cohort transplanted
for CLD renal function following transplantation was the
same.
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Modifiable patient factors are associated
with the late decline in renal function
following liver transplantation
Leithead JA, Ferguson JW, Hayes PC. Modifiable patient factors are
associated with the late decline in renal function following liver
transplantation.
Abstract: Strategies to delay or avoid the long-term decline in renal
function and progression to chronic kidney disease (CKD) in liver
transplant recipients remain unclear. Our aim was to examine the change
in estimated GFR (eGFR) from six months after liver transplantation,
and to identify modifiable factors associated with a faster rate of decline.
This was a single-center retrospective study of 97 patients who underwent
elective liver transplantation and survived > 5 yr. eGFR was estimated
using the MDRD6-variable equation, and the annualized change in
eGFR was determined using simple linear regression. The baseline eGFR
was 75 mL/min/1.73 m2. Thereafter, eGFR declined at a mean rate of
1.08 mL/min/1.73 m2 per year. 49% had a decline in renal function
greater than the rate expected with aging. Decline in eGFR was an
independent predictor of CKD by five yr post-transplant (p = 0.001).
Multivariate modeling found a higher baseline eGFR (p < 0.001), female
gender (p = 0.006), hypertension (p = 0.019), and dyslipidemia
(p = 0.034) to be associated with a faster rate of decline in renal function.
In conclusion, liver transplant recipients have a clinically relevant decline
in eGFR from six months post-transplant. Prospective studies are
required to examine the effects of aggressive blood pressure and lipid
control on the development of CKD in this setting.
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Chronic renal dysfunction is an important compli¬
cation of liver transplantation, associated with sig¬
nificant morbidity and mortality (1-3). The five-yr
cumulative incidence of severe chronic kidney dis¬
ease (CKD) has been reported to be as high as
18%, and liver transplant recipients who develop
CKD have a five times increased risk of death
(1,4). The prevention of chronic renal dysfunction
following liver transplantation has emerged as a
priority for transplant physicians.
Early postoperative renal function is an indica¬
tor of renal outcome in this setting. Most patients
demonstrate a steep decline in glomerular filtration
rate (GFR) during the first postoperative weeks
with relative stabilization thereafter, and
six months and 12 months post-transplant GFR
are consistent predictors of chronic renal dysfunc¬
tion (1, 5-9). Consequently, the perioperative per¬
iod has become a focus for interventions to lessen
the decline in GFR. Cyclosporine and tacrolimus
are considered to play a critical role in shaping
renal function after transplantation (6, 10-12).
Several randomized controlled trials examining
perioperative minimization of calcineurin inhibitor
exposure have been published (13-15). Yet, the
results are mixed failing to demonstrate any con¬
vincing long-term benefit in unselected patients.
The change in renal function beyond the initial
postoperative period has received less attention.
The steady-state long-term rate of change in GFR
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allows individuals at risk of progression to CKD
to be identified (16, 17). Furthermore, by examin¬
ing the relationship between rate of change and
modifiable risk factors, potential therapeutic inter¬
ventions can be suggested (16, 17). In renal trans¬
plant recipients, patients who receive tacrolimus or
non-calcineurin inhibitor-based immunosuppres¬
sion have a slower rate of decline in renal function
compared with patients prescribed cyclosporine
(18). In non-transplant CKD, hypertension, poor
glycemic control, smoking, and possibly dyslipi-
demia have been linked with a faster decline in
GFR (17). Renal biopsies of liver transplant
patients with chronic renal failure support a multi¬
factorial origin (19). However, the impact of such
characteristics on the long-term rate of change in
GFR and the development of renal dysfunction
following liver transplantation remains unclear.
The aim of this study was to examine the long-
term change in GFR from six months following
liver transplantation, and to identify modifiable
factors associated with a faster rate of decline.
Methods
This was a retrospective single-center case-note
study of patients who underwent elective first liver
transplantation between January 1st 1996 and
December 31st 2000. The specified time period
allowed the analysis of patients transplanted in an
experienced center with a follow-up time post-
transplant of >5 yr. This was an era when periop¬
erative renal sparing immunosuppression, and
aggressive alteration of immunosuppression in
response to moderate post-transplant renal dys¬
function, was infrequently practiced in our unit.
Furthermore, cardiovascular risk factors were not
as closely monitored. Therefore, variability of
management between patients was less. To allow
the analysis of change in renal function in a rela¬
tively homogeneous cohort of patients, the records
of the following groups were not reviewed: those
listed for acute liver failure (n = 39) or joint liver/
kidney transplantation (n = 7), those who did not
survive for five or more years post-transplant
(n = 33), and those who changed calcineurin inhib¬
itor therapy during the follow-up period (n = 9).
Eighteen patients had incomplete data available
and were also excluded from the analysis. The
study group comprised a total of 97 patients.
Immunosuppression consisted of a calcineurin
inhibitor, azathioprine, and prednisolone in most
patients. Midway through the specified time
period, the unit policy for calcineurin inhibitor
changed from cyclosporine to tacrolimus. Prednis¬
olone was usually discontinued by 3-6 months
post-transplant unless otherwise indicated.
Deviation from the protocol occurred only in the
setting of adverse event or graft rejection. Acute
rejection was usually managed with 1 g of methyl-
prednisolone intravenously for three d followed by
reintroduction of oral steroids with or without
increased dose of, or switch to, alternative calci¬
neurin inhibitor. Chronic rejection was managed
with the latter, and in seven patients, azathioprine
was changed to mycophenolate.
Data were collected on the following at the time
of listing for liver transplantation: age, gender,
race, etiology of liver disease, additional comorbid¬
ity, smoking status, MELD score, serum creati¬
nine, serum sodium (hyponatremia; serum sodium
<135 mM), presence of ascites, and need for renal
replacement therapy. Post-transplantation the fol¬
lowing complications were documented only if
occurring during the five yr follow-up period: peri¬
operative renal replacement therapy, number of
acute rejection episodes, chronic rejection, disease
recurrence, and re-transplantation. The presence
of diabetes, and diagnosed hypertension and dysli-
pidemia were noted if present during the same time
period. All blood pressures, body mass index
(BMI) measurements, calcineurin inhibitor trough
levels, and blood lipid concentrations (non-fasting)
taken during routine outpatient appointments were
recorded. These were averaged to provide the aver¬
age systolic blood pressure, average diastolic blood
pressure, average BMI, average cyclosporine
trough level, average tacrolimus trough level, aver¬
age cholesterol concentration, and average triglyc¬
eride concentration. A comparable calcineurin
trough level for the multivariate models was
obtained for all patients regardless of calcineurin
inhibitor by expressing the trough as relative to the
median value. Obesity was defined as an average
BMI greater than or equal to 30.
GFR was estimated using the Modification of
Diet in Renal Disease (MDRD) Study 6-vari-
able equation (eGFR = 170 x creatinine (mg/
dL)-° "9 x age"0 176 x 1.180 (if black) x 0.762
(if female) x serum urea nitrogen-0170 x albu¬
min0138) (20). For each patient, the estimated
GFR (eGFR) was calculated from the serum
creatinine level taken at the time of listing for
liver transplantation (pre-transplant), and from
routine outpatient clinics at 0.5, 1, 2, 3, 4, and
5 yr post-transplantation. As per the National
Kidney Foundation, CKD was defined as a sus¬
tained eGFR of <60 mL/min/1.73 m2: stage 3,
stage 4, and stage 5 CKD were defined as an
eGFR of 30-59 mL/min/1.73 m2, 15-29 mL/





Normally distributed continuous variables were
compared using the Student's /-test and nonpara-
metric continuous variables the Mann-Whitney
test. For each patient, the annualized change in
eGFR was determined using simple linear regres¬
sion of all eGFR measurements available from
six months post-transplantation (17). A negative
annualized change in eGFR represents a decline in
eGFR, and a positive annualized change in eGFR
represents an improvement in eGFR. The rate of
change in eGFR expected with aging is 1 mL/min/
1.73 m2 per year (21). Therefore, patients were
described as having a decline in renal function
greater than the rate expected with aging if the
annualized change in eGFR was >—1.00 mL/min/
1.73 m2 per year. Patients with an annualized
change in eGFR of between -1.00 and +1.00 mL/
min/1.73 m2 per year and those with an annualized
increase in eGFR of >+1.00 mL/min/1.73 m2 per
year were considered to have unchanged renal
function and improved renal function, respectively
(22).
Logistic regression analyses were used to
examine the relationship between the annualized
change in eGFR, and a decline in eGFR greater
than the rate expected with aging, and the devel¬
opment of stage 3-5 CKD. Two separate multi¬
variate models were constructed with all
clinically relevant variables entered simulta¬
neously. Pre-transplant hypertension was not
included in the models because of small patient
numbers. Multivariate linear regression analyses
were then used to determine variables associated
with the annualized change in eGFR. Again two
multivariate models were constructed with all
clinically relevant variables entered simulta¬
neously. In model 2, the binary variables, insu¬
lin-dependent diabetes, diagnosed hypertension,
and diagnosed dyslipidemia were replaced with
the continuous variables, average glucose, aver¬
age systolic blood pressure, and average choles¬
terol in an effort to examine whether
modification of these factors might influence
outcome. Age was not included in the models
because of collinearity. Finally, logistic regres¬
sion analysis was repeated to identify variables
associated with a decline in renal function
greater than the rate expected with aging,
p < 0.05 was considered statistically significant
at all times. Data were analyzed using the SPSS
18 package (SPSS Inc., Chicago, IL, USA).
The annualized change in eGFR is expressed as
the mean with 95% confidence intervals (95% CI).
All other values are expressed as mean and
standard deviation (SD), and median and inter¬
quartile range (IQR) as appropriate.
Results
Baseline characteristics of the patients at the time
of listing for liver transplantation are outlined in
Table 1. The median time from listing to trans¬
plantation was 39 (range 2-314) d.
Pre-transplant renal function
Pre-transplant, the mean eGFR of the entire
cohort was 103 (SD 34) mL/min/1.73 m2, and
the median serum creatinine was 81 (IQR 70-
97) pM. Three patients (3.1%) had an eGFR
30-59 mL/min/1.73 m2, one patient (1.0%) had
an eGFR 15-29 mL/min/1.73 m2, and 0 patients
had an eGFR <15 mL/min/1.73 m2 (Fig. 1).
Seventeen patients (17.5%) had refractory asci¬
tes, and 23 (23.7%) had hyponatremia.







Primary biliary cirrhosis 35 (36.1)
Alcoholic liver disease 21 (21.6)
Sclerosing cholangitis 11 (11.3)
Cryptogenic cirrhosis 8 (8.2)






Measure of renal function
Creatinine (pM) 81(70-97)
eGFR (mL/min/1.73 m2) 103 (34)
Sodium (mM) 138(135-140)
Hepatorenal syndrome 2(2.1)




Diagnosed hypertension 6 (6.2)
Diagnosed dyslipidemia 3(3.1)
Diabetes mellitus 12(12.4)
Insulin-dependent diabetes 8 (8.2)
Active smoker 20 (20.6)
Obesity (wet weight) 18(18.8)
MELD, model for end-stage liver disease; eGFR, estimated glomerular fil¬
tration rate.
Values expressed as mean (standard deviation), median (interquartile
range), and number (percent) where appropriate.
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Fig. 1. Prevalence of chronic kidney disease pre-liver trans¬
plantation, and at six months and five yr post-liver transplan¬
tation.
Change in renal function following transplantation
Eight patients (8.2%) required renal replacement
therapy during the immediate postoperative period.
By six months after transplantation, the mean
eGFR was 75 (SD 22) mL/min/1.73 m2, and the
median serum creatinine was 103 (IQR 92-123)
pM. Seventeen patients (17.5%) had stage 3 CKD,
one patient (1.0%) had stage 4 CKD, and no
patient had stage 5 CKD at this time point (Fig. 1).
During subsequent years, there was a progressive
increase in the prevalence of renal dysfunction. At
five yr post-transplant, 23.7%, 3.1%, and 1.0% of
patients had stage 3, stage 4, and stage 5 CKD,
respectively (Fig. 1). The mean five-yr eGFR was
69 (SD 21) mL/min/1.73 m2, and the median five yr
serum creatinine was 110 (IQR 98-129) pM.
eGFR declined at a mean rate of 1.08 mL/min/
1.73 m2 per year (95% CI 2.13-0.03, p = 0.045)
from six months post-transplant. Forty-seven
patients (48.5%) demonstrated a decline in renal
function greater than the rate expected with aging.
Twenty patients (20.6%) had no change in renal
function, and 30 (30.9%) had an improvement in
renal function. Assuming the mean annualized
change in eGFR remained constant, the estimated
prevalence of stage 3, stage 4, and stage 5 CKD by
10 yr post-transplant was 29.9%, 6.2% and 6.2%,
respectively.
Change in eGFR as a predictor of CKD by five yr
post-transplant
In patients who developed CKD, the mean rate of
decline in eGFR from six months post-transplant
was 2.50 (95% CI -4.03 to -0.97) mL/min/
1.73 m2 per year compared with 0.52 (95% CI
-1.35 to 0.30) mL/min/1.73 m2 per year for
patients who did not (p = 0.016). Sixty-seven
percent of the CKD group demonstrated a decline
in renal function greater than the rate expected with
aging during the preceding years compared with
only 41.4% of the non-CKD group (p = 0.026).
The annualized change in eGFR from
six months after transplantation remained an inde¬
pendent predictor of five-yr CKD in a multivariate
model including all clinically relevant variables
simultaneously (Table 2, p = 0.001). Here, the
more negative the change in eGFR (i.e., the greater
the decline in eGFR), the greater the likelihood of
CKD. In a similar multivariate model, a decline in
renal function greater than the rate expected with
aging was associated with a relative risk of CKD
of 6.88 (95% CI 1.75-27.14, p = 0.006, adjusted
for age, gender, hepatitis C status, pre-transplant
eGFR, refractory ascites and diabetes, periopera¬
tive renal replacement therapy, and calcineurin
inhibitor, data not shown).
Factors associated with the change in renal function
from six months after liver transplantation
Given the strong association between the decline in
renal function from six months post-transplant
and the development of CKD statistical analyses
were then performed to identify factors that may
influence the long-term change in eGFR. Clinical
characteristics of the cohort during the follow-up
period are outlined in Table 3.
In a multivariate linear regression model adjust¬
ing for renal relevant variables, with the mean
annualized change in eGFR as the dependent
variable, a higher baseline eGFR (p < 0.001),
female gender (p = 0.006), diagnosed hypertension
(p = 0.019), and diagnosed dyslipidemia (p =
0.034) were associated with a faster rate of decline
in renal function (Table 4, multivariate model 1).
There was no association between the presence of
hepatitis C infection, insulin-dependent diabetes or
immunosuppression, and change in eGFR. In a
second multivariate model, in which binary
variables were replaced with continuous, average
systolic blood pressure was strongly associated
with the change in renal function: for every
10 mmHg increase in average systolic blood
pressure, there was a 0.76 mL/min/1.73 m2 per
year faster decline in eGFR (p = 0.005, Table 4,
multivariate model 2).
Logistic regression analysis was then used to
determine variables associated with a rate of
decline in renal function greater than that expected
with aging (Table 5). In this multivariate model
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Table 2. Univariate and multivariate logistic regression analyses of variables predictive of CKD by five yr after liver transplantation
Variable
Univariate Multivariate
OR (95% CI) p Value
OR
(95% CI) p Value
Age (yr) 1.07(1.02-1.12) 0.011 1.09(1.00-1.18) 0.043
Female 7.67 (2.40-24.52) 0.001 32.11 (3.00-343.71) 0.004
gender
Hepatitis C 2.06 (0.43-9.90) 0.366 31.21 (1.41-688.86) 0.029
Pre-transplant
eGFR (mLAriin/1.73 m2) 0.97 (0.95-0.99) 0.002 0.96 (0.93-0.99) 0.011
Refractory ascites 0.76(0.23-2.59) 0.663 1.90(0.21-17.32) 0.571
Diabetes mellitus 0.85 (0.21-3.40) 0.815 5.23(0.30-91.05) 0.257
Perioperative RRT 5.08(1.12-22.98) 0.035 33.40 (3.63-307.05) 0.002
CNI: cyclosporine 1.99(0.78-5.07) 0.151 2.13(0.51-8.96) 0.302
AeGFR
(mL/min/1.73 m2
per yr) 0.86 (0.76-0.98) 0.021 0.63 (0.47-0.84) 0.001
CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; RRT, renal replacement therapy; CNI, calcineurin inhibitor; AeGFR, mean annual¬
ized change in eGFR from six months to five yr post-transplant.
Reference group (relative risk 1.00): male gender, no hepatitis C, no refractory ascites, no diabetes mellitus, no perioperative RRT, CNI: tacrolimus. Bold¬
face indicates statistical significance.
after adjusting for all clinically relevant variables,
a higher six month eGFR (p < 0.001), female gen¬
der (p = 0.024), and diagnosed hypertension
(p = 0.050) were independent risk factors. There
was a trend toward an association between cyclo¬
sporin and decline in renal function (p = 0.071).
Table 3. Clinical characteristics of patients after liver transplantation
Clinical characteristics
Graft dysfunction
Early acute cellular rejection 33 (34.0)
Late acute cellular rejection 8 (8.2)




One month cyclosporine trough 146(50)
One month tacrolimus trough 8.1 (3.0)
Comorbidity
Diagnosed hypertension 46 (47.4)
Diagnosed dyslipidemia 10(10.3)
Diabetes mellitus 21(21.6)
Insulin-dependent diabetes 13 (13.4)
Obesity 33 (34.0)
Average value
Cyclosporine trough (mM) 137 (20)
Tacrolimus trough (pg/L) 7.7(1.3)
Systolic blood pressure (mmHg) 142 (15)
Diastolic blood pressure (mmhlg) 82 (7.1)
Glucose (mM) 5.8(5.2-6.9)
Cholesterol (mM, n = 91) 5.0(1.3)
Triglyceride (mM, n = 51) 1.6 (1.3-2.7)
Body mass index 27.8 (5.1)
CNI, calcineurin inhibitor.
Values expressed as mean (standard deviation), median (interquartile
range), and number (percent) where appropriate.
Discussion
In this single-center study, we have described, for
the first time, the annualized change in eGFR fol¬
lowing liver transplantation. In a homogeneous
cohort of patients with long-term survival, we
examined the change in eGFR beyond the initial
postoperative period, and current focus of CKD
prevention. By estimating the steady-state change
in kidney function, our aim was to identify possible
modifiable risk factors for the progression to
CKD. We have shown that liver transplant recipi¬
ents had a clinically relevant decline in eGFR from
six months post-transplant. Our patients demon¬
strated a mean decline in eGFR of 1.1 mL/min/
1.73 m2 per year, and almost half had a decline in
renal function greater than the rate expected with
aging. A decline in eGFR was a strong and inde¬
pendent predictor for the development of CKD.
Multivariate modeling found a higher baseline
eGFR, female gender, hypertension, and dyslipide¬
mia to be associated with a faster rate of decline in
renal function.
Several factors have been identified that may
influence the development of chronic renal
dysfunction following liver transplantation.
Increasing age, white race, hepatitis C, pre-
transplant diabetes mellitus, pre-transplant renal
impairment, and perioperative acute renal failure
are independent predictors of CKD (1,3,7,9,23).
These variables highlight, at the time of surgery,
the patients at increased risk of renal injury in
whom preventative measures may be more crucial.
However, few are potentially modifiable, and little
E320
Late decline in eGFR after liver transplant
Table 4. Multivariate linear regression analyses of variables associated with the annualized change in eGFR from six months post-liver trans¬
plantation
Multivariate model 1 Multivariate model 2
Variable B (95% CI) P p Value B (95% CI) P p Value
Six-month eGFR (mL/min/1.73 m2) -0.108 (—0.141, -0.075) -0.650 <0.001 -0.109 (-0.145, -0.073) -0.680 <0.001
Female gender -2.080 (-3.550, -0.609) -0.284 0.006 -1.360 (-2.856, 0.137) -0.192 0.074
FHepatitis C -0.183 (-2.667, 2.300) -0.013 0.884 -1.072 (-4.233, 2.089) -0.069 0.502
Perioperative RRT -0.480 (-2.761, 1.800) -0.036 0.676 -0.118 (-2.602, 2.366) -0.009 0.925
CNI: cyclosporine -0.637 (-2.033, 0.759) -0.080 0.676 -0.820 (-2.273, 0.632) -0.106 0.264
Average CNI trough 1.447 (-2.397, 5.291) 0.063 0.456 -0.149 (-4.324, 4.026) -0.007 0.944
Insulin-dependent diabetes -0.559 (-2.484, 1.365) -0.052 0.565
Diagnosed hypertension -1.523 (-2.788, -0.258) -0.208 0.019
Diagnosed dyslipidemia -2.300 (-4.420, -0.179) -0.192 0.034
Log average glucose (mM) -0.322 (-3.195, 2.531) -0.025 0.818
Average systolic blood pressure (mmHg) -0.076 (-0.128, -0.024) -0.319 0.005
Average cholesterol (mM) -0.033 (-0.641, 0.574) -0.012 0.913
eGFR, estimated glomerular filtration rate; RRT, renal replacement therapy; CNI, calcineurin inhibitor.
Reference group (relative risk 1.00): male gender, no hepatitis C, no perioperative RRT, CNI: tacrolimus, no insulin-dependent diabetes, no diagnosed
hypertension, no diagnosed dyslipidemia. Boldface indicates statistical significance.
Table 5. Univariate and multivariate logistic regression analysis of variables associated with a rate of decline in renal function from six months
post-liver transplantation greater than the rate expected with aging
Univariate Multivariate
Variable OR (95% CI) p Value OR (95% CI) p Value
Six-month eGFR (mL/min/1.73 m2) 1.03 (1.01-1.06) 0.002 1.06(1.03-1.10) <0.001
Female gender 1.47 (0.66-3.29) 0.345 3.94(1.20-12.95) 0.024
Hepatitis C 0.40(0.07-2.17) 0.288 0.878 (0.11-7.27) 0.904
Perioperative RRT 0.61 (0.14-2.72) 0.521 1.44 (0.23-8.84) 0.697
CNI: cyclosporine 3.37(1.34-8.51) 0.010 2.68 (0.92-7.79) 0.071
Average CNI trough 0.832 (0.07-10.05) 0.885 1.10(0.06-20.44) 0.949
Insulin-dependent diabetes 0.89 (0.28-2.90) 0.859 0.86 (0.19-3.86) 0.842
Diagnosed hypertension 1.86 (0.83-4.16) 0.133 2.68(1.00-7.19) 0.050
Diagnosed dyslipidemia 1.68(0.44-6.39) 0.444 2.95 (0.56-15.43) 0.200
eGFR, estimated glomerular filtration rate; RRT, renal replacement therapy; CNI, calcineurin inhibitor.
Reference group (relative risk 1.00): male gender, no hepatitis C, no perioperative RRT, CNI: tacrolimus, no insulin-dependent diabetes, no diagnosed
hypertension, no dyslipidemia. Boldface indicates statistical significance.
information has been gained regarding appropriate
strategies to delay or avoid the progression to
CKD in high risk individuals. In two of three large
randomized controlled trials of unselected patients,
delayed perioperative administration of tacrolimus
did not impact on renal function by one yr
post-transplant (13-15). All three studies were
marred by failure to maintain low tacrolimus
trough levels, and Boudjema et al.'s trial has con¬
firmed that long-term reduced calcineurin inhibitor
exposure is probably more important (24). Reduc¬
tion or withdrawal of calcineurin inhibitor therapy
once CKD has developed results in only a mar¬
ginal improvement in kidney function (10, 25-29).
Therefore, prevention of CKD in liver transplant
patients should be a priority (10).
The key outcome of our study was the observa¬
tion that hypertension and dyslipidemia were asso¬
ciated with the rate of decline in renal function
after liver transplantation. Echoing findings in
non-transplant patients with CKD and the general
population for every increment increase in average
systolic blood pressure, there was a faster rate of
decline in GFR (17, 30, 31). This suggests that
tight blood pressure control may be of particular
importance in limiting the progression to CKD.
Diagnosed dyslipidemia was an independent pre¬
dictor of change in eGFR, although we were
unable to demonstrate a correlation with lipid lev¬
els. The diagnosis of dyslipidemia was made by pri¬
mary care or non-transplant hospital physicians,
and lipid levels were non-fasting and variably
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performed in the study cohort. Consequently, the
reported lipid levels are probably a poor reflection
of the true lipid profile. In the non-transplant
setting, the association between dyslipidemia and a
faster rate of progression of kidney disease is con¬
tentious (17). However, many studies in patients
with and without renal dysfunction have linked
high cholesterol, triglyceride and LDL levels, and
low HDL levels, with the rate of change in GFR.
Furthermore, lipid-lowering therapy has been
shown to slow the decline in renal function (17, 31,
32).
In our study, female patients had a faster rate of
decline in eGFR than men, mirroring the gender
difference demonstrated by renal transplant recipi¬
ents (22). Female gender is a risk factor for chronic
renal dysfunction following liver, heart, and lung
transplantation (1). In contrast, in non-transplant
patients male gender is linked with a faster rate of
decline in GFR (17). A possible explanation for
this discrepancy is that women may be more
susceptible to calcineurin inhibitor-mediated renal
injury.
The strong association between baseline eGFR
and change in eGFR may represent a statistical
phenomenon. Nevertheless, we attempted to mini¬
mize "regression to the mean" by estimating eGFR
slope using a large number of measurements and
by adjusting all analyses for baseline renal function
(33, 34). We speculate that patients who had a
higher eGFR at six months post-transplant had
greater calcineurin inhibitor exposure than those
with renal dysfunction. Moreover, additional
potential contributing factors such as hypertension
and dyslipidemia may have been monitored less
closely in this group.
The retrospective nature of our study and rela¬
tively small patient numbers may explain the fail¬
ure to demonstrate a relationship between
diabetes, and immunosuppression, and change in
eGFR (17). Furthermore, we did not have urate
levels or urinary protein concentrations available
on a sufficient number of patients to allow analysis
(35). On the other hand, an advantage of the popu¬
lation size and methodology was that it allowed
the close observation of risk factors over a pro¬
longed time period. Additional potential limita¬
tions were the precision of the main outcome
measures eGFR and eGFR slope. The former has
been shown to be a less precise measure of GFR in
liver transplant recipients than in other groups
(36). However, it is the most widely accepted read¬
ily available measure of renal function. The preci¬
sion of change in eGFR determined from the slope
of eGFR over time increases with the duration of
follow-up (33). All our patients had change in
eGFR calculated from six eGFR measurements
and a prolonged follow-up time of five yr.
In conclusion, our study has shown for the first
time that liver transplant recipients have a clini¬
cally relevant decline in eGFR from six months
following transplantation. We have identified mod¬
ifiable factors that may influence the change in
eGFR and increase the risk of progression to
CKD. Our study emphasizes the multifactorial
nature of renal dysfunction following liver trans¬
plantation. Prospective studies are required to
examine the effects of aggressive blood pressure
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